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Abstract 
Axonal and synaptic degeneration is a hallmark of peripheral neuropathy, brain injury, 
and neurodegenerative disease. Axonal degeneration has been proposed to be mediated 
by an active autodestruction program, akin to apoptotic cell death; however, loss-of-
function mutations capable of potently blocking axon self-destruction have not been 
described. Using a forward genetic screen in Drosophila, we identified that loss of the 
Toll receptor adaptor dSarm (sterile a/Armadillo/Toll-Interleukin receptor homology 
domain protein) cell-autonomously suppresses Wallerian degeneration for weeks after 
axotomy. Severed mouse Sarm1 null axons exhibit remarkable long-term survival both 
in vivo and in vitro, indicating that Sarm1 prodegenerative signaling is conserved in 
mammals. Our results provide direct evidence that axons actively promote their own 
destruction after injury and identify dSarm/Sarm1 as a member of an ancient axon death 
signaling pathway. This death signaling pathway can be activated without injury by loss 
of the N-terminal self-inhibitory domain, resulting in spontaneous neurodegeneration. To 
investigate the role of axon self-destruction in disease, we assessed the effects of Sarm1 
loss on neurodegeneration in the SOD1-G93A model of amyotrophic lateral sclerosis 
(ALS), a lethal condition resulting in progressive motor neuron death and paralysis. Loss 
of Sarm1 potently protects motor axons and synapses from degeneration, but only 
extends animal survival by 10%. Thus, there appears to be at least two driving forces in 
place during ALS disease progression: (1) Sarm1 mediated axon death, and (2) cell body 
destruction via some unknown mechanism. 
vii
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Preface 
 
I conducted all of the work presented here, in the laboratory of Marc Freeman, except 
where noted at the beginning of each chapter. 
 
Some negative results have been excluded from this document, including RNAi and 
mutant lines that showed no suppression of Wallerian degeneration.  
 
Excluded are data on the gene progressive motorneuronopathy, which I cloned into a 
pUASt vector, because expression of this mutant had no impact on Wallerian 
degeneration in Drosophila; I also cloned hax-1 into a pUASt vector, but it too had no 
impact on Wallerian degeneration. 
 
I recombineered a GFP tag just prior to the endogenous stop codon in a BAC containing 
full length dSarm and 40 kb of surrounding genomic region; we were unsuccessful at 
recovering successful genomic integrations of this BAC and as such this work is not 
presented here. 
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CHAPTER I: Introduction  
  
 2 
Why study axons? 
 Neurons are amazingly complex cells that broadcast information by transmitting 
electrical and chemical signals. This information is organized by the bipolar nature of 
neurons, and each compartment of a neuron plays its own exclusive role in the overall 
activity of the cell. A neuron’s dendrites may receive a variety of signals, while the axon 
delivers the output signal to the connecting neurons, muscles, or glands. An axon is a 
distinctive and select neuronal process; while most neurons will have many dendrites 
and many synaptic inputs, not all inputs will result in the neuron firing an action 
potential. However, once the threshold for signaling is reached, the singular axon, with 
its many branches, will transmit this signal as one unified output action potential to all 
cells with which the axon connects.  
Axons are incredibly unique, particularly in terms of their size: human motor 
neurons, for example, have cell bodies that can be up to 80 μm in diameter, while their 
axons can be over one meter long (Kanning et al., 2010). The sheer size of some axons 
puts a huge burden on the entire cell, especially axon transport mechanisms that bring 
proteins from the soma (De Vos et al., 2008) and the trophic support from the 
surrounding glia (Nave and Trapp, 2008). Repetitive firing and structural maintenance 
place a huge energetic drain on neurons, and axons have accordingly evolved their own 
unique biology to keep up with the strenuous demands placed on neurons (Coleman and 
Freeman, 2010). 
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Axons fragment after transection 
 Axon integrity is crucial for a neuron’s function; without an intact axon, a neuron 
is essentially useless. What happens to an axon when its integrity is compromised? 
Waller first described this phenomenon as he attempted to trace nervous system wiring 
in the frog tongue (Waller, 1850). Waller noticed that cutting an axon away from its cell 
body resulted in a stereotyped beading, blebbing, and eventual fragmentation of the 
severed axon. The axon fragments are eventually “removed by absorption.” Axon 
fragmentation and eventual engulfment after injury together is now known as Wallerian 
degeneration (Coleman, 2005). Many assumed Wallerian degeneration occurred because 
the severed axon starved, as it was no longer connected to the presumed singular cell 
nutrient source, the soma (Lubinska, 1977). This passive wasting away of the severed 
axon was suspected to have important implications during neurological diseases, as 
Waller hypothesized that one would see similar “alterations” of nerve fibers, particularly 
during paralysis (Waller, 1850).  
Many years after his initial observations, multiple groups described in detail the 
biochemical, histological, and ultra-structural changes that occur in severed axons 
(Johnson et al., 1950): first, there is acute axonal dieback (AAD) on either side of the 
lesion site, where a short segment of the axon retracts and fragments within minutes after 
injury (Kerschensteiner et al., 2005); second, the severed axon undergoes a defined 
latency period, characterized by microtubule depolymerization and a “metabolism 
failure,” with massive decreases in essential metabolic molecules such as adenosine 
 4 
triphosphate (ATP) and nicotinamide adenine dinucleotide (NAD) (Wang et al., 2005); 
and finally the severed axon undergoes robust and catastrophic fragmentation, known as 
granular disintegration of the axonal cytoskeleton (GDC) (Ma et al., 2013), that includes 
neurofilament breakdown and mitochondrial swelling (Figure 1-1) (Park et al., 2013). 
This entire process takes between 24-28 hours in vivo (Lubinska, 1977; Beirowski et al., 
2004; Beirowski et al., 2005) and 12-24 hours in vitro (Glass et al., 1993) for mammals. 
 AAD is a unique part of Wallerian degeneration in that it occurs equally both on 
the proximal and distal sides of the lesion. The 200-300 μm of axon directly on either 
side of the lesion site degenerates in less than 5 minutes, occurring within the first hour 
after lesion (Kerschensteiner et al., 2005). The axon proximal to the injury site may have 
the ability to regenerate, and AAD is believed to be important for growth cone formation 
at the remaining axon stump still attached to the soma (Spira et al., 2003). However, a 
specific role, if any, for AAD in the fragmentation of the distal severed axon remains 
unclear (Kerschensteiner et al., 2005).  
Intra-axonal calcium is required for Wallerian degeneration 
Immediately after injury and during AAD, a spike in intra-axonal calcium is 
observed (Ziv and Spira, 1993; Knoferle et al., 2010; Koch et al., 2010; Adalbert et al., 
2012; Avery et al., 2012). The immediate consequence of this calcium spike is the fusion 
of vesicles at the site of lesion, which seals off the membranes on either side of the 
lesion (Eddleman et al., 1998). A large calcium spike coincides with AAD 
(Kerschensteiner et al., 2005), and there is a slow rise in intra-axonal calcium levels in 
 5 
the distal severed axon during the subsequent latency period (Adalbert et al., 2012). This 
calcium rise does not appear to be due to ionic leaking or an electrical balance for other 
ions, as pharmacological blockade of sodium channels does not affect the calcium rise or 
Wallerian degeneration (George et al., 1995; Press and Milbrandt, 2008).  
Where is this calcium coming from? Addition of ethylene glycol tetraacid acid 
(EGTA) to cell culture media, which chelates extracellular calcium, strongly blocks 
injury-induced axon degeneration (Schlaepfer and Bunge, 1973), and this blockage is 
reversed upon the addition of calcium ions back to the media (George et al., 1995). 
Broad blockade of calcium channels with either cobalt or manganese ions also strongly 
inhibit axon degeneration after injury in vitro (George et al., 1995). Addition of calcium 
ionophores induces spontaneous axon degeneration in the absence of injury, suggesting 
that calcium influx is necessary and sufficient to induce axon destruction (George et al., 
1995). Voltage gated L-type calcium channels specifically appear to allow calcium into 
the axon after transection, as pharmacological inhibition of these, but not other calcium 
channel types, blocks injury-induced degeneration in vitro (George et al., 1995) and in 
vivo (Knoferle et al., 2010). Together, these data suggest that extracellular calcium 
specifically enters the axon via L-type calcium channels to drive Wallerian degeneration.  
Calcium entry can activate a variety of intracellular processes, including protein 
degradation due to the calcium-dependent cysteine proteases calpains. Pharmacological 
calpain inhibition completely blocks AAD (Kerschensteiner et al., 2005) and weakly 
suppresses Wallerian degeneration in the distal severed axon in vitro (George et al., 
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1995; Zhai et al., 2003). Genetically expressed calpain inhibitors also delays 
fragmentation in vivo (Ma et al., 2013). Calpains appear to be involved specifically in 
the fragmentation phase of Wallerian degeneration, as a genetically encoded calpain 
inhibitor specifically inhibits neurofilament breakdown but not microtubule disruption 
(Ma et al., 2013). The weak protection afforded by calpain inhibitors is nowhere near as 
strong as the protection with EGTA treatment, suggesting that another parallel calcium-
dependent mechanism is likely activated during Wallerian degeneration (Park et al., 
2013). 
Interestingly, axons possess an intrinsic mechanism by which to buffer axonal 
calcium levels: mitochondria. Addition of cyclosporine A (CsA) to severed mouse 
sciatic nerve explants robustly blocks degeneration by preventing calcium efflux from 
mitochondria, effectively increasing the amount of axonal calcium that these 
mitochondria can buffer (Barrientos et al., 2011). Mitochondrial calcium levels do rise 
during the latent phase of Wallerian degeneration, although it appears that their normal 
buffering capacity is not enough to offset the calcium-induced changes that occur after 
injury (Sievers et al., 2003). 
Studies using calcium chelation and channel blockers suggest that calcium 
activates calpains (see above) to induce neurofilament breakdown and microtubule 
deterioration. Intriguingly, microtubule depolymerization still occurs in injured neurons 
cultured in calcium-free media, suggesting that calcium is not required for 
depolymerization, only for microtubule breakdown (Park et al., 2013). Studies on 
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microtubule destabilization agents suggest that this sort of cytoskeletal breakdown can 
induce the variety of downstream changes seen in degenerating neurons, including 
metabolic failure and eventual fragmentation (Wang et al., 2001; Ikegami and Koike, 
2003; Park et al., 2013). It has not been reported if removal of extracellular calcium 
during the latent phase (i.e., after microtubule breakdown has occurred) can stall 
degeneration, so it is unclear if calcium is required only for the initial activating steps or 
throughout Wallerian degeneration. 
Wlds: new insights on axon degeneration 
Despite the wealth of descriptions on morphologic changes during Wallerian 
degeneration, it was assumed that this process was passive; therefore no one searched for 
a genetically encoded pathway that might control Wallerian degeneration (Coleman and 
Freeman, 2010). The search for an elusive Wallerian degeneration gene inadvertently 
and serendipitously began by studying the recruitment of macrophages to injured nerves. 
It had been previously described that a sciatic nerve lesion causes myelinating Schwann 
cells to undergo mitosis and recruit macrophages to the severed axon. While studying 
this process, a random mutant strain of mice, C57/Bl6/Ola, was found to have no 
macrophage recruitment to the injured nerve. Subsequence analysis found that axons in 
these mice were not degenerating after lesion, and thus no pro-inflammatory signal was 
being released to draw in macrophages (Lunn et al., 1989). These severed mutant axons 
remained intact for 2-3 weeks after axotomy, while wild type axons degenerate within 
36 hours of lesion (Lunn et al., 1989).  
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 What sort of mutation could block severed axons from degenerating? After 
several generations of backcrossing, it was found that the mutation (1) acted in a 
dominant fashion (Perry et al., 1990b) and (2) mapped to mouse chromosome four (Lyon 
et al., 1993). The mutation in the C57/Bl6/Ola strain was eventually termed slow 
Wallerian degeneration (Wlds) (Perry et al., 1990b) and found to be the result of a 
tandem triplication (Coleman et al., 1998). This triplication resulted in the 
overexpression of a novel chimeric fusion protein, Wlds, comprised of: the non-
enzymatic first 70 amino acids of Ubiquitin conjugation factor E4B (Ube4B); an 18 
amino acid linker from the endogenous 5’ untranslated region (UTR) of 
nicotinamide/nicotinic acid mononucleotide adenylyltransferase-1 (Nmnat1); and full 
length Nmnat1, a NAD biosynthetic enzyme (Conforti et al., 2000; Mack et al., 2001). 
Wlds cell autonomously protects severed axons (Perry et al., 1990a; Glass et al., 1993) in 
a dose-dependent manner (Mack et al., 2001). Expression of Wlds not only affects 
Wallerian degeneration in mice (Gillingwater et al., 2003; Beirowski et al., 2004; 
Beirowski et al., 2005) but also protects severed axons from Wallerian degeneration in 
cell culture (Buckmaster et al., 1995), rats (Adalbert et al., 2005), and Drosophila 
(MacDonald et al., 2006). Interestingly, local protein synthesis does occur in severed 
axons of both wild type and Wlds-expressing mice (Court et al., 2008), but de novo 
protein synthesis is not required for degeneration or Wlds protection (Gilley and 
Coleman, 2010).  Because Wlds is a chimeric molecule and not itself a normally 
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occurring gene, it was proposed to act in an unknown gain-of-function manner (Coleman, 
2005).  
 Severed Wlds nerves show histological preservation of the synapse at both the 
neuromuscular junction (NMJ) (Wang et al., 2001; Adalbert et al., 2005) as well as the 
cortex (Gillingwater et al., 2006a; Wright et al., 2010), but does this protection extend 
past morphology? Do intact severed axons still retain their membrane potential and their 
functional ability to transmit action potentials? Electrical stimulation of a severed wild 
type motor axon can evoke normal electrical responses in the muscle, measured as 
compound muscle action potentials (CMAPs), for 10 hours after lesion, but rapidly 
decay within the next 8 hours (Moldovan et al., 2009).  Wlds–expressing motor axons 
showed a substantially slower decay; CMAPs appeared normal for the first 24 hours 
after lesion, and then deteriorated for the six following days. Unlike wild type animals, 
Wlds mice retained some functionally connected synapses a week after axotomy, albeit 
at a greatly diminished level (Moldovan et al., 2009). Thus, Wlds protects axons, and to a 
lesser extent synapses, from degenerating both morphologically and electrically after 
axotomy. 
How and where does Wlds act to protect axons? 
Surprisingly, the Wlds protein was found enriched in punctae in the nucleus, 
suggesting that it played a possible role in gene regulation (Jia et al., 2007).  When 
mRNA populations were compared, Wlds expressing neurons showed a substantial 
decrease in the mRNA of a single gene, pituitary tumor transforming-1 (pttg); however, 
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pttg1 knockout mice showed normal Wallerian degeneration (Gillingwater et al., 2006b). 
Proteomic studies have been done on wild type and Wlds nerves, and there are 
significant differences in protein expression levels between the two nerves; a few 
molecules regulating Wallerian degeneration have been identified by this method, but 
mutants do not show protection at the level of Wlds (Wishart et al., 2007; Wishart et al., 
2012).  
The nuclear Wlds punctae appeared to co-localize with valosin-containing protein 
(VCP) through the Ub4b portion of Wlds (Laser et al., 2006; Wilbrey et al., 2008); it has 
been suggested that this interaction may alter the ubiquitin-proteosome system (UPS) in 
transected axons (Coleman and Freeman, 2010). Blockade of the UPS alone can delay 
injury-induced degeneration by a few days (MacInnis and Campenot, 2005; Hoopfer et 
al., 2006; Zhai et al., 2003). Interestingly, calcium ionophore-induced degeneration is 
not blocked by UPS inhibition, suggesting that the involvement of the UPS in axon 
degeneration is calcium independent (Zhai et al., 2003) or that calcium activates a 
destruction program that is unrelated to protein degradation. However, a connection 
between VCP and the UPS is not now believed to be critical for Wlds function 
(Beirowski et al., 2010). 
The nuclear localization of Wlds is a result of the nuclear localization sequence 
(nls) in Nmnat1 (Avery et al., 2009; Babetto et al., 2010). However, small amounts of 
Wlds can be found out in the synapse (Avery et al., 2012), even though the vast majority 
of this overexpressed protein is in the nucleus. While the exact mechanism of Wlds 
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protection is still unknown, the non-nuclear expression of Nmnat now appears to be 
crucial for the protective role of Wlds (Babetto et al., 2010). 
The role of Nmnat and the functional site of Wlds protection from Wallerian 
degeneration were controversial for quite some time. Multiple groups reported that 
enzymatic activity of the Nmnat1 portion was essential for the function of Wlds (Fang et 
al., 2005; Jia et al., 2007; Avery et al., 2009; Conforti et al., 2009), as were the first 16 
amino acids of the Ube4B portion (Avery et al., 2009; Conforti et al., 2009). Some 
groups reported no protection from Wallerian degeneration with overexpression of 
Nmnat1 in vitro (Watanabe et al., 2007) and in vivo (Conforti et al., 2007), while other 
groups did see protection in vitro (Araki et al., 2004).  
These discrepancies were eventually rectified when groups looked at the effect of 
other Nmnat1 homologs on Wallerian degeneration. In mammals, there are 3 homologs 
of Nmnat: Nmnat1, which is in the nucleus; Nmnat2, which is in the golgi; and Nmnat3, 
which is mitochondrial (Berger et al., 2005; Lau et al., 2010). Of the homologs, Nmnat2 
is enriched specifically in mammalian neurons (Cahoy et al., 2008). Overexpression of a 
mutated form of Nmnat1 with a disrupted nls, which relocalizes the protein from the 
nucleus to the cytoplasm, confers robust protection after axotomy in vivo (Sasaki et al., 
2009). Fusion to a peptide from amyloid precursor protein (APP), which targets the 
protein out of the nucleus, also confers Wlds-like protection (Babetto et al., 2010), as 
does expression of Nmnat3 (Yahata et al., 2009). Mutations in the nls of Nmnat1 within 
Wlds (termed “non-nuclear Wlds”) protect severed axons significantly better than the 
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original Wlds protein – up to 7 weeks after axotomy (Beirowski et al., 2009). All of these 
data taken together suggests that overexpression of non-nuclear Nmnat can protect axons 
from Wallerian degeneration. Thus, the N-terminus (i.e., Ube4B portion) of Wlds likely 
helps to direct some of the protein out of the nucleus, where even small amounts of 
axonal Wlds protect from Wallerian degeneration (Coleman and Freeman, 2010). 
Furthermore, addition of cytosolic Nmnat1 protein directly to axons after injury through 
a lentiviral vector can prevent Wallerian degeneration (Sasaki and Milbrandt, 2010), 
strongly arguing that Wlds is acting somewhere in the axon after injury to prevent 
Wallerian degeneration.  
Where within the axon could Wlds or non-nuclear Nmnat1 be acting? The 
protection by overexpression of mitochondrial Nmnat3 hinted that mitochondrial Wlds 
might be important for its protective abilities (Yahata et al., 2009). Subcellular 
fractionation has identified Wlds protein in the mitochondria (Yahata et al., 2009; 
Babetto et al., 2010), and multiple groups have presented evidence that specifically the 
levels of Nmnat in the mitochondrial matrix is what correlates with axonal protection 
(Yahata et al., 2009; Avery et al., 2009; Avery et al., 2012). Furthermore, mitochondria 
from Wlds-expressing animals have a fundamental difference compared to wild type 
mitochondria: they are able to buffer higher levels of calcium (Avery et al., 2012). Wlds-
expressing axons also do not show normal calcium spikes after injury (Avery et al., 
2012; Adalbert et al., 2012), supporting the hypothesis that Wlds protects axons by 
increasing the calcium buffering capacity of mitochondria (Figure 1-2). 
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NAD and axon degeneration 
How exactly a NAD biosynthesis enzyme is able to potently protect severed 
axons from degeneration remains unclear. Basal NAD levels are not different in Wlds 
nerves when compared to wild type (Mack et al., 2001). However, NAD levels fall 
quickly after axotomy in wild type neurons but not Wlds neurons (Wang et al., 2005). 
The addition of NAD in vitro before injury can delay degeneration, suggesting that NAD 
depletion may be a driving force in the initiation of Wallerian degeneration (Araki et al., 
2004).  Addition of NAD at very high levels (1-20 mM) a few hours after axotomy can 
also delay Wallerian degeneration (Wang and He, 2009), as can addition of adenosine 
(Press and Milbrandt, 2009) or nicotinamide (Wang et al., 2005). This would suggest 
that NAD depletion alone is responsible for Wallerian degeneration, but mutating genes 
involved in NAD catabolism is not enough to block axon degeneration, even though the 
axons have higher levels of NAD before injury (Sasaki et al., 2006). Furthermore, 
lowering neuronal levels of NAD did not block the ability of non-nuclear Nmnat1 to 
protect severed axons (Sasaki et al., 2006). This suggests that there is something unique 
about Nmnat in the context of Wallerian degeneration beyond its ability to synthesize 
NAD. While enzymatic activity of Nmnat is essential for its protective abilities (Avery 
et al., 2009; Conforti et al., 2009), it is unknown if Nmnat’s enzymatic activity is 
restricted to producing NAD. There have not been reports on other substrates for Nmnat, 
but it remains possible that the protective abilities of Wlds are related to an unknown 
enzymatic function of Nmnat beyond NAD biosynthesis. This enzymatic activity may be 
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related to increasing mitochondrial calcium buffering capacity (see above), and it is 
unknown if addition of NAD directly to mitochondria can increase this buffering 
capacity.  
Three additional models for the role of NAD in Wallerian degeneration have 
emerged: (1) axotomy triggers the increased activation of NAD-consuming proteins, 
which deplete the NAD pool and lead to eventual energetic catastrophe (Wang and He, 
2009); (2) high levels of NAD are simply required for normal maintenance of the axon, 
and the axon falls apart when these maintenance needs are unmet (Wang and He, 2009); 
or (3) NAD can modulate calcium channel openings (Tamsett et al., 2009), and the high 
levels found in Wlds axons after injury prevent the influx of calcium and all of the 
downstream consequences of high axonal calcium levels (Wang and Barres, 2012). 
However, none of these explanations fully explains the Wlds phenomenon; nevertheless, 
both Nmnat and NAD appear to play important, albeit mysterious, roles in protecting 
axons from Wallerian degeneration.  
An endogenous axon survival signal? 
Axonal Nmnat has the unique ability to protect severed axons from Wallerian, so 
it was suggested that endogenous Nmnat may play a role in normal neuronal health. 
Knock down of Nmnat1 or Nmnat3 has no effect on cultured neurons; however, knock 
down of Nmnat2 induces spontaneous degeneration. This spontaneous degeneration is 
blocked with expression of Wlds, which has been proposed to protect these axons by 
substituting for the enzymatic activity of Nmant2 (Gilley and Coleman, 2010). 
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Coincidentally, the half-life of endogenous Nmnat2 after axotomy correlates with the 
onset of degeneration (i.e., microtubule disruption and neurofilament breakdown) 
(Gilley and Coleman, 2010). This has been interpreted to mean that Nmnat2 is an 
endogenous “survival factor” coming from the soma that is required for axon integrity, 
and that Wallerian degeneration occurs because this survival factor is no longer coming 
from the nucleus. However, Nmnat2 is a crucial component of metabolism, so it is not 
surprising that knock down induces spontaneous degeneration. While it is an intriguing 
observation, half-life correlation with the latent phase is hardly enough to show that 
Nmnat2 is an endogenous survival factor, and it is unknown how many other molecules 
show a similar half-life in a degenerating axon. 
An endogenous axon death signal? 
If there is not a survival factor being actively transported from the soma to the 
axon, then a “death signal” may somehow be activated in the axon after injury. It has 
been suggested that this death signal, activated by injury, uncages calcium, allowing for 
the activation of the calcium-dependent destructive mechanisms associated with 
Wallerian degeneration (Wang and Barres, 2012). However, there are calcium-
independent changes associated with injury-induced degeneration, such as microtubule 
depolymerization (Park et al., 2013). Nonetheless, there is evidence of calcium-activated 
kinases, such as calcium/calmodulin-dependent protein kinases (CaMKs), which 
regulate cellular stress responses (Ding and Nam Ong, 2003; Song, 2013). Could 
axotomy trigger a pro-degeneration kinase-signaling cascade? Recent studies have 
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linked c-Jun kinase (JNK) signaling through dual leucine kinase (DLK) to axon 
degeneration (Miller et al., 2009) as well as glycogen synthase kinase 3 (GSK3) and Iκβ 
kinase (IKK) (Gerdts et al., 2011). Importantly, pharmacological inhibition of any of 
these kinases affords axon protection that is far weaker than Wlds, so these kinase 
cascades are likely not the only regulatory pathway governing Wallerian degeneration. 
A clear signaling cascade has not been identified which drives Wallerian 
degeneration, so axons could be degenerating via a mechanism similar to necrosis. In 
support of this, severed axons undergo the rapid ATP loss, which is a hallmark of 
necrosis (Wang and He, 2009); however, another chacteristic of necrosis is the release of 
calcium from intracellular stores (mainly the endoplasmic reticulum (ER) and 
mitochondria), and the calcium influx during Wallerian degeneration has been shown to 
be from an extracellular source (George et al., 1995). If not necrosis, then could severed 
axons being “dying” via apoptotic cell death pathways? 
Apoptosis seemed like a logical candidate as a mechanism for Wallerian 
degeneration, as fragmenting axons share some features of apoptosis (Coleman, 2005), 
such as phosphatidylserine residue exposure on the plasma membrane and loss of 
mitochondrial membrane potential (Sievers et al., 2003). Canonical apoptosis signaling 
was found to be nonessential for Wallerian degeneration, as bax-bak double knock out 
mice are not protected against Wallerian degeneration despite a broad blockade of cell 
death (Whitmore et al., 2003). Pharmacological inactivation of caspases (Finn et al., 
2000) and serine-proteases (Zhai et al., 2003) were also unable to block Wallerian 
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degeneration. All of this taken together suggests that if Wallerian degeneration is indeed 
a genetically encoded program, then it occurs through some unique mechanism 
independent of known cell death pathways (Coleman and Freeman, 2010). 
Axon degeneration beyond injury 
Wlds raised another important question: are all forms of axon degeneration the 
same? Axons can undergo degeneration not only after physical lesion, but also during 
(1) developmental pruning; (2) programmed cell death (both induced and 
developmental); and (3) during neurodegenerative diseases (Luo and O'Leary, 2005). 
Expression of Wlds does not block developmental neurite pruning in either mice or 
Drosophila (Hoopfer et al., 2006), although it may offer a slight delay (Schoenmann et 
al., 2010). Interestingly, the UPS plays a major role in axon degeneration due to 
developmental pruning, so Wallerian degeneration and pruning may eventually funnel 
through some common degeneration mechanisms, although the initiating element 
appears to be unique for each process (Saxena and Caroni, 2007). Developmental cell 
death occurs normally in Wlds mice, also suggesting that Wlds does not affect apoptosis 
(Deckwerth and Johnson, 1994). Furthermore, Wlds protection appeared to be axon-
specific: during neuronal apoptosis induced by nerve growth factor (NGF) deprivation, 
Wlds neurites are spared, but not their cell bodies (Deckwerth and Johnson, 1994). 
Recent studies highlight that trophic factor-induced degeneration is clearly molecularly 
distinct from Wallerian degeneration (Nikolaev et al., 2009; Vohra et al., 2010). Thus, 
there appears to be multiple ways to kill an axon: via apoptosis (i.e., developmental or 
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NGF withdrawal), developmental pruning, or injury induced Wallerian degeneration 
(Luo and O'Leary, 2005). 
Wallerian-like degeneration during disease 
Axon degeneration can also occur when neurons are exposed to toxic agents; for 
example, peripheral neuropathies are hallmarks of chemotheraphy treatment (Coleman, 
2005). Wlds was found to delay axon degeneration resulting from a variety of chemical 
insults in vitro, including vincristine (Wang et al., 2001), taxol (Wang et al., 2002), and 
vinblastine (Ikegami and Koike, 2003).  These agents cause what is now termed 
“Wallerian-like degeneration,” meaning that the spontaneous degeneration observed is 
modified by Wlds, even though there has not been a physical transection. Amazingly, 
Wlds protection is specific to the axon, as cell body death is not prevented with any of 
the above treatments. These drugs act by destabilizing microtubules, to which the axon 
seems especially sensitive; this suggests that Wlds may to be acting, either directly or 
indirectly, by stabilizing microtubules. Overexpression of cytosolic Nmnat1, like Wlds, 
can also delay pharmacologically induced axon degeneration: rotenone, a mitochondrial 
complex 1 inhibitor that causes a catastrophic accumulation of reactive oxygen species 
(ROS), induces axonal degeneration that is blocked by cytosolic Nmnat1 (Press and 
Milbrandt, 2008). Thus, Wlds appears to be broadly protective against chemically 
induced axon degeneration. 
Waller speculated that the degeneration he witnessed after cut may have some 
connection with neurodegenerative disease (Waller, 1850). Even though physical 
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transection is clinically rare (Coleman and Freeman, 2010), axon degeneration is a 
hallmark of essentially every neurodegenerative condition (Raff et al., 2002), and the 
severity of axon damage is often linked with outcome and the severity of the disease 
(Medana and Esiri, 2003). In many neurodegenerative diseases, synaptic and axonal loss 
occurs long before symptoms develop (Saxena and Caroni, 2007). However, it is 
unknown if the axonal pathology is a driving force in the disease or merely the result of 
a sick neuron (i.e., the soma) (Cavanagh, 1964). The Wlds mouse allowed for this 
question to be addressed: if a particular disease model were suppressed in the Wlds 
background, this would argue that the axonal-die back is a driving force in disease 
progression (Coleman and Perry, 2002).  
This appears to be the case in the progressive motorneuronopathy (pmn) mouse 
model of motor neuron disease. This disease model, the result of a mutation in a tubulin 
chaperone, causes severe motor neuron loss and animal death within 6 weeks of birth 
(Martin et al., 2002) and is used as a model for spinal muscular atrophy (SMA) (Luo and 
O'Leary, 2005). Wlds strongly protects against both axon and cell body death in pmn 
mice (Ferri et al., 2003; Simonin et al., 2007), suggesting that in this model of motor 
neuron disease, axonal degeneration is a initiating factor behind cell body death. 
Unfortunately, this robust protection was not seen in other mouse models of a 
motorneuron disease, such as the superoxide dismutase-1 (SOD1) models of 
amyotrophic lateral sclerosis (ALS) (Vande Velde et al., 2004; Fischer et al., 2005).  
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Other models of neurodegeneration show some degree of protection with 
expression of Wlds; while axon protection appears to delay overall disease progression, 
this effect is not nearly as robust as in the pmn mice. Wlds is able to modestly protect 
axons in a mouse model of myelin-related axonopathy, a severe inherited peripheral 
neuropathy found in humans due to deficiencies in myelin component P0 (Samsam et al., 
2003). Injection of another myelin component, myelin oligodendracyte glycoprotein 
(MOG), causes experimental autoimmune encephalomyelitis (EAE), a mouse model for 
multiple sclerosis (MS). Wlds modestly protects in this EAE model, as does injections 
with nicotinamide (Kaneko et al., 2006). In a rat model of Charcot-Marie-Tooth disease 
(CMT) 1A, caused by a duplication of the peripheral myelin protein of 22kDa (PMP22) 
(Meyer zu Horste et al., 2011), and a mouse model of gracile axonal dystrophy (GAD) 
(Mi et al., 2005), Wlds protects against axon and synapse loss, although it does not alter 
clinical impairments, such as grip strength and rotarod performance. Parkinson’s like 
symptoms can be induced in mice by injection of 6-hydroxydopamine (6-OHDA) into 
the striatum; Wlds can protect axons, but not cell bodies, from 6-OHDA induced death 
(Sajadi et al., 2004). These data taken together suggests that axon death is likely not the 
only driving force in disease progression, but preserving axon integrity can prolong the 
lifespan of these neurons to some extent. Furthermore, these studies on Wlds and 
neurodegenerative disease models link axon death with injury induced axon 
degeneration, suggesting that a common axon death pathway may exist. 
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Unfortunately, because Wlds is not an endogenous molecule, it does not itself 
present a druggable-target for pharmaceutical treatment. However, if an endogenous 
pathway was discovered that mediated Wallerian degeneration, this pathway could 
potentially be a target for pharmaceutical treatment of a variety of disorders that result in 
axon death, including chemotherapy-induced peripheral neuropathies (CIPNs).  There is 
a crucial need to identify, if it does indeed exist, this endogenous axon death pathway. 
Vertebrate and pharmacological studies have been unable to shed any light on this 
mysterious endogenous pathway so far; thus, a new model needed to be established with 
which the genetics of Wallerian degeneration could be studied. 
Drosophila: an ideal genetic tool for studying Wallerian degeneration 
Currently, there are two model organisms well suited for performing genome-
wide genetic screens with respect to neuronal function: the nematode Caenorhabditis 
elegans and the fruit fly Drosophila melanogaster. C. elegans severed axons rarely 
undergo Wallerian degeneration; in fact, regenerating axons fuse with the intact severed 
axon to restore axonal integrity and function (Neumann et al., 2011). In contrast, 
Drosophila severed axons undergo Wallerian degeneration in a manner that is 
morphologically and molecularly very similar to vertebrate axons (MacDonald et al., 
2006). Thus, the fruit fly appears ideal for the discovery of a unique genetically encoded 
axon death program. 
Recent advances in Drosophila genetics have primed the community to perform 
robust unbiased forward genetic screens. First, specific subsets of cells can be labeled 
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and manipulated with the binary Gal4/UAS (upstream activating sequence) system. 
Derived from yeast, expression of the transcription factor Gal4 under the control of a 
tissue-specific promoter will enhance transcription of a gene downstream of the Gal4 
binding sites (Fischer et al., 1988). These sites, referred to as the UAS, enhance the 
expression of a gene following a UAS promoter and restrict its expression to the subset 
of cells that express Gal4 (Brand and Perrimon, 1993). This system can be used to label 
specific sets of cells, for example with a membrane tethered GFP (UAS-mCD8::GFP), to 
distinguish a subset of cells within a tissue, or to drive misexpression of transgenes to 
determine the cellular impact.  
Another important advancement for the use of Drosophila genetic screens was 
the development of the flippase/flippase recognition target (FLP/FRT) system, also using 
genes derived from yeast. This system allows for FLP-mediated site-specific 
recombination at transgenic FRT sites on homologous chromosomal arms (Golic and 
Lindquist, 1989). If a parent cell expresses FLP during mitosis and carries FRT sites at a 
homologous region of a specific chromosomal arm, then a recombination event can 
occur at the FRT sites. During chromosomal segregation, there is a 25% chance of the 
daughter cell becoming homozygous specifically at the region distal to the FRT site 
while remaining homozygous throughout the rest of the chromosomes (Theodosiou and 
Xu, 1998).  This technique allows for analysis of mutants distal to FRT sites in a tissue-
specific subset of cells instead of the entire animal, allowing for examination of mutants 
that might otherwise be lethal if homozygous. While traditional screening techniques 
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only allow for the “first essential function of a gene” to be analyzed (St Johnston, 2002), 
this development permits analysis of mutations at a variety of developmental stages in 
the given tissue type of choice. 
One issue remained with the FLP-mediated recombination technique: how do 
you know which cell is mutant and which is not? This technique was greatly enhanced 
and optimized by the development of a system with which you could specifically label 
the mutant mitotic clone generated with FLP-mediated recombination: mosaic analysis 
with a repressible cell marker (MARCM). MARCM combines the FLP/FRT system with 
the Gal4/UAS system, including Gal80, another yeast protein that binds to Gal4 and 
represses its ability to bind to a UAS. Now, specific clones are made by expression of 
tissue-specific flp and subsequently labeled in a tissue-specific manner by Gal4-
mediated expression of a cellular marker under UAS control (Lee and Luo, 1999; Lee 
and Luo, 2001). Because of the transgenic placement of a ubiquitously-expressed Gal80 
distal to a FRT on the chromosome of choice, this system specifically labels only the 
daughter cells that are homozygous and without the Gal80-induced Gal4 repression. 
Thus, we are able to specifically label our homozygous mutant cells. This mosaic system 
allows for the analysis of normal cells during development with single-cell resolution, as 
well mutant cells within an otherwise phenotypically normal tissue (Lee and Luo, 2001). 
All of the above genetic tools allow for rapid analysis of potential Wallerian 
degeneration mutants, even those that may cause lethality. One additional tool is 
missing: the mutagen. While many studies have used P-element transposons because of 
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the ease of insertion identification (Salzberg et al., 1997), these insertions are not 
random and rarely cause stops or deletions. With the advances in genome-wide 
sequencing (Gonzalez et al., 2012), use of another mutagen, ethyl methane sulphonate 
(EMS), has become advantageous. EMS-induced mutagenesis acts randomly and causes 
a high rate of single point mutations (St Johnston, 2002).  Many EMS-mutations result in 
protein coding changes, which increases the chances for identifying mutants that have 
altered function. Therefore, we have assembled a genetic system that can be randomly 
mutagenized with a high rate of protein coding changes. 
The final detail remaining is to decide which Drosophila neurons to use in the 
study of Wallerian degeneration. These neurons must exist within a defined subset that 
can be labeled with the Gal4/UAS system and be accessible for axotomy. Strong 
candidates are peripheral neurons, where axotomy may be performed with minimal 
damage to the surrounding tissue. Drosophila olfactory neurons (ORNs) thus are an 
excellent tool with which to study Wallerian degeneration using MARCM. First, ORNs 
house their cell bodies and dendrites in the antennae and project their axons to the 
antennal lobe of the brain (Couto et al., 2005); injury can be induced by simple non-
lethal surgical ablation of the antennae, leaving the axons in the brain behind to undergo 
Wallerian degeneration. This also removes any possible interference from regenerating 
axons because the cell bodies are no longer attached to the animal. Second, small subsets 
of ORNs have been identified based on their olfactory receptor expression (Clyne et al., 
1999) and their axonal projections to the antennal lobe of the Drosophila brain have 
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been mapped (Couto et al., 2005). One subset, the approximately 20 OR22a+ ORNs in 
each antenna (Dobritsa et al., 2003), can be identified with near single-axon resolution 
when labeled with a membrane tethered GFP by OR22a-Gal4, UAS-mCD8::GFP 
(MacDonald et al., 2006), as opposed to the large axon bundles found with many other 
subsets of ORNs. ORNs are derived from sensory organ precursor (SOP)-like 
progenitors that express the transcription factor eyeless (ey); when flp expression is 
driven under the control of the ey promoter, then FLP activity is induced in ORN 
progenitors (Newsome et al., 2000), allowing for the production of mosaic ORN clones. 
Importantly, ey-flp activity occurs only in the eye-antennal disc, so (1) all resulting 
mosaic clones are clearly of neuronal, not glial, origin (Hummel et al., 2003), and (2) 
ablation of ey+ progenitors does not cause lethality. Mosaic clones induced with ey-flp, 
even if completely ablated, will have little or no effect on the rest of the animal. Thus, 
Drosophila ORNs are an excellent model with which to study Wallerian degeneration: 
they are easily labeled with the Gal4/UAS system; we have tools in place to reliably 
generate mosaic clones with MARCM; and we have a method to easily and quickly 
induce Wallerian degeneration by simply removing the antennae. 
Using this system, we performed the first forward genetic screen to identify 
mutants that potently block Wallerian degeneration after injury. In this thesis, I describe 
the identification and initial characterization of sarm (sterile alpha and Armadillo motif), 
the first gene required for severed axons to undergo Wallerian degeneration. In Chapter 
2, I describe the genetic screen used to isolate three loss of function mutations in dSarm 
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(Drosophila Sarm) that potently protected severed axons from degeneration. The role of 
Sarm in promoting axon self-destruction after injury is highly conserved, as axons from 
Sarm KO mice are also robustly protected from Wallerian degeneration. In all assays to 
date, protection from Wallerian degeneration by loss of Sarm phenocopies the protection 
of axons by expression of Wlds. I present my initial characterization of Sarm function in 
Chapter 3, where I have performed a structure-function analysis to determine the roles of 
each of Sarm’s predicted subdomains in its function. In Chapter 4, I address the role of 
axon death in a mouse model of ALS and show that loss of Sarm can block axonal 
degeneration in SOD1-G93A ALS mice. Finally, I present a model for the molecular 
action of Sarm in promoting Wallerian degeneration in Chapter 5 and suggest future 
experiments to further understand these molecular mechanisms. First, however, I will 
present a summary of the previous work from other groups on Sarm and its potential 
function(s) beyond promoting Wallerian degeneration. 
Identification of mammalian Sarm1 
Sarm1 was first identified in a genome-wide screen of highly conserved regions 
among mammals. The human gene is located on chromosome 17q11 and occurs in a 
region syntenic with mouse chromosome 11 (Mink et al., 2001). Interestingly, human, 
but not mouse, cDNA libraries revealed the presence of a 350 bp antisense transcript that 
overlaps with the 5’end of sarm1, indicating that there may be endogenous RNAi 
regulatory mechanisms in place to control Sarm1 levels (Mink et al., 2001).  In humans, 
Sarm1 mRNA transcripts are found mainly in the kidney, liver and placenta (Mink et al., 
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2001), and in the mouse, transcripts occur almost exclusively in the brain (Kim et al., 
2007). Both human and mouse forms of sarm contain 9 nearly identical exons, with first 
exon being larger in the mouse (Mink et al., 2001). Notably, this gene is highly 
conserved across phyla, as C. elegans and Drosophila sarm (tir-1 and dsarm, 
respectively) share over 40% identity with human Sarm1 (Mink et al., 2001).  
Endogenous expression in both the worm and fly is very low, although it is detected in 
neurons (Chuang and Bargmann, 2005; Osterloh et al., 2012). Interestingly, tir-1 is also 
controlled by an endogenous microRNA, mir71, although it is unknown if this regulation 
occurs in flies or mice (Hsieh et al., 2012). 
Sarm and neural development 
 Sarm loss-of-function mutants do not broadly disrupt neural development (Kim 
et al., 2007; Osterloh et al., 2012); however, there are finer roles for Sarm during neural 
patterning (Chuang and Bargmann, 2005) and dendritic outgrowth (Chen et al., 2011). C. 
elegans has two bilateral olfactory neurons, AWCL (left) and AWCR (right), that are 
essential for chemotaxis. While born identical, one neuron will switch to AWCON, which 
expresses the receptor str-2 and detects butanone, while the other will remain in the 
default AWCOFF, which detects pentanedione and does not express str-2 (Chuang and 
Bargmann, 2005). It is random which AWC (left or right) will become AWCON, but in 
wild type animals there is always one AWCON and one AWCOFF. In tir-1 loss-of-function 
mutants, however, both neurons become AWCON, indicating that during development, 
tir-1 activity falls in the neuron that is fated to become AWCON, altering transcription of 
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str-2 (and other possible unidentified genes) (Chuang and Bargmann, 2005). Epitasis 
experiments ultimately put AWC fate under control of a calcium-dependent mitogen-
activated protein kinase (MAPK) pathway, requiring: unc-43 (calcium/calmodulin-
dependent protein kinase-II, CaMKII), tir-1, and nsy-1 (the MAPKKK apoptosis 
signaling kinase-1 (ASK1)). Interestingly, this pathway is also controlled by the 
endogenous microRNA mir-71, which acts to downregulate levels of tir-1 specifically in 
the AWCON neuron (Hsieh et al., 2012). Thus, there are two parallel pathways regulating 
tir-1 during neural development in the worm: calcium-dependent activation, and 
microRNA-dependent control of protein expression.  
 tir-1 also plays a role in serotonin-based learning and behavior in C. elegans. 
During olfactory adaptation, the serotonin biosynthesis gene tph-1 is upregulated, 
resulting in changes in calcium adaptation, and ultimately behavior, causing the worm to 
avoid certain odors (Inoue et al., 2013) or pathogens (Xie et al., 2013). Behavioral 
plasticity due to odor adaptation signals through the CaMKII-TIR-ASK1 pathway (Inoue 
et al., 2013), while pathogen avoidance plasticity signals only through CaMKII-TIR to 
activate transcription factors unrelated to AWC fate (Xie et al., 2013). Thus, tir-1 plays 
multiple roles in mediating neuronal transcription factor activation, depending on 
context, and, intriguingly, all of the roles described thus far require CaMKII activity, 
suggesting Sarm is intimately coupled to calcium-dependent events. 
 Sarm1 also plays a role in mammalian neural development. Sarm1 is partially 
regulated by Syndecan-2, a heparan sulfate proteoglycan that activates dendritic spine 
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formation during development (Chen et al., 2011). Endogenous mouse Sarm1 localizes 
in puncta through neurites and near the synaptic density marker PSD-95 (Chen et al., 
2011). Knockdown of Sarm1 in hippocampal neurons results in decreased dendritic 
length and arborization, however developmental pruning still occurs normally (Chen et 
al., 2011). Conversely, overexpression of Sarm1 results in longer dendrites; this effect is 
suppressed with a JNK inhibitor, suggesting Sarm is regulating dendritic morphology in 
a JNK-dependent manner. Notably, these cultured neurons fail to establish polarity, as 
40% never develop a dominant axon (compared to 10% in wild type cultures) (Chen et 
al., 2011). Sarm1 knockdown in vivo results in a slight reduction in brain size (10%) and 
shorter branches in cortical CA1 neurons (Chen et al., 2011). However, Sarm KO mice 
are viable and show no overt behavioral defect (Kim et al., 2007), indicating that gross 
neural function remains intact despite loss of Sarm. Extensive behavioral tests have not 
been performed on these mice however, and it remains possible that the above 
alterations in morphology may result in learning and memory defects. 
Sarm plays mixed roles in innate immunity 
 Sarm’s function in the brain was tested because mouse Sarm is expressed almost 
exclusively there; however, Sarm’s protein structure (see below) predicts that it would 
have a role in innate immunity (O'Neill et al., 2003), and as such much of the previous 
work on Sarm has been in this context. The Sarm protein product was predicted to have 
three domains: armadillo/HEAT domain (ARM), sterile alpha motif (SAM), and 
Toll/Interleukin-1 receptor homology domain (TIR) (O'Neill et al., 2003). Toll-like 
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receptors (TLRs), which recognize specific pathogens, signal through their intercellular 
TIR domain via downstream adaptor proteins, which also contain a TIR domain, to 
activate gene expression (Yamamoto and Takeda, 2010). In mammals, TLR activation 
leads to activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB), interferon regulatory factors (IRF), activator protein-1 (AP-1) and MAPKs to 
stimulate expression of pro-inflammatory genes in order to eliminate a pathogenic threat 
(Jenkins and Mansell, 2010; Yamamoto and Takeda, 2010). 
The roll of Sarm in immunity was first investigated in C. elegans. Worms have 
only two TIR-containing proteins: Tol-1, the ortholog of TLRs, and Tir-1, the Sarm 
ortholog and presumed cytosolic adaptor for Tol-1. Knockdown of tir-1 with RNAi or 
genetic ablation of tir-1 resulted in increased susceptibility to death by fungal and 
bacterial infections (Liberati et al., 2004; Couillault et al., 2004), as well as noxious 
chemical insults, such as heavy metals (Kurz et al., 2007). tir-1 mutants showed no 
major defects in development or longevity, suggesting that the role of tir-1 is involved in 
stress-induced responses (Liberati et al., 2004; Couillault et al., 2004). Interestingly, Tir-
1 signals independently of Tol-1 through a p38-MAPK pathway to activate expression of 
antimicrobial genes (Liberati et al., 2004; Couillault et al., 2004) (Kurz et al., 2007); the 
signaling complex downstream of Tol-1 remains a mystery (Fekonja et al., 2012). 
This transcriptional antimicrobial response appears to have evolutionarily 
diverged in animals that contain multiple TIR-containing adaptor proteins. Unlike in 
worms, Sarm acts as a negative regulator of antimicrobial responses in shrimp (Wang et 
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al., 2013) and Drosophila, downstream of tollo/toll-8 activation (Akhouayri et al., 2011). 
In mammals, overexpression of TIR adaptor proteins in vitro leads to activation of NF-
κB, with the notable exception of Sarm, which has no effect on this activation (Carty et 
al., 2006). Instead, Sarm appears to negatively regulate innate immune responses 
specifically through another TIR-domain containing protein, TIR-domain-containing 
adapter-inducing interferon-β (TRIF): Sarm1 knockdown increases TRIF-induced gene 
expression, while Sarm1 overexpression decreases this response in a dose-dependent 
manner (Carty et al., 2006; Peng et al., 2010; Yuan et al., 2010). Interestingly, Sarm1 
overexpression also results in a decrease of p38 activation (Peng et al., 2010).  As in 
worms, Sarm seems to interact with the MAPK pathway; unlike C. elegans, however, 
Drosophila and mammalian Sarm appear to negatively regulate innate immunity. This is 
perhaps to prevent excess inflammatory responses, which can possibly be lethal, as is the 
case with septic shock (O'Neill, 2006). Sarm transcript levels rise after infection, 
supporting this theory (Belinda et al., 2008; Peng et al., 2010). However, immune cells 
from Sarm KO mice show normal responses to a variety of insults, and the animals have 
no obvious defect in immunity (Kim et al., 2007), so there are likely other redundant 
mechanisms in place that work together to fine-tune inflammatory responses (Fekonja et 
al., 2012). 
Sarm plays an additional, unique role during melioidosis, a condition in which 
bacteria specifically infect macrophages. Macrophages, which do not normally express 
detectable levels of Sarm, upregulate Sarm within 30 minutes of infection; it appears that 
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the bacteria’s machinery has purposefully induced this Sarm expression so as to dampen 
the host’s inflammatory response. Knockdown of Sarm increases macrophage resistance 
to infection (Pudla et al., 2011), supporting Sarm’s role as a negative regulatory of innate 
immunity.  
Intracellular localization of Sarm 
 The mechanism(s) of Sarm function, whether it is in neural development, innate 
immunity, or Wallerian degeneration, may be dependent on a specific subcellular 
localization. In COS-1 and HEK-293 cells, used because human Sarm is expressed in the 
kidney (Mink et al., 2001), overexpression of Sarm::EGFP localizes to mitochondria  
(Kim et al., 2007; Panneerselvam et al., 2012); however, high expression levels cause 
mitochondria to swell into large, round clusters that center around microtubule 
organizing centers (Kim et al., 2007). Sarm expression also seems to increase stabilizing 
tubulin acetylation, even in neuronal cell lines (Chen et al., 2011), suggesting that Sarm 
may mediate mitochondrial localization relative to microtubules or microtubule stability 
directly (Kim et al., 2007). In HEK-293 cells, the first 27 amino acids of mammalian 
Sarm are responsible for the in vitro mitochondrial localization, as confirmed with 
transmission electron microscopy (Panneerselvam et al., 2012).  
In vitro localization studies have all used overexpression in kidney-derived cell 
lines, not neurons; interestingly, in vivo studies have only investigated Sarm localization 
in neurons, where Sarm has not been found to localize with mitochondria in any 
organism (Chuang and Bargmann, 2005; Chen et al., 2011; Osterloh et al., 2012). 
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Preliminary in vitro work suggests that Sarm1::GFP, when highly overexpressed in 
neuronal cultures, will eventually co-localize to mitochondria (M. Coleman, personal 
communication), suggesting that mitochondrial localization may be an artifact of cell 
culture and/or overexpression. While endogenous expression was not detectable, 
overexpression of Tir-1::EGFP in worm olfactory neurons showed a punctate 
localization in the axon, with exclusion from the dendrite and cell body (Chuang and 
Bargmann, 2005). This fusion protein co-localized with post-synaptic sites in the axon 
(Chuang and Bargmann, 2005). Chemical disruption of microtubule polymerization 
causes a tir-1 loss of function like phenotype in AWC neurons; likewise, this chemical 
disruption diminishes the activity of tir-1 gain of function mutants (Chang et al., 2011). 
Tir-1 puncta in the axon are also greatly disrupted with this treatment, suggesting that 
Sarm function and localization requires microtubule stability in this context (Chang et al., 
2011). Tir-1 localization is regulated by Unc-104, the transport motor for presynaptic 
vesicles along microtubules. Intriguingly, Unc-104 acts non-cell autonomously to 
regulate AWC fate, suggesting that some other presynaptic factor regulated by Unc-104 
is impacting Tir-1 localization and function in worms in vivo (Chang et al., 2011). 
Together, this suggests that Sarm localization, and perhaps function, involves 
interactions with microtubules, but the importance of this interaction in Wallerian 
degeneration is unknown. 
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Suggested function of Sarm domains 
Because the mechanism of action for Sarm is so mysterious, investigating the 
potential function of the individual domains of Sarm may shed some light into Sarm’s 
mode of action. Loss of the TIR or ARM domains showed normal localization of tir-
1::EGFP, while loss of the SAM domain resulted in broad axonal distribution (Chuang 
and Bargmann, 2005), suggesting that the SAM domain controls subcellular localization. 
Loss of the ARM domain resulted in a gain-of-function phenotype in AWC development 
(Chuang and Bargmann, 2005). Loss of the TIR or SAM domain generally yielded a 
non-functional molecule (Carty et al., 2006; Peng et al., 2010; Panneerselvam et al., 
2012; Panneerselvam et al., 2013). Thus, the ARM domain appears to be involved in 
auto-regulation, the SAM domain in localization, and the TIR domain in signaling. 
Possible signaling partners 
Tir-1 acts in multiple roles through a CaMKII-TIR-ASK1 pathway (Chang et al., 
2011), but there are likely more binding partners that (1) signal though Sarm and (2) 
confer downstream specificity. Overexpression of Sarm in COS-1 cells pulls JNK3 from 
its normally cytoplasmic distribution to mitochondrial clusters (Kim et al., 2007), further 
supporting a role for Sarm in MAPK signaling. A yeast two hybrid screen on individual 
domains of horse shoe crab Sarm found four interactors with the TIR domain (HAX-1, 
involved in apoptosis regulation; SUMO-1, involved in sumoylation; Proteosome 
Subunit α; and DnaJ/Hsp40, a chaperone) and one with the SAM domain (CaMKI) 
(Belinda et al., 2008), but the importance of these interactions, if they are indeed real, is 
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unknown in any context. Overexpression of a constitutively active CaMKI with Sarm1 
and TRIF increased Sarm’s inhibitory effect on TRIF-signaling (Belinda et al., 2008), 
suggesting that Sarm’s activity may be regulated by a calcium-dependent protein kinase. 
Coaffinity purification from Drosophila cells yielded over 40 potential binding partners 
for dSarm (Guruharsha et al., 2011). Together, these data indicate that Sarm may have 
multiple binding partners, depending on the experimental context, and it remains unclear 
which if any are involved in Wallerian degeneration. However, these data are consistent 
with Sarm acting as a kinase scaffold, potentially bringing together calcium-activated 
kinases with their downstream effectors to induce Wallerian degeneration. 
Immunoprecipation experiments with domains of Tir-1 support this hypothesis, as the 
ARM domain specifically interacts with the calcium activated CaMKII and the TIR 
domain interacts with the kinase ASK1 (Chuang and Bargmann, 2005). 
Sarm and cell death 
 Wallerian degeneration is not cell death, and Sarm KO mice have defects in 
Wallerian degeneration but not developmental cell death (Osterloh et al., 2012). 
However, new mechanisms of caspase-independent cell death are beginning to emerge, 
and Sarm may play a role in this process. C. elegans linker cell death, which is 
developmental but caspase independent, is blocked in tir-1 mutants (Blum et al., 2012). 
tir-1 mutants also show an increase in survival under anoxic, but not hypoxic conditions; 
this survival is mediated by MAPK signaling but not p38 nor JNK (Hayakawa et al., 
2011). In mice, Sarm KOs are protected from oxygen-glucose-deprivation (OGD)-
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induced cell death, a hypoxia model, at twice the rate of wild type animals (Kim et al., 
2007).  Thus, Sarm appears to function normally to promote neurodegeneration. 
Interestingly, this function also extends to infected neurons, where Sarm-mediated axon 
destruction prevents pathogenic spread. During West Nile Virus (WNV) infection, 
which broadly affects neurons, Sarm1 KO mice are twice as succeptable to death after 
WNV infection, despite comparable viral loads and normal T and B cell responses 
(Szretter et al., 2009). This suggests that the ability to promote axon destruction may 
actually be advantageous in some situations, as it may allow an infected neuron to 
destroy contaminated processes to prevent further viral spreading between neurons. How 
or why a pathway that responds to viral attacks also responds to physical injury is 
unclear, but suggests a common link between axon degeneration and innate immunity. 
 A role for Sarm in mediating stress-induced cell death appears to be coupled with 
levels of Sarm protein.  Overexpression of full length Sarm induces death, without any 
upstream signal, in ~25% of cultured HEK cells (Panneerselvam et al., 2012). This death 
appears dependent on that 1-27aa stretch that confers mitochondrial localization in 
kidney cells (Panneerselvam et al., 2012). When Sarm is expressed in primary T cells, 
over 80% of the cells undergo classical apoptosis, resulting in sequential activation of 
caspase -9, then -3, then -8 (Panneerselvam et al., 2013). Sarm overexpression also 
induces a decrease in mitochondrial membrane potential and an increase in ROS 
(Panneerselvam et al., 2013). In these cells, this apoptosis could be partially blocked by 
overexpression of the anti-apoptotic gene bcl-xl and enhanced by addition of a MAPK 
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inhibitor (Panneerselvam et al., 2013). Knock down of Sarm in T-cells leads to increases 
in survival and proliferation, supporting the role for Sarm in moderating and negatively 
regulating immune responses (Panneerselvam et al., 2013). Together, this suggests that 
Sarm functions in regulating stress-induced cell death, possibly by mediating 
interactions between kinases.  Notably, in COS-1 cells, where overexpression of Sarm 
causes mitochondrial clumping and JNK redistribution, no activation of cell death has 
been reported. Thus, Sarm appears to play many cellular roles under a variety of 
circumstances, highlighting the importance of studying Sarm’s mechanism of action 
within the specific context of Wallerian degeneration. 
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Figure 1-1. Progression of Wallerian 
degeneration in wild type nerves 
Healthy axons (top) maintain an intact 
cytoskeleton comprised of 
neurofilaments (red) and microtubules 
(green). Examples of changes during 
Wallerian degeneration are presented: 
AAD (second from top), the latency 
phase (middle), and GDC (bottom two). 
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Figure 1-2. Proposed mechanism of 
Wlds—mediated protection of severed 
axons from Wallerian degeneration 
Recent evidence suggest that 
mitochondria from Wlds-expressing 
animals are able to buffer larger 
concentrations of calcium than their wild 
type counterparts (Avery et al., 2012), 
blocking the following processes: 
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CHAPTER II: dSarm/Sarm1 is required for activation of an injury-induced axon 
death pathway 
 
 
 
 
 
The following work is the final author manuscript; all supplemental figures have 
been incorporated into the manuscript and all figures subsequently renumbered and 
reformatted. This work appears in the Science article of the same name, published as: 
 
Osterloh JM, Yang J, Rooney TM, Fox AN, Adalbert R, Powell EH, Sheehan AE, 
Avery MA, Hackett R, Logan MA, MacDonald JM, Ziegenfuss JS, Milde S, Hou YJ, 
Nathan C, Ding A, Brown RH Jr, Conforti L, Coleman M, Tessier-Lavigne M, Zuchner 
S, Freeman MR. (2012). Science 337, 481-484. 
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Drosophila work, with the exception of: the pruning and tdc neuron experiments, which 
were performed by Tim Rooney; and the mRNA in situ and L1 dMP2 experiments, 
which were performed by Nicki Fox. Michelle Avery counted the axons in Table 2-2. 
Amy Sheehan cloned dSarm.  Mammalian primary culture experiments were performed 
by Jing Yang, in the laboratory of Marc Tessier-Levigne, with the exception of the SGC 
explants. Ying-Ju Hou, Carl Nathan, and Aihao Ding provided primary cultures for Marc 
Tessier-Lavigne’s group. For Sarm1 -/- experiments, I dissected the SGCs, which were 
subsequently injured and imaged by Robert Adalbert in the laboratory of Michael 
Coleman. Wlds SCG experiments were performed by Laura Conforti, and Steven Milde 
stained wild type nerves for Sarm localization, both in the laboratory of Michael 
Coleman. I performed all animal handling, surgeries and dissections; Robert Adalbert 
performed the sciatic nerve preparation and imaging for EM; Jing Yang performed the 
immunohistochemistry. Eric Powell was responsible for the Drosophila sequencing in 
the laboratory of Stephan Zuchner.  
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Abstract 
Axonal and synaptic degeneration is a hallmark of peripheral neuropathy, brain injury, 
and neurodegenerative disease. Axonal degeneration has been proposed to be mediated 
by an active auto-destruction program, akin to apoptotic cell death; however, loss-of-
function mutations capable of potently blocking axon self-destruction have not been 
described. Here, we show that loss of the Drosophila Toll receptor adaptor dSarm (sterile 
α/Armadillo/Toll-Interleukin receptor homology domain protein) cell-autonomously 
suppresses Wallerian degeneration for weeks after axotomy. Severed mouse Sarm1 null 
axons exhibit remarkable long-term survival both in vivo and in vitro, indicating that 
Sarm1 prodegenerative signaling is conserved in mammals. Our results provide direct 
evidence that axons actively promote their own destruction after injury and identify 
dSarm/Sarm1 as a member of an ancient axon death signaling pathway. 
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Results and Discussion 
Axons have traditionally been thought to be strictly dependent upon the cell body for 
survival, as axons robustly degenerate upon separation from the soma (Waller, 1850). 
However, this notion was directly challenged by the identification of the slow Wallerian 
degeneration (Wlds) mutant mouse in which the distal portion of severed axons remained 
morphologically intact for 2-3 weeks after axotomy (Lunn et al., 1989; Glass et al., 
1993). The remarkable long-term survival of severed axons in the WldS mouse also 
raised the intriguing possibility that Wallerian degeneration is driven by an active 
molecular program akin to apoptotic cell death signaling (Raff et al., 2002; Coleman and 
Perry, 2002). However numerous studies have demonstrated that WldS is a gain-of-
function mutation that results in the neuronal overexpression of a chimeric fusion protein 
containing the NAD+ biosynthetic enzyme Nmnat1 (Mack et al., 2001; Coleman and 
Freeman, 2010).  As such, the WldS phenotype may be unrelated to normal Nmnat1 
function and NAD+ metabolism, despite its ability to inhibit endogenous axon death 
pathways.  Wallerian degeneration appears to be molecularly distinct from apoptosis 
since potent genetic or chemical inhibitors of cell death (Deckwerth and Johnson, 1994; 
Finn et al., 2000; Whitmore et al., 2003) or the ubiquitin proteasome pathway ; Hoopfer 
et al., 2006, Neuron, 50, 883-95} do not block Wallerian degeneration.  Mutants 
reported to affect Wallerian degeneration, such as wnd/DLK, delay the clearance of 
degenerating axons in Drosophila for only ~1-2 days, and mouse axons for several hours 
(Miller et al., 2009) – an extremely weak degree of suppression when compared to WldS. 
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Thus the existence of axon death pathways has remained only speculative. 
If Wallerian degeneration is indeed an active process, we reasoned that loss of 
function mutants that exhibit Wlds-like protection of severed axons should exist.  We 
first revisited the question of whether Wallerian degeneration might be related to 
previously described cell destruction programs.  We performed a comprehensive screen 
of existing mutants and dominant negative constructs for Drosophila genes affecting 
apoptosis, autophagy, or other defined cell degradative pathways, but these failed to 
suppress Wallerian degeneration in vivo at any level (Table 2-1).  
To identify novel genes required to promote Wallerian degeneration, we 
performed a F2 forward genetic screen for mutants that exhibited long-term survival of 
distal severed axons (Figure 2-1).  Because genes required for Wallerian degeneration 
may cause lethality when mutated, we designed our screen to allow for characterization 
of both viable and lethal mutants though MARCM clonal analysis (Lee and Luo, 1999).  
In control animals, severed olfactory receptor neuron (ORN) axons degenerated and 
were completely cleared from the right antennal lobe 7 days after axotomy.  We 
identified three lines, l(3)896, l(3)4621, and l(3)4705, where severed homozygous 
mutant axons generated by MARCM remained fully intact 1 week after axotomy (Figure 
2-2A).  While the number of uninjured axons is slightly reduced in each mutant, 100% 
of GFP-labeled axons exhibited long-term preservation after injury (Table 2-2).  
Remarkably, mutant axons remained fully intact 30 days after injury (Figure 2-2B) and a 
significant but reduced number remained morphologically intact even 50 days after 
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injury (Figure 2-2C).  l(3)896, l(3)4621, and l(3)4705 therefore provide axonal 
preservation that rivals that of Wlds in Drosophila, and which lasts essentially for the 
lifespan of the fly.  Neuroprotection in these mutants extended to synapses: 
synaptobrevin punctae localized to synaptic terminals even 30 days after axotomy 
(Figure 2-2D,E). 
All three mutants are lethal and recessive in their axon degeneration phenotype 
(Figure 2-3A), and each failed to complement one another for lethality; thus each line 
represented an independently isolated lethal mutation in the same gene.  Neuronal 
morphology appears normal in mutant animals (Figure 2-2; Figure 2-3B), indicating 
these mutations do not grossly affect neuronal development.  
Previous work (Finn et al., 2000; Whitmore et al., 2003; Hoopfer et al., 2006) 
and the above data argue that Wallerian degeneration is molecularly distinct from 
apoptosis and developmental neurite pruning.  We next asked whether l(3)896 is broadly 
required for neuron pruning or apoptotic cell death.  We examined MARCM clones in 
Drosophila mushroom body (MB) γ neurons, as these neurons undergo both dendritic 
and axonal pruning during metamorphosis (Luo and O'Leary, 2005). In both control and 
l(3)896 animals, mushroom body γ neuron axons and dendrites were pruned normally 
(Figure 2-4A).  During early embryogenesis, dMP2 neurons are present in each segment, 
but by late embryogenesis, all but the posterior 3 pairs undergo developmentally-
programmed apoptosis (Miguel-Aliaga et al., 2008).  We found that dMP2 neurons were 
generated normally in l(3)4621 animals, and the appropriate subset of neurons 
 45 
underwent apoptosis (Figure 2-4B). Finally, we expressed the pro-apoptotic gene hid in 
the Drosophila visual system (Grether et al., 1995) to induce widespread apoptotic death 
in cells of the developing eye disc.  We found that l(3)896 mutant clones failed to 
suppress activation of cell death (Figure 2-4C,D).   
To identify the gene mutated in l(3)896, l(3)4621, and l(3)4705, we took two 
complementary approaches.  First, we mapped the lethality of each mutant using small 
chromosome deficiencies, and identified a single gene at cytogenetic region 66B (Figure 
2-5A).  At the same time we utilized next-generation sequencing technology to re-
sequence the entire genome of each mutant (along with our unmutagenized control line) 
to an average read depth of 70x (Table 2-3).  We identified a single gene affected in all 
three mutants, which resided in cytogenetic region 66B: ect4, which we refer to as dsarm 
(Drosophila sterile alpha and Armadillo motif).  The dsarm gene encodes a protein with 
an Armadillo/HEAT (ARM) domain, two sterile alpha motifs (SAM), and a 
Toll/Interleukin-1 Receptor homology (TIR) domain. Each identified dsarm allele 
contained a unique premature stop codon in dsarm open reading frame (Figure 2-5B,C). 
From these data we conclude that l(3)896, l(3)4621, and l(3)4705 are loss-of-function 
alleles of dsarm.  Consistent with this interpretation, expression of full length dsarm 
cDNA using the postmitotic OR22a-Gal4 driver in l(3)896 mutant clones was sufficient 
to fully revert the suppression of axonal degeneration observed in dsarm mutants (Figure 
2-5D).  In addition, we rescued both the lethality and suppression of Wallerian 
degeneration phenotypes of l(3)896/l(3)4621 and l(3)896/Df(3L)BSC795 trans-
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heterozygous animals with a BAC clone containing the dsarm gene (Figure 2-5D).  
Together these data indicate that dsarm is necessary in post-mitotic neurons for axonal 
destruction after axotomy, and loss of dsarm function is sufficient to provide long-term 
preservation of severed axons.   
Based on RNA in situ hyridizations to embryos, larval brains, and adult brains, 
RT-PCR from dissected neural tissues, and analysis of a dsarm-Gal4 driver line, dsarm 
appears to be widely expressed in the Drosophila nervous system (Figure 2-6).  This 
observation suggests that dSarm is broadly required to promote Wallerian degeneration 
in the nervous system.  
We next assayed Wallerian degeneration in null mutants for the mouse ortholog 
of dsarm, Sarm1.  We first grew 5 day cultures of superior cervical ganglia (SCG) from 
wild type, Sarm1 -/- , and Wlds mice, severed axons, and scored axonal integrity over the 
next week.  Sarm1 -/- SCG explants exhibited robust protection from degeneration up to 
72 hours after axotomy, similar to what is observed with WldS SCG neurons, while wild 
type axons degenerated within 8 hours (Figure 2-7). This robust protection was also seen 
in cultured Sarm1 -/- cortical neuron axons (Figure 2-8A,B) and dorsal root ganglia 
(DRG) (Figure 2-8C,D).  Notably, Sarm1 -/- DRG explants were not protected from 
nerve growth factor (NGF) deprivation (Figure 2-9), a mouse model for developmental 
axon pruning (Raff et al., 2002; Luo and O'Leary, 2005; MacInnis and Campenot, 2005; 
Buss et al., 2006), suggesting that in mammals Sarm1 protection is specific to injury-
induced axon degeneration. Thus Sarm1 loss of function robustly suppresses Wallerian 
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degeneration in multiple types of mammalian axons in vitro.  In addition, based on our 
highly selective growth conditions, our data argue that Sarm1 is required cell 
autonomously for programmed axonal death. 
To test whether Sarm1 is required in vivo for Wallerian degeneration we 
performed sciatic nerve lesions of the right hind limb of Sarm1 -/- mice and their 
heterozygous littermate controls.  Impressively, while Sarm1 +/- controls exhibited a 
dramatic breakdown of the axon and myelin sheath within 3 days of injury, 61.2% of 
lesioned Sarm1 -/- axons were protected from degeneration at least 14 days after injury 
(p = 0.002) (Figure 2-10).  Analysis of sciatic nerve ultrastructure revealed a remarkable 
structural preservation at 14 days after axotomy of the Schwann cell and myelin sheath, 
axonal neurofilaments, and axonal mitochondria (Figure 2-10).  We performed Western 
blots of sciatic nerve and probed them with antibodies to neurofilament-M (NF-M), α-
Internexin, and β-tubulin class III (TUJI).  While we observed a dramatic breakdown of 
these proteins in wild type nerves, they remained largely intact in Sarm1 -/- axons 
(Figure 2-11A).  We also observed preservation of the NF-M signal by 
immunofluorescent staining of the nerve in Sarm1 mutants (Figure 2-11B,C). 
We next examined neuromuscular junctions (NMJs) in tibialis anterior muscles 
after sciatic nerve transection.  Synaptic integrity was scored by co-localization of 
presynaptic marker (NF-M/synaptophysin) with the post-synaptic acetylcholine receptor 
(AChR).  In wild type animals, motor endplate denervation was complete by 2 days after 
axotomy.  However in Sarm1 -/- animals, the majority of synaptic of terminals were 
 48 
partially innervated even at 6 days after injury (Figure 2-12).  We also note that 
macrophage/monocyte infiltration of lesioned nerves was suppressed in Sarm1 knockout 
animals (Figure 2-13). Taken together, our results indicate that Sarm1-/- mutations 
provide a dramatic preservation of sciatic nerves in vivo from initial axonal cytoskeletal 
breakdown to recruitment of macrophages for myelin clearance.  
Finally, we assayed in vivo localization of dSarm and Sarm1.  Expression of 
dSarm::GFP in larval neurons resulted in punctate localization in neuronal cell bodies, 
and broad localization to neurites (Figure 2-14).  Similarly, stains with anti-Sarm1 
antibodies to in vitro cultured mammalian neurons showed a broad, punctate pattern in 
neurites, and we note that endogenous Sarm1 did not show preferential localization with 
a mitochondrial marker (Figure 2-14). 
Molecular pathways that mediate axon self-destruction have long been elusive. 
Our identification of dsarm/Sarm1 provides direct evidence that Wallerian degeneration 
is driven by an ancient, conserved axonal death program.  How is dSarm activated after 
axotomy?  Influx of extracellular calcium is known to be necessary and sufficient to 
trigger Wallerian degeneration (George et al., 1995).  Intriguingly, Tir-1 functions 
downstream of the Ca2+-CaM kinase signaling cascade in C. elegans (Chuang and 
Bargmann, 2005; Chang et al., 2011), therefore dSarm/Sarm1 may respond directly to 
axonal calcium increases after axotomy.  Intriguingly, Sarm1-/- neurons in slice cultures 
have been found to exhibit reduced cell death in response to oxygen/glucose deprivation 
(OGD) (Kim et al., 2007), whether this is an indirect result of axonal preservation 
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remains untested, but is an exciting possibility. Pharmacological inhibition of Sarm1 
now represents a promising therapeutic avenue for patients with axonal loss, particularly 
if Sarm1 deletion is shown to benefit animal models of neurodegenerative disease.  
Based on the functional conservation we report for dSarm/Sarm1, it seems likely that 
similar forward genetic screens in invertebrates will uncover additional proteins that 
potently influence axon survival in mammals. 
Materials and Methods 
Drosophila stocks, transgenics, and injury protocol 
The following Drosophila strains were used in this study: OR22a-Gal4; dMP2-Gal4 
(Miguel-Aliaga et al., 2008); pUAST-mCD8::GFP; pUAST-nSynaptobrevin::GFP; 201y-
Gal4; FRT2A/FRT82B; GMR-hid; Ubi-GFP::nls; FRT2A, tub-Gal80; ey-flp; usp2 
(Tp(3;1)KA21); Ect4-Gal4 (Drosophila Genetic Resource Center); and the 3(L) 
Deficiency Kit (all from Bloomington Stock Center unless noted). Mutants listed in 
Supplementary Table 2-1 are all from Bloomington Stock Center or generous gifts from: 
E. Baehrecke; E. Arama; R. Tanguay; M. Guo; N. Tapon; and K. McCall. Lethal 
mutants were recombined onto a chromosome harboring a flippase recognition target 
(FRT) sequence and screened using MARCM clonal analysis with ey-flp. To establish 
mutant stocks for screening, we used the mutagen ethyl methane sulfonate (EMS) and 
established ~2000 individual third chromosome F2 mutant stocks containing FRT sites 
on both chromosomal arms (2A and 82B). We induced antennal injury using a 
modification of a previously described protocol (MacDonald et al., 2006). Adult flies 
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were aged for 7 days at 25°C after ablating the right third antennal segment only. Both 
antennae were ablated for synaptic preservation studies, as ORNs from each antenna 
synapse on both glomeruli. Injured flies were aged at 25°C for the indicated time (7, 30, 
or 50 days) before dissecting and fixing the brain. Axonal integrity was scored as 
previously described (MacDonald et al., 2006; Avery et al., 2009). 
Cloning  
The first 630-4828 nucleotides of the partial dsarm cDNA GH07037 (DGRC) was 
cloned into the pCashsp40-LacZ vector with BglII/XhoI. The remaining sequence was 
obtained by PCR amplifying a fragment from cDNA IP03452 (DGRC) using 5’ECT4-D 
NotI (ATATATATGCGGCCGCAAAACATGGGCAATCGTTTGAGCGGC) and 
PM001 (CGTTAGAACGCGGCTACAAT), then cut with NotI/BglII and ligated into 
the pCashsp40-LacZ vector.  The resulting full length dsarm was then PCR amplified off 
the pCashsp40-LacZ vector using the above 5’ECT4-D NotI and 3’ Ect4-D aa1610-1637 
(AGATACTCGAGTTACCAAAATATCATGCGCCCGGCATTGGGGGAGGTGGCC
TTGGACAGAATGATGCCCGAAAGTTCCTCGTCCTCCATTTCGTTGTTTTTTAT
CAGCGAGCGGACCTTCTTCATCG), cut with NotI/XhoI, and ligated into pUAST 
vector (generating pUASt-dsarm).  pUASt-dsarm::GFP was generated by cloning into 
the NotI/SpeI sites of pUASt-CT EGFP with PCR-amplification off the pUASt-dsarm 
construct using 5’ECT4-D NotI and 3’ ECT4-D SpeI 
(GATCACTAGTCCAAAATATCATGCGCCCGGCATTGG). 
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The mito-tagRFP construct was created by PCR amplification of the 
mitochondrial targeting sequence (aa 1-24) of Mus musculus cytochrome c oxidase 
subunit VIIIb (GenBank AK003116) and insertion into the MCS of the pTagRFP-N 
vector (Evrogen). 
Drosophila immunohistochemistry 
Eye-imaginal discs from third instar larvae were dissected and TUNEL stained using In 
Situ Cell Death Detection Kit (Roche) as previous described (Klein, 2008). Embryos 
expressing dMP2-Gal4, UAS-mCD8::GFP were fixed as previously described (Miguel-
Aliaga et al., 2008). 1st instar larvae expressing dMP2-Gal4, UAS-mCD8::GFP were 
imaged live.  Whole brains from either pre-pupae or pupae 18 hrs APF were dissected 
and staining with anti-FasII as described (Lee and Luo, 2001). Embryos from yw or 
mutant stocks were fixed and staining with anti-FasII as preciously described (Lee and 
Luo, 2001).  Fas II antibody was used at a 1:10 dilution (Developmental Studies 
Hybridoma Bank).  For dsarm rescue experiments, 22aGal4 was recombined with UAS-
dsarm using standard fly techniques, and MARCM clones were generated using a line 
containing ey-flp, UAS-mCD8::GFP.  Tdc-Gal4 neurons were imaged using a live fillet 
preparation (Ataman et al., 2008). Secondary antibodies were obtained from Jackson 
Immunolabs and used at 1:200.   
Drosophila confocal microscopy 
Samples were mounted in Vectashield antifade reagent and viewed on a III Everest 
Spinning disk confocal microscope.  The entire antennal lobe was imaged in 0.27 μm 
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steps for each sample for scoring axonal integrity. TUNEL-stained eye-imaginal discs 
were imaged on a Zeiss LSM5 Pascal confocal microscope. 
Drosophila sequencing 
We utilized next-generation sequencing technology to re-sequence the entire genome of 
each mutant (along with our unmutagenized control line) to an average read depth of 70x.  
We identified between ~92,000 and ~140,000 variants, with ~14,000 to ~20,000 of these 
being non-synonymous or splice site changes genome wide.  By filtering these variants 
for unique and coding changing lesions, only six genes were shared genome-wide among 
all three mutants (Supplementary Table 2-3). Since we sequenced heterozygous adult 
animals, we then narrowed these criteria to heterozygous and non-synonymous or splice 
site changes on chromosome 3L. 
Additional details regarding this genome-wide resequencing can be found here:  
Gonzalez MA, Van Booven D, Hulme W, Ulloa RH, Lebrigio RFA, Osterloh J, Logan 
M, Freeman M, Zuchner S. Whole Genome Sequencing and a New Bioinformatics 
Platform Allow for Rapid Gene Identification in D. melanogaster EMS Screens. Biology. 
2012; 1(3):766-777. 
 
Drosophila in situs 
Standard methods were used for collection, fixation, and immunohistochemistry 
of Drosophila yw animals. dSARM cDNA corresponding to exon 5 in dsarm transcript 
RD was PCR-cloned into pCRII (Invitrogen). Digoxigenin-labeled RNA probes were 
generated according to the manufacturer's instructions (Roche). RNA in situ 
hybridization to embryos was carried out as described previously (Broadus et al., 1998). 
Third-instar larvae were decapitated in 1× PBS and fixed in 9% formaldehyde in PBS for 
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45 mins.  Larval heads were hybridized in hybridization buffer (50% formamide, 5X 
SSC, 5X Denhardts, 250 ug/ml yeast tRNA, 500 ug/ml herring sperm DNA, 50 ug/ml 
heparin, 2.5 mM EDTA, and 0.1% Tween-20). Adult heads were decapitated on CO2 and 
transferred to plastic embedding molds containing Tissue-Tek OCT. The samples were 
frozen on dry ice, and 15 μm frozen sections were processed for in situ hybridization as 
previously described (Vosshall et al., 1999), with digoxigenin-labeled riboprobes and  
detected with TSA-Plus Fluorescein System (Perkin Elmer).  Anti-digoxigenin-POD was 
diluted 1:500 (Roche). 
Antibodies and reagents for mammalian studies 
Antibodies used in this study were: mouse monoclonal anti-Tau-1 (clone PC1C6, 
#MAB3420), and rabbit anti-neurofilament-M (#AB1987) from Millipore; rabbit 
monoclonal anti-b-tubulin class III (#MRB-435P), and rabbit anti-a-internexin (#PRB-
572C) from Covance; mouse monoclonal anti-b-actin (clone AC-15, #A5441) from 
Sigma; rat monoclonal anti-CD11b (clone M1/70.15, #MCA74EL) from AbD Serotec; 
rabbit anti-synaptophysin (#08-0130) from Invitrogen. Monoclonal neutralizing antibody 
against mouse NGF was previously described (Nikolaev et al., 2009). Secondary 
detecting antibodies conjugated with indicated Alexa dyes, and Alexa-594 conjugated a-
bungarotoxin were from Invitrogen. Goat serum, donkey serum, and horseradish-
peroxidase conjugated donkey anti-rabbit IgG and donkey anti-mouse IgG were from 
Jackson ImmunoResearch. All other chemicals were from Sigma unless otherwise 
specified. 
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Neuronal cultures 
SCG explants were dissected from 0-2 day old pups and cultured as previously described 
(Gilley and Coleman, 2010). Axons were allowed to extend for 5 days before separation 
from the cell body mass using a scalpel. The degeneration of the isolated axons was 
followed at different time points for 72 h after cut. Bright field images were acquired on 
a microscope (IX8I; Olympus) coupled to a digital camera (U-TV 0.5XC; Olympus) 
using AnalySIS software (Soft Imaging Systems GmbH, Germany). Axonal protection 
was quantified as described (Gilley and Coleman, 2010). Typically an image of intact 
axons has a protection index (PI) value around 1. A PI around 0 occurs when axons 
detach from the dish. A two-way repeated measures analysis of variance (ANOVA) was 
used to show the difference in axonal protection between wild-type and Sarm-/-. For 
dissociated SCG cultures, cells were microinjected as previously described (Gilley and 
Coleman, 2010) with 50ng/µμl of mito-tagRFP construct. 24 hours after microinjection 
cultures were immunostained using 0.3µg/ml mouse monoclonal anti-SARMI antibody 
(Chen et al., 2011) and Alexa-488 secondary antibody. Cultures were visualized on an 
Olympus FV1000 point scanning confocal microscope using a 60x 1.35NA apochromat 
objective. 
For cortical neuron cultures, Campenot dividers (Tyler Research) were set up in 
poly-D-lysine/laminin-coated 2-well chamber culture slides. On DIV 0 (Day In Vitro 0), 
neocortices were dissected from six E16.5 Sarm1 +/+ or Sarm1 -/- embryos, pooled, and 
dissociated in Hank's Balanced Salt Solution (withouth Ca2+ and Mg2+, Invitrogen) 
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containing 0.05 % (w/v) trypsin / EDTA at 37oC for 10 min. After adding a final 
concentration of 10 % (v/v) heat-inactivated fetal bovine serum (HI-FBS), the tissues 
were spun down at 500 g for 3 min. The tissues were then suspended and triturated in 
Neurobasal / B-27 medium [Neurobasal medium supplemented with 2 % (v/v) B-27, 2 
mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin] containing 10 % HI-
FBS. The cells were plated in the cell-body compartment of Campenot dividers at a 
density of 2.5 x 105 per well. To facilitate the axotomy later, Campenot dividers were 
removed after 6 hours, when the cells already attached to the slides. From DIV 3, half of 
the culture medium was replaced every other day by fresh Neurobasal / B-27 medium 
containing 5 mM 5'-flourouridine and 5 mM uridine to suppress the proliferation of non-
neuronal cells. On DIV 10, the cultures were subjected to axotomy.  
 For the dorsal root ganglion (DRG) cultures, DRGs were dissected from four 
E13.5 Sarm1 +/+ or Sarm1 -/- embryos on DIV 0. The explants from each embryo were 
individually plated in poly-D-lysine / laminin-coated 4-well chamber culture slides in F-
12 / N-3 medium [Ham's F-12 medium supplemented with 40 mM glucose, 4 % (v/v) N-
3 supplement, and 50 ng/ml mouse NGF]. On DIV 1, the cultures were changed to fresh 
F-12 / N-3 medium containing 1 μM cytosine β-D-arabinofuranoside to suppress the 
proliferation of non-neuronal cells. On DIV 3, the explants were subjected to either the 
axotomy, or the NGF deprivation with a final concentration of 50 mg/ml anti-NGF 
antibody. 
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 To visualize the axons, the cultures were fixed in 4 % paraformaldehyde (w/v)/ 
phosphate-buffered saline (PBS) at room temperature for 30 min, followed by the 
permeabilization with 0.1% (v/v) Triton X-100 / PBS for 30 min. The axons were then 
immunostained with the indicated primary antibodies in 0.1% Triton X-100 / PBS 
containing 2 % (w/v) bovine serum albumin, and 2 % (v/v) goat serum at 4oC overnight, 
followed by the corresponding Alexa-488 or Alexa-568 conjugated secondary antibodies. 
To quantify axon degeneration, the images of distal axons were taken from 2 random 
fields per well, and 40 to 80 singly distinguishable axons in each field were examined, 
with any sign of fragmentation scored as degeneration. For each time point, 4 wells of 
Sarm1 +/+ or Sarm1 -/- cortical neuron cultures, or the DRG explants from 4 embryos 
of Sarm1 +/+ or Sarm1 -/-, were included. 
Mouse surgery and immunohistochemistry 
All surgical and experimental procedures in mice were performed in compliance with 
the protocols approved by the Institutional Animal Care and Use Committee of The 
Rockefeller University, Cornell Weill Medical College, and The University of 
Massachusetts Medical School.  Mice were anesthetized with isoflurane, and the skin on 
their right hind limb was shaved and prepared with iodine and alcohol. An incision was 
made between the knee and the hip joint, and the gluteal muscles were separated 
carefully with a pair of forceps. The sciatic nerve was transected as close to the thigh 
with a pair of sterile surgical scissors, and 1- to 2-mm of nerve segment was removed to 
prevent the regeneration of axons into the distal stump. The gluteal muscles were then 
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brought back into their original anatomical position, and the overlying skin was re-
approximated by surgical staples or sutures.  
 For light microscopy, the animals were euthanized at indicated time points post-
surgery and nerve segments 3-6 mm distal to the lesion fixed with 4% paraformaldehyde 
and 2.5% glutaraldehyde in 0.1 M PBS, pH 7.4 (72h at 4ºC). After an extensive wash in 
0.1 M PBS, 2 h of postfixation (1% osmium tetroxide) and dehydration in graded 
ethanol and propylene oxide, nerve segments were embedded in Durcupan resin (Fluka 
Chemie). After polymerization for 48 h at 60ºC, transverse semithin sections (0.5µm) 
were cut on a Leica ultramicrotome, stained with toluidine blue and photomicrographed. 
To quantify survival, 500 randomly chosen axons were counted. Survival criteria were 
normal myelin sheaths, uniform axoplasm and intact, unswollen mitochondria. A two-
tailed one sample t-test was performed using GraphPad Prism 5.  
 For the biochemical analysis of sciatic nerves, the animals were euthanized at 
indicated time points post-surgery. A 10-mm segment of the nerve distal to the 
transection site was harvested, and immediately homogenized in 200 ml Urea / SDS 
buffer [50 mM Tris-Cl (pH 6.8), 8.0 M urea, 10 % (w/v) SDS, 10 mM sodium EDTA, 
and 50 mM DTT]. The nerve samples from two Sarm1 +/+ or Sarm1 -/- mice were 
processed for each time point. After heating at 95oC for 10 min, 10-ml aliquot of each 
nerve homogenate was subjected to 4 - 15 % gradient Tris-glycine SDS-PAGE (Bio-
Rad), and transferred to Immobilon-P PVDF membranes (Millipore) for immunoblot 
analysis. The membranes were immunoblotted with the indicated primary antibodies, 
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and then the corresponding secondary antibodies in PBS/Tween-20. The bound 
antibodies were visualized by SuperSignal chemiluminescence reagents (Pierce). All 
membranes were exposed to Phoenix Blue X-ray film for 5 to 10 sec. 
 For immunohistochemistry, the mice were lethally anesthetized at the indicated 
time points post-surgery, and transcardially perfused with 4 % paraformaldehyde/PBS. 
The sciatic nerves distal to the transection site was dissected, and post-fixed in 4 % 
paraformaldehyde/PBS at 4oC overnight. After washing three times in PBS, the nerves 
were cryoprotected in 30 % (w/v) sucrose / PBS at 4oC overnight, and then frozen in the 
2:1 mixture of 30 % sucrose/PBS:OCT (Tissue Tek) for 12-mm longitudinal 
cryosections. The nerves were permeabilized in 0.5 % Triton X-100 / PBS for 1 hour, 
and blocked in 0.5 % Triton X-100/PBS containing 2 % bovine serum albumin, and 4 % 
goat serum at 4oC overnight.  Immunohistochemistry was carried out with either rabbit 
anti-neurofilament-M (1:500) or rat anti-CD11b (1:500) in the same blocking buffer at 
4oC overnight, followed by washing for 1 hour in 0.5 % Triton X-100/PBS three times. 
The sections were then labeled with the corresponding Alexa-488 or Alexa-568 
conjugated secondary antibodies for 2 hours, washed in PBS, and mounted in 
fluoromount-G. Images were taken at 2-mm distal to the transection sites, and 3 
nonadjacent sections of each nerve sample were examined. Four (neurofilament-M 
axons) or three (CD11b macrophages / monocytes) mice of Sarm1+/+ or Sarm1-/- were 
included per time point. 
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 To examine denervation at neuromuscular junctions, the tibialis anterior muscles 
were dissected from perfused animals, and post-fixed in 1% paraformaldehyde/PBS at 
4oC overnight. After washing three times in PBS, muscles were cryoprotected in 30% 
sucrose/PBS at 4oC overnight, and embedded in OCT for 80-mm longitudinal 
cryosections. The tissues were permeabilized in 0.5 % Triton X-100/PBS for 1 hour, and 
blocked in 1% Triton X-100/PBS containing 4% bovine serum albumin, and 4% donkey 
serum at 4oC overnight. To label axons and neuromuscular junctions, muscles were 
stained with rabbit anti-neurofilament-M (1:500) and rabbit anti-synaptophysin (1:5) in 
the same blocking buffer at 4oC for at least 24 hours. After washing for 1 hour in 0.5% 
Triton X-100/PBS three times, the muscles were incubated with Alexa-647 conjugated 
donkey anti-rabbit antibody (1:500) and Alexa-594 conjugated a-bungarotoxin (1:1000) 
overnight. After washing in PBS for 4 hours, sections were mounted in fluoromount-G, 
and imaged by LSM 510 laser scanning confocal microscope. To analyze presynaptic 
structures, maximum-intensity projections of z-stack images from 6 to 8 nonadjacent 
sections of each muscle sample were generated by AutoQuant X. Partial or full 
denervation was determined as the postsynaptic AChR sites not apposed by the 
presynaptic marker (colored in green for better visualization). About 100 neuromuscular 
junctions were examined for each muscle, and four Sarm1 +/+ or Sarm1 -/- mice were 
included per time point. 
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Figure 2-1. Crossing schemes for EMS mutant lines and generating MARCM lines 
for screening 
A. Crossing scheme for generating a collection of ~2000 mutant stocks, each with a 
unique EMS-mutagenized third chromosome containing FRT sites on each arm. 
B. Scheme for generating MARCM clones and screening mutants for phenotypes in 
OR22a-positive neurons using ey-flp. 
OR22a-Gal4, UAS mCD8-GFP; FRT2A, FRT82B 
EMS 
X OR22a-Gal4, UAS mCD8-GFP: Dr TM3,Sb 
OR22a-Gal4, UAS mCD8-GFP; *, FRT2A, FRT82B , * 
TM3,Sb 
X 
OR22a-Gal4, UAS mCD8-GFP; *, FRT2A, FRT82B , * 
TM3,Sb 
self cross males and females to 
establish stock 
single male 
(2000 individual 
crosses) 
A    Generating EMS mutant lines: 
OR22a-Gal4, UAS mCD8-GFP: Dr TM3,Sb 
B    MARCM crosses: 
X 
ey-flp, UAS-mCD8-GFP 
tub-Gal80, FRT2A 
or   
FRT82B, tub-Gal80 ;; TM3,Sb FM7 
OR22a-Gal4, UAS mCD8-GFP *, FRT2A, FRT82B , * ; ey-flp, UAS-mCD8-GFP 
+ ; 
tub-Gal80, FRT2A 
or   
FRT82B, tub-Gal80 
+ 
1)  collect females only 
2)  clones generated in OR22a+ ORN axons (by ey-flp) 
3)  unilateral ablation à assay severed axon integrity at 7 
days 
OR22a-Gal4, UAS mCD8-GFP; *, FRT2A, FRT82B , * 
TM3,Sb 
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Figure 2-2. Identification of three mutations that suppress Wallerian degeneration 
in vivo 
A. ORN MARCM clones in control, l(3)896, l(3)4621, and l(3)4705.  Right, 
axotomy; left, uninjured control.  Boxed regions are enlarged at right. n≥15. 
B. Control and l(3)896 brains 30 days after injury. n≥10. 
C. l(3)896 clones 50 days after injury. n=11. 
D. Control ORN MARCM clones labeled with UAS-nSyb::GFP, uninjured (top) and 
30 days after axotomy (bottom). n≥15. 
E. l(3)896 MARCM clones labeled with UAS-nSyb::GFP, uninjured (top) and 30 
days after axotomy (bottom). n≥15. 
 
  
	  control axotomy 
wi
ld 
typ
e 
l(3
)8
96
 
l(3
)4
62
1 
l(3
)4
70
5 
A 
da
y 7
 
axons 
(mCD8-GFP) 
	  
	  
l(3
)8
96
 d
ay
 30
 
wi
ld 
typ
e 
B 
C 
control axotomy 
da
y 5
0 
l(3
)8
96
 
axons 
(mCD8-GFP) 
synapses 
(nSyb-GFP) 
day 30 
control 
wi
ld 
typ
e 
D 
E 
l(3
)8
96
 
day 30 
control 
 62 
 
 
Figure 2-3. Mutants that suppress Wallerian degeneration are recessive and do not 
affect neuronal development 
A. Axon integrity was assayed in heterozygous animals of the indicated genotypes 7 
days after axotomy. Axons are labeled with OR22aGal4, UAS-mCD8::GFP in a 
non-MARCM background. n≥7 antennal lobes. 
B. Embryonic motorneurons and interneurons were labeled using anti-FasII staining 
(anti-1D4, red) in control and l(3)4621 backgrounds. Motor neuron innervation 
of muscles in the body wall appeared unaffected in mutants (not shown). n≥10 
for both. 
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Figure 2-4. Wallerian degeneration mutants do not block other forms of neural 
degeneration 
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Figure 2-4. Wallerian degeneration mutants do not block other forms of neural 
degeneration 
A. MARCM clones MB ϒ neurons in control and l(3)896 backgrounds at the 
indicated developmental stages. dorsal (d) and medial (m) axonal branches 
(arrows), and dendrites (circled). n≥15 for all. 
B. dMP2 neurons with GFP. Ventral views (anterior up) of stage 16 embryos (left) 
and 1st instar larvae. dMP2 neurons before (arrows) and after (arrowheads) 
segment-specific apoptosis. n≥20 at each time point. 
C. Wild type and l(3)896 mutant clones with (right) or without (left) ectopic 
expression of hid. n≥20. 
D. Wild type and l(3)896 mutant clones in the eye-antennal disc of 3rd instar larvae. 
Homozygous mutant clones are labeled as GFP-negative (circled).  Red, TUNEL 
staining. n≥10. 
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Figure 2-5. Mutations in dsarm block Wallerian degeneration 
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Figure 2-5. Mutations in dsarm block Wallerian degeneration 
A. The lethality of l(3)896, l(3)4621, and l(3)4705 was mapped to region 66B. Red 
boxes, deficiency/mutants is lethal; green boxes, deficiency complements 
lethality. 
B. The locations of the point mutations in dsarm that block axon degeneration and 
their corresponding resulting protein change. nt, nucleotide 
C. Dsarm protein domains, positions and effect of predicted point mutations. 
D. UAS-dsarm, a dsarm transgenic BAC, or a translocation of dsarm to the X 
chromosome (usp2) rescue axonal degeneration defects 7 days after injury in the 
listed mutants.  n=12. 
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Figure 2-6. dsarm has broad endogenous expression  
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Figure 2-6. dsarm has broad endogenous expression  
A. A P[GawB] insertion in the dsarm locus (dsarm-Gal4) drives UAS-mCD8::GFP 
in the larval (left) and adult (right) brain. Larval brains were co-stained for FasII, 
n>5 brains each. 
B. RNA in situ hybridization to embryos using dsarm probes.  Note low level, but 
broad expression throughout embryo with antisense probes. 
C. RNA in situ hybridization to adult brain sections.  Note broad expression 
throughout cell cortex and in visual system, and low signal in the neuropil 
(consistent with cell body localization of transcripts). 
D. RNA in situ hybridization to larval brain sections.  Note low level, but broad 
expression throughout larval brain in dorsal cell body-rich regions, in lateral 
regions of the ventral nerve cord in more medial regions, and low expression in 
the neuropil with antisense probes. 
E. Non-quantitative RT-PCR for the dsarm transcript. Lane 1: yw embryos; lane 2: 
unmutagenized control strain, L1 larvae; lane 3: l(3)896/Df(3L)BSC796 L1 
larvae; lane 4: unmutagenized control strain, adult brain; and lane 5: canton S 
adult brain. 
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Figure 2-7. Sarm1 -/- SCG cultures are protected from Wallerian degeneration 
A. Phase contrast images of SCG explant cultures from wild type (top), Sarm1 -/- 
(middle), and Wlds expressing (bottom) animals at the indicated time after 
axotomy. 
B. Quantification from A. Mean ± SEM, *p<0.01.  
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Figure 2-­‐8. Sarm1 -­‐/-­‐ primary cultures are protected fromWallerian
degeneration
A. Axon preservation at the indicated time points in cortical neuron cultures from 
E16.5 mouse embryos. a-Tau, red. 
B. Quantification from C. Mean ± SEM, *p<0.01.  
C. Axon preservation at the indicated time points in DRG cultures from E13.5 
mouse embryos. a-TUJI, green. 
D. Quantification from E. Mean ± SEM, *p<0.01. 
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Figure 2-9. Sarm1 -/- primary cultures are not protected from NGF withdrawal-
induced axonal degeneration 
A. DRG explant cultures from E13.5 mouse embryos after NGF withdrawal at the 
indicated time points. a-TUJI, green. 
B. Quantification from G.  Mean ± SEM, *p<0.01. 
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Figure 2-10. Sarm1 is required for Wallerian degeneration in mice in vivo  
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Figure 2-10. Sarm1 is required for Wallerian degeneration in mice in vivo  
A. Sciatic nerve distal to the injury site stained with Toludine blue.  Time points and 
genotypes as indicated. 
B. Ultra-structural analysis of Sarm1+/- and Sarm1 -/- axons before or 14 days after 
axotomy. my, myelin; nf, neurofilaments, m, mitochondrion. 
C. Additional images of Sarm1 -/- axons 14 days after injury. 
D. Quantification from A. n=5 for all. (p = 0.0002). 
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Figure 2-11. Cytoskeletal markers are persevered after injury in Sarm1 -/- axons 
A. Immunoblot analysis of distal injured nerve segment.  n=4 at each time point and 
genotype. 
B. Transected nerves were stained for neurofilament-M as a marker of structure 
integrity of the injured axon at the indicated time points. n=4 mice for all. 
C. Quantification of B. Values are presented as mean ± SEM, *p<0.01. 
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Figure 2-12. NMJs are preserved in Sarm1 -/- transected nerves 
A. NMJ preservation at tibialis anterior muscles.  red, AChR (post synapse/muscle); 
green, NF-M / synpatophysin (presynapse).  
B. Quantification from A. n >200 synapses for each genotype and time point.  
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Figure 2-13. Macrophages do not infiltrate severed axons in Sarm1 -/- animals 
A. Macrophage/monocyte infiltration into transected nerves was assayed by staining 
for CD11b (macrophages) and DAPI (all cells) at the indicated time points after 
lesion. n=4 mice for all. 
B. Macrophage infiltration at the primary injury site was assayed using CD11b 
staining. scale bar is 100 μm. n=4 mice for all. 
C. Quantification of A. Values are presented as mean ± SEM, *p<0.01. 
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Figure 2-14. dSarm and Sarm1 localize to neurites in vivo 
A. UAS-dsarm::GFP  and UAS-mCD8::mCherry were driven with tdc-Gal4 in third 
instar larvae. Arrows: cell bodies. n >5 larvae. 
B. More distal axons from animals in A. 
C. A single neurite from a wild type dissociated SCG cultured neuron expressing 
mito::RFP was stained for endogenous Sarm1 (green). 
D. A web of multiple neurites from a wild type dissociated SCG cultured neuron 
was stained for endogenous Sarm1 (green). 
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Table 2-1. Mutants tested that fail to suppress Wallerian degeneration 
All mutants or misexpression constructs were crossed into a background where a subset 
of ORNs were labeled with GFP (22a-Gal4, UAS-mCD8::GFP). ORN axons were 
severed, and degeneration was scored 5 days after axotomy. LOF = reported amorphic 
loss of function allele; OE = over expression of construct under UAS-promoter control; 
DN = dominant negative; FL = full length of unmutagenized gene. n ≥10 antennal lobes 
for all.  
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mosaic chromosome 
number of axons, 
uninjured* 
number of axons, 7 days 
after axotomy* 
wild type 11.08±1.52 0 
l(3)896 4.71±1.76 5.43±2.12 
l(3)4621 7.44±0.66 6.13±0.74 
l(3)4705 4.94±0.85 5.00±1.61 
 
Table 2-2. Production of MARCM clones and persistence of severed axons in 
mutant backgrounds 
*Represents number of individual axon fibers identified in z-stacks from confocal 
imaging of entire antennal lobe.  n≥10 antennal lobes for all. 
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Table 2-3. Identification of dsarm through re-sequencing of mutant genomes 
The number of identified variants are indicated within and across mutant lines.  Filtering 
strategy is as indicated, see methods for details. 
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CHAPTER III: Identification of key domains in dSarm for promotion of 
Wallerian degeneration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following work was performed in the laboratory of Dr. Marc Freeman. Amy 
Sheehan cloned all of the constructs used in this study, and I performed all experiments 
presented here. Lukas Neukomm has confirmed many of these experiments in the 
Drosophila wing sensory neurons, which are not presented here. 
 
 
The following publication is in preparation as follows: 
 
Osterloh, JM, Neukomm, L, Sheehan A, and Freeman MR. Removal of auto-
inhibitory domain of dSarm induces spontaneous Wallerian-like degeneration. 
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Abstract 
dSarm/Sarm1 is required for severed axons to undergo Wallerian degeneration, although 
the mechanism by which dSarm/Sarm1 promotes axon self destruction is unknown. To 
investigate this mechanism, we made truncated dSarm constructs lacking predicted 
protein domain(s). dSarm function requires both the sterile alpha motif (SAM) and 
Toll/Interluekin-1 receptor homology domain (TIR) to promote Wallerian degeneration, 
and this SAM domain is required for localization. Interestingly, the third domain, 
Armadillo/HEAT domain (ARM), appears to normally auto-inhibit dSarm activity, as 
loss of the ARM domain results in spontaneous Wallerian-like degeneration in uninjured 
adult neurons. dSarmΔARM expression induces not only degeneration of axons, but also 
of dendrites and cell bodies that occurs independently of caspases. This suggests that the 
ARM domain in dSarm may be a crucial regulator of Wallerian degeneration activation 
and axon-death machinery can also promote the destruction of other neuronal parts. 
Amazingly, Wlds co-expression potently protects neurons from this induced 
degeneration, indicating that Wlds functions downstream of dSarm to protect severed 
axons.  
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Introduction 
 Axon degeneration is a hallmark of most neurodegenerative disorders (Coleman, 
2005). Axonal pathology during disease states often resembles that of an axon transected 
from its cell body (Coleman and Perry, 2002). Such a transection induces Wallerian 
degeneration, where the severed axon fragments and is engulfed by surrounding tissue 
(Waller, 1850).  While long believed to be a passive wasting way, Wallerian 
degeneration is now known to be controlled by a genetically encoded axon self-
destruction program, akin to but molecularly distinct from apoptosis (Miller et al., 2009; 
Osterloh et al., 2012; Xiong et al., 2012). 
 Wallerian degeneration can be inhibited with multiple genetic mutations. The 
first discovered was an overexpression of a chimeric fusion protein, termed slow 
Wallerian degeneration (Wlds), in which enzymatically active Nmnat is redistributed 
from the nucleus to the axon, conferring protection via a mechanism(s) of action that 
remains controversial (Lunn et al., 1989; Conforti et al., 2000; Mack et al., 2001; 
Beirowski et al., 2010).  To investigate further pathway(s) involved in axon degeneration, 
we recently reported the first forward genetic screen for mutants defective in Wallerian 
degeneration (Osterloh et al., 2012). With this screen in Drosophila, we identified dSarm 
(Drosophila sterile alpha and armadillo motif containing protein) as a gene required for 
severed axons to undergo Wallerian degeneration. Its highly conserved mammalian 
ortholog, Sarm1, is also required for Wallerian degeneration, as severed axons are 
protected from degeneration for weeks in vivo in Sarm1 null mice (Osterloh et al., 2012). 
dSarm/Sarm1 plays a vital role in regulating an axon’s response to injury. 
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 The cellular function of Sarm is beginning to emerge as a scaffold for 
signaling kinases that together promote cellular destruction. The C. elegans ortholog 
TIR-1 interacts with the calcium-activated CaMKII and the MAPK ASK1 to regulate 
downstream transcription (Chuang and Bargmann, 2005). All predicted domains of Sarm 
are anticipated to be involved in protein-protein interactions and without enzymatic 
activity. Together, this suggests that Sarm may act as a framework to bring together and 
direct pro-Wallerian degeneration kinase activation. Interestingly, in mammalian T-cells, 
overexpression of Sarm1 can induce apoptosis and Sarm1 knock down increases T-cell 
survival and proliferation (Panneerselvam et al., 2013), indicating a potential role for 
Sarm in cell survival. Interestingly, Sarm appears to localize to mitochondria with 
overexpression in human kidney cell lines (Kim et al., 2007; Panneerselvam et al., 2012), 
but not in neurons either in vitro or in vivo (Chuang and Bargmann, 2005; Chen et al., 
2011; Osterloh et al., 2012). The reason for this variance remains unknown, although it 
may be due to an artifact of tissue culture. A role for Sarm has also recently been 
described in regulating neuronal polarity and dendritic outgrowth (Chen et al., 2011), 
further suggesting that Sarm has multiple responsibilities depending on cell type and 
context.  
 To investigate how dSarm regulates Wallerian degeneration, we turned to its 
predicted protein structure. Sarm was predicted to have three domains: armadillo/HEAT 
domains (ARM), sterile alpha motif (SAM), and Toll/Interleukin-1 receptor homology 
domain (TIR) (O'Neill et al., 2003). Both the ARM and SAM domains are predicted to 
play a role in protein-protein interactions, although there is no clear target for these 
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interactions. The SAM domain has been implicated in localization (Chuang and 
Bargmann, 2005), while the ARM domain may be auto-regulatory (Chuang and 
Bargmann, 2005; Carty et al., 2006; Peng et al., 2010).  TIR domains traditionally 
mediate signaling between Toll-like receptors (TLRs) and their downstream signaling 
molecules (Brikos and O'Neill, 2008), although what part, if any, TLR signaling plays in 
Wallerian degeneration remains to be seen.  
 To investigate the function of dSarm in Wallerian degeneration, we created 
truncated deletion constructs and assayed their ability to promote or inhibit axon 
degeneration in vivo. We show here that the SAM and TIR domains are critical for 
dSarm function. While the SAM domain dictates dSarm localization, the ARM domain 
acts as an auto-inhibitory domain. Removal of the ARM domain results in an activated 
form of dSarm that induces spontaneous Wallerian-like degeneration in the absence of 
an injury signal.  This suggests that regulation of the ARM domain is a critical step in 
activating Wallerian degeneration. Furthermore, dSarmΔARM induced degeneration 
occurs independently of caspases but is blocked by co-expression with Wlds. This argues 
further that Wlds normally functions downstream of dSarm to block Wallerian 
degeneration. 
Materials and Methods 
Drosophila stocks, transgenics, and injury protocol 
The following Drosophila stocks were used in this study: OR22a-Gal4; Elav-Gal4; 
GH146-Gal4; PDF-Gal4; 109(2)80-Gal4; ey-flp; FRT2A, tubulin-Gal80; Gal80ts;UAS-
mCD8::GFP; UAS-myr::tdt::tomato; FRT2A, dSarm896 (Osterloh et al., 2012); and UAS-
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dSarm::EGFP (Osterloh et al., 2012), all from the Bloomington Stock Center unless 
otherwise noted. We induced antennal injury using a modification of a previously 
described protocol (MacDonald et al., 2006). Adult flies were aged for 7 days at 25°C 
after ablating the right third antennal segment only. Axonal integrity was scored as 
previously described (MacDonald et al., 2006; Avery et al., 2009) and injured axon 
counts were normalized to the mean axon number in uninjured samples to generation 
percentage of intact axons after injury. Data sets were compared using a paired t-test 
with Graph Pad Prism 5 software. Larval sensory neurons were dissected as previously 
described (Grueber et al., 2007) 
Cloning 
UAS-dSarm::myc was cloned by amplifying the full length dSarm isoform D (Osterloh et 
al., 2012) with 5’Ect4-D NotI 
(atatatatgcggccgcaaaacATGGGCAATCGTTTGAGCGGC) and 3’Ect4-D NotI 
(atatatatagcggccgCCAAAATATCATGCGCCCGGCATTGG) and inserted into pUASt-
myc using Not1. 
UAS-dSarmΔARM::GFP was cloned by amplifying nucleotides 1-2091 (amino acids 1-
697) with 5’Ect4-D NotI and 3’Ect4-D Xho/Spe/NotI  nt 2091 
(aattactaagcggccgcccactagtgatcctcgagATCCAGACCATTATCCACCACATGTTTGC) 
and nucleotides 2437-4911 (amino acids 813-1637) with 5’Ect4-D XhoI nt  2437 
(gattctcgagAACAAGGAGATTGAAGCCGAGG) and 3’Ect4-D SpeI from UAS-dSarm. 
Both products were inserted into pUASt-CT EGFP with Not1/Xho1 and Xho1/SpeI, 
respectively.  
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UAS-dSarmΔARM::myc was made by cutting out dSarmΔARM from the above 
construct with Not1/Spe1 and inserting it into pUASt-CT myc. 
UAS-dSarmΔSAM::GFP was made by PCR amplifying nucleotides 1-2820 (amino aicds 
1-940) with 5’Ect4-D NotI and 3’Ect4-D Xho/Spe/NotI  nt 2820 
(aattatatatagcggccgcccactagtgatcctcgagCAAGGGAACCTGTTGGGACAGCTTGTGC) 
and nucleotides 3217-4911 (amino acids 1073-1637) with 5’Ect4-D XhoI nt  3217 
(gatcctcgagAACTTGGAGAATTCGC) and 3’Ect4-D SpeI from UAS-dSarm. Both 
products where inserted into pUASt-CT EGFP with NotI/XhoI and XhoI/SpeI, 
respectively.  
UAS-dSarmΔSAM::myc was made by cutting out dSarmΔSAM from the above construct 
with Not1/Spe1 and inserting it into pUASt-CT myc. 
UAS-dSarmΔTIR::EGFP was made by PCR amplifying nucleotides 1-3270 (amino acids 
1-1090) with 5’ Ect4-D NotI and 3’Ect4-D Xho/Spe/Not nt 3270 
(aattatatatagcggccgcccactagtgatcctcgagTAGCGTCTTGGCCATGTTCTCCTCC) and 
nucleotides 3685-4911 (amino acids 1229-1637) with 5’Ect4-D XhoI nt  3685 
(tgatactcgagCGCGGCGAAAAGAATATCGATCGCATTGC) and 3’Ect4-D SpeI from 
UAS-dSarm. Both were inserted into UAS-CT EGFP with NotI/XhoI and XhoI/SpeI, 
respectively.  
UAS-dSarmΔTIR::myc was made by cutting out dSarmΔTIR from the above construct 
with Not1/Spe1 and inserting it into pUASt-CT myc.  
 88 
UAS-ARM::EGFP was made by PCR amplifying nucleotides 1-2820 (amino acids 1-
940) with 5’Ect4-D NotI and 3’Ect4-D Xho/Spe/NotI  nt 2820 and nucleotides 3685-
4911(amino acids 1229-1637) with 5’Ect4-D XhoI nt  3685 and 3’Ect4-D SpeI from 
UAS-dSarm. Both were inserted into UAS-CT EGFP with NotI/XhoI and XhoI/SpeI, 
respectively.  
UAS-ARM::myc was made by cutting out ARM from the above construct with 
Not1/Spe1 and inserting it into pUASt-CT myc.   
UAS-SAM::HA was made by PCR amplifying nucleotides 1-2091 (amino acids 1-697) 
with 5’Ect4-D NotI and 3’Ect4-D Xho/Spe/NotI  nt 2091, nucleotides 2437-3271 (amino 
acids 813-1090) with 5’Ect4-PD Xho 2437 and 3’Ect4 PacI/AgeI/XbaI 3271 
(ggacctcgtctagagatcaccggtgatcttaattaaTAGCGTCTTGGCCATGTTCTCCTCCG), and 
nucleotides 3685-4911 (amino acids 1229-1637) with 5’Ect4 PacI 3685 
(ccgtccgggatcttaattaagCGCGGCGAAAAGAATATCGATCGCATTGC) and 3’Ect4 
stop SpeI from UAS-dSarm. All three were inserted into UAS-CT HA with NotI/XhoI, 
XhoI/AgeI, and AgeI/SpeI, respectively. 
Immunohistochemistry 
Drosophila ORNs were not antibody stained, except where noted (Figure 3D), and 
instead were visualized by their expression of either a membrane tethered GFP (UAS-
mCD8::GFP) or tomato (UAS-myr-tdt-tomato). When antibody staining, adult brains 
were fixed as previously described (MacDonald et al., 2006) and incubated with 1:200 of 
mouse anti-GFP (Invitrogen) overnight and then with 1:100 Alexa488-anti-mouse 
(Jackson ImmunoResearch) for 1 hour at room temperature. Anti-PDF (Developmental 
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Studies Hybridoma Bank) was used at 1:10 under the same conditions as above. 
Drosophila embryos were fixed and stained as previously described (Broadus et al., 
1995) using anti-eve at 1:10 (Developmental Studies Hybridoma Bank). Anti-HRP 
conjugated with Cy5 was used at 1:200 (Jackson ImmunoResearch). 
Confocal microscopy 
Samples were mounted in Vectashield antifade reagent and viewed on an Intelligent 
Imaging Innovations (3i) Everest Spinning disk confocal microscope.  The entire 
antennal lobe was imaged in 0.27 μm steps for each sample for scoring axonal integrity. 
Abdominal segments of the ventral nerve cord from embryos and body wall neurons in 
3rd instar larvae were also imaged in 0.27 μm steps. PDF neurons and projection neurons 
in the adult were imaged in 1.0 μm steps when viewed with the 10x objective lens and 
0.27 μm steps when viewed with the 63x objective. 
Results 
Expression of dSarm truncation constructs does not interfere with Wallerian 
degeneration 
We first sought to identify key functional domains required for dSarm to induce 
Wallerian degeneration. We created truncated dSarm constructs lacking either the SAM 
or TIR domain, or both (Figure 3-1), and fused them with either a C-terminal green 
florescent protein (GFP) or myc tag. First, we expressed these constructs in wild type 
olfactory receptor neurons (ORNs) to determine if expression of any of these constructs 
could interfere with the function of endogenous, wild type dSarm. Expression of these 
constructs with either C-terminal tag had no effect on Wallerian degeneration 7 days 
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after unilateral antennal ablation in wild type nerves (Figure 3-1), indicating these 
constructs do not act in a dominant-negative manner to block Wallerian degeneration. 
dSarm requires both the SAM and TIR domains to promote Wallerian 
degeneration 
Loss-of-function mutations in dsarm are able to potently block axon 
degeneration in Drosophila ORNs up to 50 days after injury (Osterloh et al., 2012). We 
next assayed if any of the deletion constructs could functionally rescue Wallerian 
degeneration in a dsarm mutant (dsarm896) background. While both GFP- and myc-
tagged full-length dSarm were able to restore degeneration in dsarm mutant axons, all of 
the truncated constructs were unable to rescue the mutant phenotype (Figure 3-2). Thus, 
dSarm requires both the SAM and TIR domains to induce Wallerian degeneration. 
dSarm localization varies in different neurons but requires the SAM domain 
We next wanted to determine where dSarm localized in vivo. Studies in cultured 
human kidney cells have suggested a role for Sarm1 in mitochondria in vitro (Dalod, 
2007; Panneerselvam et al., 2012), although neuronal Sarm1 shows no localization to 
mitochondria (Osterloh et al., 2012). To assay dSarm localization in Drosophila in vivo, 
we turned to PDF neurons, where a small subset of neurons can be visualized in their 
entirety in the adult Drosophila brain with both a PDF antibody and expression of pdf-
Gal4 (Kaneko et al., 2000). The fully functional GFP-tagged dSarm localizes primarily 
to the cell body and main neurite branches of PDF neurons, but not throughout the entire 
axon or the dendritic field (Figure 3-3A-C, top row). Removal of the SAM domain 
redistributes the molecule throughout the entire neuron (Figure 3-3A-C, second row 
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from top), while loss of the TIR domain does not appear to affect localization (Figure 
3-3A-C, second row from bottom). The ARM domain alone localizes throughout the 
neuron (Figure 3-3A-C, bottom row). To determine if this localization was consistent in 
multiple neuron types, we also expressed these constructs in larval sensory neurons 
(Figure 3-4A) and adult projection neurons (Figure 3-4B), where a similar pattern 
emerges: dSarm appears to be actively excluded from some neurites, and this specific 
localization requires the SAM domain. However, localization appears to vary among 
neurons. In adult projection neurons, dSarm::GFP is mainly in the cell body and 
dendrites while excluded from axons (arrows) (Figure 3-4B); however, in adult PDF 
neurons, dSarm::GFP is mainly in the cell body and part of the axon while excluded 
from dendrites (Figure 3-3A-C). Interestingly, in OR22a+ ORNs, dSarm::GFP is only 
detectable in the glomeruli with anti-GFP staining (Figure 3-3D); even with signal 
amplification, dSarm is barely detectable. The reason for this variety in localization 
remains unknown; there are likely other functions of dSarm beyond promoting Wallerian 
degeneration, possibly in neural development (Chen et al., 2011), and variances in 
localization may be due to unknown differences in the function of dSarm in these 
individual neurons. Nevertheless, in all neuron cell types tested, loss of the SAM domain 
resulted in widespread redistribution of the protein throughout the cytosol, indicating 
that the SAM domain is required for localization of dSarm. 
Loss of the ARM domain induces spontaneous degeneration of adult neurons 
In C. elegans, the ARM domain of TIR-1 acts an auto-inhibitory domain, 
suggesting that loss of the ARM domain in dSarm may induce Wallerian-like 
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degeneration in the absence of injury. To test this, we first expressed dSarmΔARM in 
OR22a+ ORNs without injury. Normally, these axons are robustly labeled with a 
membrane-tethered GFP (OR22aGal4, UAS-mCD8::GFP). However, when the 
dSarmΔARM construct was co-expressed, OR22a+ ORNs were barely visible within 
two days of eclosion (Figure 3-5A), indicating that these ORNs had either (1) 
spontaneously degenerated or (2) a drastic developmental defect. To test the impact of 
adult-specific expression, we expressed either full length or dSarmΔARM specifically in 
adult OR22a+ ORNs using a temperature sensitive mutant of the Gal4-repressor Gal80.  
Within 5 days of activation, ORNs expressing dSarmΔARM showed dramatic axonal 
defects, including fragmentation (Figure 3-5B, bottom), while expression of full-length 
dSarm had no obvious effect on these axons (Figure 3-5B, top). Together, this suggests 
that dSarmΔARM is inducing axon degeneration in the absence of injury. 
To further investigate the effect of dSarmΔARM, we expressed this molecule 
specifically in adult PDF neurons, again using a temperature sensitive Gal4-repressor, 
Gal80ts. Within one day of expression, PDF neurons expressing dSarmΔARM undergo 
robust fragmentation, with most neuronal debris undetectable within 5 days of 
dSarmΔARM expression (Fig 3-5C, left column). Remarkably, dSarmΔARM is able to 
kill not only the axon, but also the cell body and dendrites of adult neurons, suggesting 
that activation of an axon-death pathway can also trigger somal and dendritic death.  
dSarmΔARM-induced degeneration is blocked by Wlds but not p35 
To determine if dSarmΔARM was inducing neuronal apoptosis, we co-expressed 
dSarmΔARM with p35, a baculovirus protein that broadly inhibits caspase-dependent 
 93 
cell death in Drosophila. Expression of p35 had no effect on dSarmΔARM-induced 
destruction of PDF neurons (Figure 3-5C, middle column). However, co-expression of 
Wlds potently blocked the ability of dSarmΔARM to destroy these neurons (Figure 3-5C, 
right column), suggesting that (1) dSarmΔARM is able to induce Wallerian-like 
degeneration independent of axonal injury and (2) Wlds acts downstream of dSarm to 
protect against axonal degeneration. 
dSarmΔARM expression does not grossly alter neuronal patterning or 
differentiation in the embryo 
We next sought to determine whether dSarmΔARM could kill embryonic 
neurons, or if its killing ability was restricted to adult neurons. To address this, we drove 
dSarmΔARM expression in embryonic neurons with elav-Gal4 and assayed the presence 
of eve+ neuronal nuclei. Expression of full-length dSarm in all embryonic neurons 
results in the expected number and organization of eve+ neurons per hemi-segment 
(13.06 ± 0.18), as did expression of dSarmΔARM (12.93 ± 0.19) (Figure 3-6). While 
expression of dSarmΔARM in embryonic neurons lead to head involution defects, the 
pattern of eve+ neurons in abdominal segments remained unchanged, suggesting that 
dSarmΔARM does not grossly affect embryonic patterning of the nervous system. 
However, there appeared to be disruptions in the anti-HRP staining, which labels of all 
neuronal processes (blue, Figure 3-6A). This suggests that either dSarmΔARM 
expression is not high enough or turned on for long enough to induce cell death in 
embryonic neurons, or embryonic neurons are more resistant than adult neurons to 
dSarmΔARM-induced cell death. 
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Discussion 
dSarm/Sarm1 plays a crucial role in activating Wallerian degeneration following 
injury to an axon, although the details of Sarm signaling during this process are 
unknown. We sought to investigate these details by performing a structure function 
analysis on dSarm. Deletion of the SAM or TIR domains renders the molecule 
dysfunctional. Interestingly, the SAM domain is required for both dSarm localization 
and function, suggesting that sub-cellular localization may be critical for dSarm activity. 
While others have reported Sarm1 localization to mitochondria, staining of endogenous 
Sarm1 in mouse neurons argues against mitochondrial localization (Chen et al., 2011; 
Osterloh et al., 2012). Nevertheless, this localization appears to correlate with dSarm’s 
function in promoting axon self-destruction.  
The TIR domain is crucial for dSarm’s function, although its signaling partners 
remain unknown. In C. elegans, the TIR domain interacts with apoptosis signaling 
kinase-1 (ASK1) to alter transcription; unfortunately available Drosophila ASK1 
mutants have no effect on Wallerian degeneration (Osterloh et al., 2012). Thus, it 
remains essential to uncover what downstream molecules interact with dSarm’s TIR 
domain, as these are likely key molecules in executing axon destruction. Screening for 
suppressors of auto-activated dSarm may unearth these critical downstream signaling 
molecules.  
Deletion of the ARM domain in dSarm results in spontaneous Wallerian-like 
degeneration in adult neurons. Work in C. elegans suggests that the calcium-activated 
CaMKII interacts with the ARM domain (Chuang and Bargmann, 2005; Chang et al., 
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2011), however, as with ASK1, available mutations in CaMKII have no effect on 
Wallerian degeneration (Osterloh et al., 2012). It has been well documented that 
increases in intra-axonal calcium occur after injury and are required for Wallerian 
degeneration (Schlaepfer and Bunge, 1973; George et al., 1995; Adalbert et al., 2012; 
Avery et al., 2012), so it remains an intriguing possibility that a calcium-activated 
protein interacts with the ARM domain in dSarm to remove its auto-inhibitory properties. 
What distinguishes the intra-axonal calcium spike after injury from other calcium spikes, 
such as during action potential propagation, remains entirely unclear, and there are likely 
other “stress” signal(s) involved that together activate dSarm to induce Wallerian 
degeneration. Further screening to identify other Wallerian degeneration mutants may 
illuminate this activation step. It also remains possible that dSarm affects transcription 
before injury to “prime” axons for injury-induced death, and no transcriptome or 
proteomic studies to date have analyzed differences in wild type versus Sarm null axons. 
dSarmΔARM expression induces degeneration of not only axons, but also 
dendrites and the soma. This suggests that activating axon death mechanisms can also 
result in degeneration of other neuronal parts. Remarkably, it does so in a p35-
insensitive manner, arguing that this process is caspase-independent. Interestingly, 
immature embryonic neurons may be partially resistant to dSarmΔARM-induced death, 
but young axons appear to still be vulnerable to destruction. This suggests that possibly 
adult neurons are fundamentally more vulnerable to destruction than their younger 
counterparts, or all of the required downstream machinery to execute degeneration is not 
expressed or active until later developmental stage. It remains to be seen what effect 
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expression of a well-established pro-apoptotic gene, such as grim or reaper, has on 
neuronal processes and Eve staining of embryos at this point. It is also unknown if 
degenerating dSarmΔARM neurons show hallmarks of classical apoptosis, such as 
positive TUNEL labeling, nuclear condensation, and phosphatidylserine exposure. 
 Auto-activation of Wallerian-like degeneration with dSarmΔARM is another tool 
with which to investigate how Wlds blocks axon degeneration. Co-expression of Wlds 
with dSarmΔARM potently blocks degeneration of all neuronal parts, arguing that Wlds 
acts downstream of dSarm to block Wallerian degeneration. Previously, Wlds was 
thought to only protect axons and not cell bodies from death (Coleman and Freeman, 
2010); however, Wlds appears to block somal destruction from dSarmΔARM, indicating 
that in this instance axon death precedes cell body death as a driving force in overall 
cellular destruction; that is, the axon has to commit to self-destruction before the entire 
neuron dies, and Wlds blocks this commitment.  
 The molecular pathways facilitate Wallerian degeneration have long been elusive, 
but recent mutants (Osterloh et al., 2012; Xiong et al., 2012) are beginning to bring this 
process to light. We present here that the ARM domain within dSarm is a crucial self-
regulatory domain, and it is imperative to uncover relevant interactions and regulators of 
this domain and their importance in promoting Wallerian degeneration. The SAM 
domain appears to regulate localization, although the importance and consequences of 
this localization remains to be determined. Finally, the TIR domain likely interacts with 
downstream effectors that promote the morphological changes associated with Wallerian 
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degeneration; further understanding of these interactions should further illuminate the 
molecular mechanisms activated during Wallerian degeneration.  
  
 98 
 
 
Figure 3-1. Expression of dSarm constructs does not interfere with nor induce 
Wallerian degeneration 
A, B. Wild type ORNs expressing indicated dSarm construct (left) were unilaterally  
injured and degeneration was scored 7 days later. dSarm constructs were tagged 
with either a C-terminal GFP (A) or a C-terminal myc (B) tag. *SAM construct 
was tagged with a C-terminal HA epitope only (no GFP or myc construct). 
C, D. Quantification of A and B, respectively. Axon counts for injured samples  
were normalized to mean axon number in uninjured samples. Values presented as 
mean ±SEM, p<0.0001. n≥6 for all. 
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Figure 3-2. dSarm requires both the SAM and TIR domains to promote Wallerian 
degeneration 
A, B. dsarm896 ORNs expressing indicated dSarm construct were unilaterally injured  
and degeneration was scored 7 days later. dSarm constructs were tagged with 
either a C-terminal GFP (A) or a C-terminal myc (B) tag. *SAM construct was 
tagged with a C-terminal HA tag only (no GFP or myc construct). Wild type 
ORNs expressing indicated dSarm construct (left) were unilaterally  
C, D. Quantification of A and B, respectively. Axon counts for injured samples were  
normalized to mean axon number in uninjured samples. Axon counts for dsarm896 
alone are included in quantification (C). Values presented as mean ±SEM, 
p<0.0001. n≥6 for all.  
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Figure 3-3. dSarm localization requires the SAM domain in adult neurons 
A-C. Expression of indicated GFP-tagged dSarm constructs in PDF neurons (red, anti- 
         PDF). (A) Adult PDF neurons in one hemi-brain (8 neurons total). (B) Zoomed in  
         view of adult PDF axons. (C) Zoomed in view of adult PDF dendrites. n≥10      
         animals for all. 
D. dSarm::GFP in adult OR22a+ neurons stained with anti-GFP. n=5 animals. 
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Figure 3-4. dSarm localization requires the SAM domain 
Expression of indicated GFP-tagged dSarm constructs. n≥6 animals for all. 
A. Larval body wall sensory neurons, labeled with 109(2)80-Gal4. Constructs are 
co-expressed with myristoylated tomato, which labels cell membranes. A 
zoomed in merge view of the dendrites is shown on the far right. 
B. Adult projection neurons (PNs) labeled with GH146-Gal4.Axons are indicated 
with arrows. 
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 Figure 3-5. Expression of dSarmΔARM induces spontaneous Wallerian-like  
degeneration in adult neurons 
A. UAS-dSarmΔARM::GFP was expressed with UAS-mCD8::GFP by OR22aGal4. 
Adult brains were dissected without injury within 48 hours of eclosion. n=12. 
B. Either UAS-dSarm::GFP (top) or UAS-dSarmΔARM::GFP (bottom) was 
expressed with OR22aGal4 specifically in the adult in a temperature sensitive 
manner for 5 days. Membranes are labeled with a myrstoylated tomato. n=10 
each. 
C.  dSarmΔARM::GFP was expressed specifically in adult PDF neurons in a 
temperature sensitive manner either alone (left), with the anti-apoptotic protein 
p35 (middle), or with Wlds (right) for the indicated time points. White, anti-PDF 
to label all neurons expressing the construct(s). n≥25 brains for all. 
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Figure 3-6. Expression of dSarmΔARM induces axon loss but not cell body death 
in embryonic neurons 
A. Either dSarm::GFP (top) or SarmΔARM::GFP (bottom) was broadly expressed 
in all embryonic neurons with elav-Gal4. Anti-eve (red) labels a small, specific 
set of differentiated neuronal nuclei, while anti-hrp (blue) labels all neuronal 
processes. n= 12 embryos. 
B. Eve-positive nuclei from (A) were counted per hemisegment. Values presented 
as mean ±SEM, n≥40 hemisegments. 
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CHAPTER IV: Sarm1 loss prevents axon degeneration in a mouse model of 
Amyotrophic Lateral Sclerosis (ALS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The work described in this chapter was performed in the lab of Dr. Marc 
Freeman. I performed all of the animal handling, behavioral experiments, and tissue 
dissections. Dr. Johnny Salameh performed the electrophysiology recordings. Dr. Owen 
Peters is currently staining tissue from the animals used here (data not presented). The 
following publication is in process: 
 
Osterloh JM, Peters, O, Salameh J, Brown RH, and Freeman, MR. Sarm1 loss 
prevents axon degeneration in a mouse model of ALS 
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Abstract 
Amyotrophic lateral sclerosis (ALS) is a fatal, progressive neurological disease 
that specifically targets motor neurons and affects 25,000 Americans at any given time. 
Because disease progression is so rapid and devastating, it is essential to understand the 
underlying causes of motor neuron death in ALS. Genetic abolishment of cell death 
pathways has only provided some extension of lifespan in mouse models of ALS. To 
determine if programmed axon death is involved in ALS progression, we bred Sarm1 
knockouts, which are robustly protected from injury induced Wallerian degeneration, to 
the SOD1-G93A mouse model of ALS. We found loss of Sarm1 robustly preserves 
axons and synapses and modestly prolongs lifespan in these ALS mice, suggesting that 
Sarm1 regulates a common axon death pathway that is activated both after injury and 
during the course of this neurodegenerative disease. This new insight into ALS 
pathogenesis may be important for future human therapies. 
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Introduction 
Amyotrophic lateral sclerosis (ALS) is a progressively fatal motor neuron disease 
and manifests clinically as progressive muscle weakness and atrophy, ultimately 
resulting in fatal respiratory failure.  Pathologically, dying motor neurons exhibit 
swellings in the axon and soma, as well as aggregates of phosphorylated neurofilaments 
and ubiquitinated proteins. Activated microglia and astrocytes are also present (Pasinelli 
and Brown, 2006). Unfortunately, there are few available treatments for this disease, and 
the symptomatic measures provide little temporary relief. 
There are approximately 25,000 people living with ALS in the USA, with a 
lifetime risk between 1:800 and 1:2,000 (Cleveland and Rothstein, 2001; Rothstein, 
2009). Approximately 90% of all cases are sporadic; the remaining 10% of ALS cases 
are autosomal dominant and inherited (Rothstein, 2009). Of the familial ALS patients, 
20% have mutations in Cu/Zn superoxide dismutase-1 (SOD1), a ubiquitous cytosolic 
protein. (Pasinelli and Brown, 2006). There have been multiple loci linked to familial 
ALS, but SOD1, the first ALS-linked gene discovered, is by far the most heavily studied 
causative gene (Pasinelli and Brown, 2006). Over 150 mutations in SOD1 have been 
linked to ALS, with mutations spanning all 5 exons. Enzymatic activity appears to play 
no role in disease progression, and SOD1 mutants are believed to act via some unknown, 
gain-of-function toxic mechanism (Pasinelli and Brown, 2006). SOD-1 inclusions have 
been found in sporadic ALS patient tissue, suggesting a possible role for this molecule 
outside of familial ALS . In order to better understand the mechanisms of human disease, 
several animal models of ALS have been generated; many of these experimental models 
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involve expression of human mutant SOD1 (McGoldrick et al., 2013). The first of 
these animal models contains a glycine to alanine substitution (SOD1-G93A), which is 
expressed under control of the human promoter and with over 20 copies of the coding 
sequence. In mice, this results in progressive motor neuron death in the spinal cord, 
leading to paralysis and ultimately death by 6 months of age (Gurney et al., 1994). 
Subsequent analysis has revealed that these animals share many features seen in post-
mortem human samples, including axon transport defects, mitochondrial dysfunction, 
progressive neuromuscular junction (NMJ) denervation, and reactive gliosis 
(McGoldrick et al., 2013). Many other transgenic ALS mice have since been created, 
including lines expressing other SOD1 mutations, but the SOD1-G93A mice remain the 
most highly studied experimental model of ALS (McGoldrick et al., 2013). 
Transgenic ALS mice allow for the investigation of not only disease 
pathogenesis, but also for testing potential therapeutic treatments. There have been many 
suggestions regarding the nature of motor neuron stress and death in ALS, including: 
oxidative damage, toxic protein aggregates, mitochondrial dysfunction, apoptosis, axon 
transport blocks, growth factor defects, toxic glia, glutamate excitotoxicty, and altered 
RNA metabolism (Rothstein, 2009). A wide variety of transgenic and pharmaceutical 
therapies have been tested in an attempt to alleviate the above conditions; however, none 
to date have proven to be effective in the treatment of human disease. These results 
highlight the complexity surrounding ALS pathogenesis and treatment studies.  
ALS is not merely a disease where motor neurons undergo apoptosis, as 
transgenic animals that potentially block cell death offer only modest protection 
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(Vukosavic et al., 1999; Gould et al., 2006; Reyes et al., 2010). Axon degeneration is 
also a hallmark of ALS (Cleveland and Rothstein, 2001), although it is unknown if this 
is a driving force behind disease progression. Apoptosis inhibitors are able to block 
motor neuron cell body death, but not axonal loss, suggesting that another mechanism 
may be activated in degenerating neurons. Because axonal dieback during ALS looks 
morphologically similar to Wallerian degeneration, it is possible that same genetically 
encoded program controls both axon death after injury and axon death during ALS. 
Unfortunately, expression of the chimeric slow Wallerian degeneration (Wlds) gene, 
which potentially blocks injury induced degeneration (Coleman and Freeman, 2010), 
showed little effect on transgenic ALS models (Vande Velde et al., 2004; Fischer et al., 
2005). However, the protective effects of Wlds may decline with age, and the dose of 
Wlds may be altered in motor neurons expressing such high levels of SOD1 
(Gillingwater et al., 2002; Wright et al., 2010). We recently described the first loss of 
function mutants, in dsarm/Sarm1, that potently block Wallerian degeneration to the 
same extent as Wlds expression (Osterloh et al., 2012). Sarm1 null neurons are also 
protected from cell death due to oxygen-glucose deprivation (Kim et al., 2007), 
excitotoxicity (Massoll et al., 2013), and some neurological viruses (Mukherjee et al., 
2013). With the discovery of Sarm1 and its role in axon death, we sought to determine if 
injury-induced axon death is related to axon degeneration during ALS progression. Here, 
report that loss of Sarm1 remarkably preserves axons and the NMJ and also modestly 
prolongs lifespan in SOD1-G93A mice. 
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Materials and Methods 
All experimental procedures in mice were performed in compliance with the protocols 
approved by the Institutional Animal Care and Use Committee of The University of 
Massachusetts Medical School.  
Animal breeding 
Sarm1 null females (Osterloh et al., 2012) were bred with SOD1-G93A males on the 
C57/Bl6 background (Jackson Laboratories). Sarm +/-, huSOD+ males were bred to 
Sarm1 null females. The resulting huSOD+ mice were used in the studies below, and the 
huSOD- littermates were kept for at least 250 days as lifespan controls. Only mice 
containing at least 25 copies of huSOD, as confirmed by QRT-PCR as previously 
described (Caraganis et al., 2008) were used for this study. Wild type C57/Bl6 mice 
were purchased from Jackson Laboratories. 
Behavioral studies 
Beginning at 50 days old, huSOD+ mice were trained twice weekly on a rotarod 
(Omnitech Electronics) set at a constant speed of 20 revolutions per minute. Beginning 
at 70 days of age, the mice were placed on the moving rotarod (20 revolutions per 
second) and required to stay on the rotarod for 600 seconds. Testing sessions were 
performed twice weekly in the afternoon with 2-3 days between testing. Before each 
rotarod session, each mouse was weighed. During each session, each animal had up to 
three trials on the rotarod, without resting between trials. The longest performance for 
each animal was recorded. Mice were no longer tested when unable to stay on the 
rotarod for at least 10 seconds. These mice were then housed with food and gel packs on 
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the cage floor; these animals were euthanized at endpoint, when unable to right 
themselves after 10 seconds on one side. The animals were euthanized with a lethal dose 
of isoflurane and then perfused with phosphate buffered saline, followed by 
4%paraformaldehyde, 4% sucrose in 0.1M phosphate buffered saline. After incubating 
for 24 hours at 4°C in fixative, mice were placed in phosphate buffered saline for 
another 24 hours at 4°C. Spinal cords, ventral roots, and sciatic nerves were then 
dissected and housed in 30% sucrose at 4°C. Lifespan was compared using a Kaplan-
Meyer survival analysis on Graph Pad Prism 5 software. Weight and rotarod 
performance were compared using average area under the curve, with at least 3 data 
points per time point, followed by a student’s t-test on Graph Pad Prism 5 software, 
Electrophysiological recordings 
Electrophysiological recordings were done as previously described (Xia et al., 2010) on 
130-day-old mice. Mice were deeply anesthetized with isoflurane, and their rear legs 
were shaved with an eye brow trimmer (Remington) and wiped with alcohol pads. Mice 
were restrained on a Styrofoam platform on top of a heating pad with adhesive tape. A 
pair of monopolar disposable 28G needle electrodes and ring electrodes (CareFusion) 
were lightly coated with electrode gel (SignaGel) and used for stimulation and recording, 
respectively. The active recording electrode was placed over the gastrocnemius muscle, 
with the reference electrode over the tendon. The stimulating cathode was placed 5 mm 
proximal to the recording electrode in the midline of the posterior thigh. The anode was 
placed subcutaneously in the midline over the sacrum.  A surface electrode (CareFusion) 
was grounded on the mouse’s tail. Motor conduction studies and motor unit estimate 
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(MUNE) were performed using a portable electrodiagnostic system (Cardinal 
Synergy). For the motor nerve conduction studies, the low-pass filter was set at 30 HZ, 
and the high-pass filter was set at 10 kHZ. The nerve was stimulated with single square-
wave pulses of 0.1-ms duration. Supramaximal responses were gradually generated, and 
maximal responses were obtained with stimulus currents <20 mA (most often <10 mA). 
The distance between distal and proximal stimulation sites was measured with a 
millimeter-graduated tape measure. Data were acquired with a sensitivity of 20 
mV/division and sweep speed of 3 ms/division. The distal latency, distal and proximal 
compound motor action potential (CMAP) amplitudes, and distal and proximal CMAP 
durations (measured from onset of initial negative deflection to initial return to baseline) 
were determined for each nerve studied.  
For the MUNE recordings, the incremental technique was used (Shefner et al., 
2002; Shefner et al., 2006). The setting was the same as for the motor nerve conduction 
test reported above. The low pass filter was set at 20 HZ, and the high-pass filter was set 
at 10 kHZ. Data were acquired with a sensitivity of 100 μV/division and sweep speed of 
1 ms/division. Using a repetition rate of 1/s, stimulus intensity was slowly increased 
from subthreshold levels until a small all or none response was produced. Thus the 
sciatic nerve was stimulated with single pulses of gradually increased intensity until the 
first response appeared, representing the first motor unit recruited. With the next stimuli, 
quantal increases in the response were recorded. Increments >25 μV were considered as 
likely the recruitment of an additional motor unit. The amplitude of a single motor unit 
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was calculated as the mean of 5 consistent increases, with the overall MUNE 
calculated as follows: 
MUNE = CMAP!"#$!%! !"#$%&'()mean surface detectedmotor unit action potential 
MUNE values were compated using an unpaired t-test on Graph Pad Prism 5 software. 
After recording from each side, the animals were euthanized with a lethal dose of 
inhaled isoflurane and perfused as described above. 
Results 
To study the role of axon death genes in ALS, we bred Sarm1 null mice with 
SOD1-G93A mice and then backcrossed Sarm1 +/-, huSOD1-G93A+ males with Sarm1 
null females. The resulting huSOD1-G93A+ littermates with at least 25 copies of the 
human mutant SOD1 were compared in the subsequent experiments. 
Loss of Sarm1 does not delay disease onset 
 First, animal weight was measured twice a week starting at day 75. Both Sarm1 
+/- and Sarm1 null animals reached their peak weight at day 99, and showed progressive 
weight loss for the rest of the animals’ life span (Figure 4-1A).  There was no statistical 
difference between the two groups. huSOD1-G93A- littermates showed no decline in 
weight over time (Figure 4-1B), indicating weight loss was a result of the huSOD1-
G93A+ transgene and not due to the loss of Sarm1. Peak weight is generally considered 
to be the time of onset in this model of ALS, and the above data indicates that Sarm1 
loss does not alter disease onset. 
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Gross motor performance is not preserved in Sarm1 null mice 
 Next, motor performance was scored twice weekly by assessing latency to fall on 
a constant speed rotarod. Both Sarm1 +/- and Sarm1 null huSOD1-G93A+ mice show 
progressive decline in rotarod performance overtime with no difference between groups 
(Figure 4-1C). There was no significant difference between groups when comparing the 
mean age at which functional paralysis (time on rotarod ≤10 seconds) set in, which was 
146 days for Sarm1 nulls and 150 days for Sarm1 +/- animals (Figure 4-1D). Sarm1 null 
animals alone show no defects in rotarod performance with age (Figure 4-1E). Thus, 
there appears to be no gross preservation of motor circuit function at this test speed with 
loss of Sarm1. 
Loss of Sarm1 modestly prolongs lifespan 
 Notably, loss of Sarm1 extends lifespan of SOD1-G93A mice by approximately 
10%; Sarm1 null huSOD1-G93A+ mice lived an average of 184.5 days, while their 
Sarm1 +/- huSOD1-G93A+ littermates lived only 169.0 days (Figure 4-2).  Sarm1 null 
animals alone live at least 250 days (Figure 4-2). Loss of Sarm1 extends lifespan in 
SOD1-G93A mice, suggesting that axon death may play a role in disease progression of 
ALS.  
Axons and synapses are preserved with loss of Sarm1 
We next assayed the direct ability of Sarm1 loss to preserve both axons and 
synaptic terminals in these ALS mice. CMAPs from the gastrocnemius muscle after 
stimulation of the sciatic nerve were recorded from 130-day-old mice (Figure 3). Sarm1 
+/-, huSOD1-G93A+ mice at day 130 showed remarkably low MUNE scores: 23.8± 2.9. 
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These mice are undergoing mid-stage paralysis; they are still able to stay on the 
rotarod for some time, but they are showing appreciable signs of muscle atrophy and 
weakness. Interestingly, Sarm1 null, huSOD1-G93A+ mice at day 130 showed similar 
decline on the rotarod, and no observable behavioral difference between littermates was 
noted; however, their MUNE scores show remarkable preservation at the NMJ: 94.1± 
17.0, indicating that loss of Sarm1 robustly preserves axons and synapses in SOD1-
G93A mice. While there was variability in the MUNE score, much of this is due to 
asymmetric innervation from leg to leg of the same animal (i.e., one leg has a higher 
score than the other); intriguingly, this uneven distribution is also found in human 
patients (Baumann et al., 2012). 
Discussion 
The role of axon self-destruction genes in neurodegenerative disease has long 
been speculated (Raff et al., 2002) but until the discovery of dSarm/Sarm1 there were 
few tools available to investigate this phenomenon. ALS appeared as a clear first 
stepping stone for investigating the roll of axon death genes in neurodegeneration, as 
many studies have clearly shown that preventing cell body death does not block axon 
loss and ultimate animal death (Vukosavic et al., 1999; Gould et al., 2006; Reyes et al., 
2010).  To investigate this possibility, we bred axon self-destruction deficient mice into 
the SOD1-G93A mouse model of ALS. While Sarm1 loss does not appear to delay 
disease onset or gross motor decline, lifespan is modestly extended (10%). 
Electrophysiological recordings from gastrocnemius muscle show that axons and 
synapses are remarkably well preserved in late stages of ALS progression in Sarm1 null 
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mice, indicating that axon loss is prevented and arguing that a genetically encoded 
axon death program may be activated during disease progression to destroy axons. 
 The work here enhances earlier studies on axon death and disease pathogenesis 
in mouse ALS models. Expression of the chimeric protein Wlds in multiple ALS models 
provided few changes in disease progression, although NMJs did remain innervated at a 
slightly higher (~10%) rate during pre- and early-symptomatic stages (Vande Velde et 
al., 2004; Fischer et al., 2005). At the time, it was concluded that axon death was not a 
factor in ALS progression; however, electrophysiological recordings were not performed. 
Wlds protection, particularly at the synapses, may be age and is definitely dose-
dependent (Mack et al., 2001; Wright et al., 2010), and these variables may account for 
the lack of axonal protection in Wlds-SOD1 mice. Fortunately, these variables are 
removed by studying axon degeneration with Sarm1 null animals, and this may explain 
the differences in preservation between Wlds-SOD1 and Sarm1 KO-SOD1 results. There 
may also be unknown differences in the mechanism of axon protection between Wlds 
and Sarm1 KO mice, especially because one strain is the result of gene overexpression 
(Wlds) and the other a knock out (Sarm1). 
 Curiously, axons and synapses are preserved but there was no improvement in 
rotarod score. This is not necessarily surprising, given that the animals were tested at a 
constant speed; this test cannot pick up the subtle differences that an accelerating rotarod 
test would have. Alternatively, there is known to be cell death in the motor cortex of 
ALS mice and patients; if the motor cortex is not properly wired to the corresponding 
motor neurons in the spinal cord, then NMJ preservation would be not be detectable with 
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a behavioral assay. The motor neuron cell bodies could also not be functioning 
correctly, thus depriving the axon and synapses of necessary materials for producing 
endogenous action potentials; however, because the machinery to fire an action potential 
is still in place, we may be detecting intact NMJs in a situation where the neuron is no 
longer firing normally itself. It would be interesting to directly stimulate other neurons in 
the motor circuit, such as the motor cortex or upper motor neurons, in these mice to test 
if this circuit is intact. Spontaneous amplitudes could also be recorded from the muscle 
to determine if the motor unit is still able to fire normally. However, dendrites may not 
be intact or functional in these animals. It is likely that all of these possibilities play 
some role in functional motor neuron output during ALS progression, as any disruption 
in the complex motor circuitry would result in a behavioral defect, even if one 
component is highly preserved. The fact that we still observe functional NMJs (even if 
they are not actually functioning endogenously) is quite remarkable. 
Even if these motor units are not working by propagating endogenous action 
potentials, their functional preservation is still exciting and novel. This suggests that 
axon death genes do indeed get turned on during disease progression to drive destruction 
of the axon. It is unknown if Sarm mRNA or protein levels rise in the axon during ALS 
progression, and we unfortunately currently have no biochemical read out for “activated” 
Sarm (i.e., phosphorylation or cleavage at a specific site). However, because the Sarm1 
null animals show only slight lifespan extension, there are likely distinct somal-death 
mechanisms in place to destroy the cell body. Together with data on cell death-deficient 
mice (Gould et al., 2006; Reyes et al., 2010), this argues that during disease both axon-
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specific and soma-specific death programs are initiated. However, histological 
studies are still needed to determine if cell bodies are still dying in Sarm1-G93A mice 
and to confirm that axons are morphologically preserved. Also, while loss of Sarm1 is 
not predicted to alter expression levels of transgenic SOD1, testing for even expression 
levels of mutant SOD1 remains an important control remaining to be done. How a gain-
of-function, toxic molecule can activate both death programs remains unknown but 
highlights some of the limitations of the SOD1 mouse in modeling ALS. 
ALS mouse models have provided a remarkable tool with which to study the 
potential mechanism(s) of disease progression; however, there are limitations with the 
model used in this study. Because SOD1 is normally involved in removing ROS, it was 
assumed that ALS might be a disease of oxidative stress. However, work done on 
several models of ALS with various gain-of-function SOD1 mutations has shown that 
neurodegeneration is induced independently of ROS production (Van Den Bosch, 2011). 
Unfortunately, loss-of- function SOD1 mutants do not show ALS-like 
neurodegeneration, and it is still unclear how these mutants induce neuronal death. 
Disease progression is heavily dependent on the number of transgenic copies of mutant 
SOD1 present. The model tested here is considered a very aggressive form of ALS, and 
thus may not represent most human cases of the disease (Van Den Bosch, 2011). While 
over-expression of a mutant protein is a major limitation of this model, at this time it is 
one of the few available tools to investigate pathogenic mechanisms of ALS. Even 
recent models from familial-ALS-linked genes, such as TDP-43, encounter the same 
limitations: the disease models are a result of protein overexpression well beyond 
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“normal” levels, not due to the loss of function of a gene. These limitations make the 
above Sarm1 results more promising: there is a difference with loss of Sarm1 even when 
using a “sledgehammer” model such as SOD1-G93A.  Loss of Sarm in a less aggressive 
model of ALS may highlight larger differences in disease progression than the model 
used here. This makes Sarm1 a potential pharmaceutical target for neuroprotection in 
human disease, which is arguably less aggressive than the model used here. 
It remains to be seen how well Sarm1 loss can preserve axons in a variety of 
neurodegenerative disease models. Studies on Wlds indicate that Sarm1 loss should 
protect against a variety of chemically induced axon degeneration and models of 
peripheral neuropathies. However, Wlds is not universally protective, and it is unlikely 
that Sarm1 loss will be. Thus, it remains important to understand the specific underlying 
mechanisms of a variety of neurodegenerative diseases, as some may be linked 
specifically with Sarm1-induced death, and others not.  Wlds protection suggests that 
there is likely not a universal axon self-destruction program that always gets turned on to 
induce axon degeneration; in fact, we already know that Sarm1-mediated axon 
degeneration is genetically separate from developmental axon and dendrite pruning 
(Osterloh et al., 2012). However, the possibility of a universal “stress”-activated (i.e., 
non-developmental) self-destruction program remains an intriguing possibility that 
warrants further study. 
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Figure 4-1. Sarm loss does not rescue weight loss or motor performance decline in 
the SOD1-G93A mouse model of ALS 
n= 14 Sarm1 KO huSOD1-G93A+, n=12 Sarm1+/- huSOD1-G93A+, n=4 Sarm1 KO 
A. Mean percent of maximum weight verses age in  Sarm1+/- and Sarm1 KO 
littermates with huSOD1-G93A, ± SEM. ns between cohorts. 
B. Weight (in g) of individual Sarm1 KO, huSOD- animals with age. 
C. Mean time on rotatod (maximum = 500s) verses age in Sarm1 +/- and Sarm1 KO 
littermates with huSOD1-G93A. ns between cohorts. 
D. Kaplan-Meyer plot of age when Sarm1+/- and Sarm1 KO littermates with 
huSOD1-G93A are unable to remain on the rotarod for at least 10 seconds 
(functional paralysis). ns between cohorts. 
E. Mean time on rotarod for Sarm1 KO, huSOD- animals. 
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 Figure 4-2. Sarm loss modestly extends lifespan in the SOD1-G93A model of ALS. 
Kaplan-Meyer plot of survival of Sarm1 KO, Sarm1 +/-, huSOD1-G93A+, and Sarm1 
KO, huSOD1-G93A+ littermates. Median survival for Sarm1 +/-, huSOD1-G93A+ is 
169.0 days, while median survival for Sarm1 KO, huSOD1-G93A+ is 184.5 days. 
p=0.0136. All Sarm1 KO, huSOD- controls were alive for at least 250 days. n= 14 
Sarm1 KO huSOD1-G93A+, n=12 Sarm1+/- huSOD1-G93A+, n=15 Sarm1 KO 
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Figure 4-3. Sarm loss protects axons and synapses in the SOD1-G93A mouse 
MUNE scores for 130 day old Sarm1 +/-, huSOD1-G93A+ mice (, 23.8± 2.9; n=4 
legs) and Sarm1 KO, huSOD1-G93A+ mice (,94.1± 17.0; n=8 legs).  *, p=0.0174 
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CHAPTER V: Discussion 
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 Wallerian degeneration was long assumed to be a passive wasting away of 
the severed axon (Lubinska, 1977). The discovery of Wlds (Lunn et al., 1989) induced a 
paradigm sift in which many began to suspect Wallerian degeneration to be a genetically 
encoded axon death program. However, the identity of this death program remained an 
elusive target as it became clear that Wallerian degeneration is unrelated to known 
cellular destruction programs such as apoptosis and pruning (Coleman and Freeman, 
2010). Using a forward genetic screen in Drosophila, we identified the first endogenous 
gene, Sarm, required for severed axons to undergo Wallerian degeneration. While many 
experiments remain to test the potential molecular mechanisms of Sarm activity, there is 
finally strong evidence that Wallerian degeneration is in fact a unique, genetically 
encoded death program. I will propose a model in this chapter for Sarm function in 
governing axon death. 
Model for Sarm-mediated destruction of severed axons 
 Sarm is highly conserved at both the protein and genomic level between 
invertebrates and vertebrates (Mink et al., 2001); thus, the well-described calcium-
sensitive MAPK signaling activity of TIR-1 appears as a foundation with which to 
model Sarm function in promoting Wallerian degeneration. In C. elegans, TIR-1 is 
activated by the calcium sensitive CaMKII during development. This interaction 
between CaMKII and TIR-1 subsequently activates an ASK1-dependent MAPK 
pathway to alter transcription of odorant receptor genes in olfactory neurons (see 
Chapter 1). While the context described in C. elegans is very different from axon death, 
the connection between calcium-dependence in both TIR-1 signaling and Wallerian 
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degeneration is difficult to ignore. I propose that Sarm is activated by dual signals, 
including calcium, after injury to induce downstream effector kinase activity to promote 
Wallerian degeneration. During AAD, a sharp spike in intra-axonal calcium is observed 
(Avery et al., 2009); this calcium spike activates a calcium-dependent kinase that binds 
the ARM domain of Sarm. A decrease in axonal ATP levels activates a second kinase 
complex that also binds the ARM domain; when both kinases bind the ARM domain, the 
auto-inhibition of Sarm is removed. This conformational change allows for the TIR 
domain to bind with and activate a downstream effector kinase(s), which ultimately 
contributes to promoting many of the morphological and molecular changes associated 
with Wallerian degeneration. One of the main effects of Sarm activation maybe the 
opening of L-type calcium channels, which allows for axonal calcium influx to 
devastating levels. Based on the localization and rescue data presented in Chapter 4, the 
SAM domain likely dictates a unique subcellular localization that is critical for 
executing this pathway after axonal injury (Figure 5-1). 
Upstream activator(s) of Sarm 
Work in the worm (Chuang and Bargmann, 2005; Chang et al., 2011) indicates 
that TIR-1 acts downstream of CaMKII, suggesting that CaMKII, or some other 
calcium-activated kinase, may specifically activate Sarm after injury. Unfortunately, in 
Drosophila overexpression of a dominant negative CaMKII mutant, which may or may 
not be fully functional, has no affect on Wallerian degeneration (Table 2-1), and loss-of-
function mutants are not available because of the few existing genetic tools for work 
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with genes on the fourth chromosome. If the above model for Sarm function is 
correct, then calcium-sensitive kinase-binding sites should exist in the ARM domain of 
Sarm.  
Using the group prediction site (GPS) software (http://gps.biocuckoo.org) to 
predict kinase-binding sites, dSarm is expected to have a variety of potential kinase 
interaction positions (Xue et al., 2011). Very few of these sites rest in the ARM domain; 
most are in the SAM and TIR domains. While there are no predicted CaMKII binding 
sites in dSarm, there are however two predicted adenosine monophosphate (AMP) 
kinase binding sites in the ARM domain, and AMPK has previously been shown to be 
activated by high levels of AMP (i.e., low levels of ATP relative to AMP levels) to help 
regulate cellular metabolism (Hawley et al., 2005). This suggests that low ATP levels, 
which occur after injury in the severed axon, could be one factor that activates Sarm to 
promote Wallerian degeneration. 
There are no predicted CaMKII binding sites in Sarm; however, there is evidence 
that AMPK can be activated by calcium-calmodulin kinase kinase (CaMKK)-2, another 
calcium-sensitive signaling kinase (Ng et al., 2012). AMPK functions as a trimer, with 
three subunits, all of which have multiple splice forms: α, which contains the catalytic 
kinase site; β, which is regulatory and uses glycogen as a co-factor; and γ, which is also 
regulatory and responds to AMP:ATP ratios (Amato and Man, 2011). Recently, multiple 
groups have found that CaMKK2 can replace the AMPK γ-subunit to form a calcium, 
but not AMP, sensitive complex (Racioppi and Means, 2012). These different forms of 
AMPK (i.e., with and without CaMKK2) show different regulatory activities in vitro in a 
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variety of contexts (Amato and Man, 2011). If these predicted AMPK binding sites 
in the ARM domain are real and functional, together this suggests a two-part activation 
of Sarm: (1) a drop in cellular ATP levels activates calcium-independent AMPK 
signaling, possibly involving Sarm and microtubules (see below), upon which the 
AMPK α-β-γ complex binds one of the AMPK binding sites in the ARM domain of 
Sarm; and (2) increases in intra-axonal calcium activate a CaMKK2-AMPK complex 
that binds the second predicted AMPK-binding site in the ARM domain of Sarm.  
I would predict based on this model that both calcium influx and low ATP levels 
in the severed axon act as activation steps and are both required for Sarm to promote 
Wallerian degeneration, which is why Sarm is not activated (and therefore Wallerian-
like degeneration does not occur) during normal calcium influxes (i.e., cellular ATP 
levels are high, so AMPK is not activated) or during low energetic states, such as 
starvation (calcium levels are low, so CaMKK is not activated). Interestingly, NAD and 
ATP levels fall after injury in wild type but not Wlds axons (Wang et al., 2005); however, 
NAD and ATP levels fall in severed Sarm1 KO axons (J. Gilley and M. Coleman, 
personal communication), suggesting that metabolic failure (and therefore AMPK 
activation) occurs upstream of Sarm. This also suggests that energetic failure alone is not 
enough to kill an axon or even induce necrosis, further highlighting the importance of 
Sarm in promoting Wallerian degeneration. Additional bioenergetics studies on Sarm1 
KO severed axons are needed to investigate this further, but these initial results are 
consistent with a model in which Sarm is activated downstream of a metabolic failure 
after injury.  
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The above two-step activation model can also explain the calcium-insensitive 
features of Wallerian degeneration. Sarm has been shown previously to regulate 
microtubule stability (i.e., knock-down of Sarm reduces tubulin acetylation (Chen et al., 
2011)), and microtubule depolymerization after injury is calcium-independent (Park et 
al., 2013). AMPK could be partially activated after injury by low ATP levels, and this 
pulls Sarm away from microtubules, destabilizing them and causing depolymerization. 
However, Sarm mislocalization and microtubule depolymerization is not enough to 
initiate all of the features of Wallerian degeneration; for this, a calcium-sensitive kinase 
is also needed to further activate Sarm. With dual-activation from both calcium and ATP 
sensitive kinases, the ARM domain could release Sarm auto-inhibition after increases in 
calcium levels to induce the calcium-dependent features of Wallerian degeneration, such 
as cytoskeletal fragmentation and eventual GDC. This two-step activation not only 
explains the calcium dependent and independent part of Wallerian degeneration but also 
helps to explain a potential role for Sarm during development: if local ATP levels fall, 
then Sarm could destabilize microtubules in a manner that would assist with neurite 
remodeling, which is suggested by in vitro work in hippocampal neurons (Chen et al., 
2011). However, if calcium levels are not high enough to activate CaMKK2, then 
Wallerian-like degeneration does not proceed and instead neuronal processes can be 
refined and altered during development.  
Further study is needed on these potential AMPK and CaMKK2 binding sites, 
particularly in terms of their affinity for the various forms of activated AMPK (i.e., α-β-
γ AMPK verses CAMKK2-α-β AMPK). It remains a possibility that these binding sites 
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are slightly promiscuous and can be phosphorylated by either kinase, where extreme 
levels of either activating factor can induce Sarm-dependent death. For example, 
knockdown of Nmnat2, which induces spontaneous Wallerian-like degeneration (Gilley 
and Coleman, 2010), may create such an energetic crisis that α-β-γ AMPK levels are 
high enough to cross-activate the normally calcium-sensitive binding site on Sarm. In 
support of this, Sarm1 KO axons are protected from Nmnat2-RNAi induced spontaneous 
degeneration (J. Gilley and M. Coleman, personal communication), suggesting that 
metabolic devastation signals for axon degeneration through a Sarm-dependent 
mechanism. It will be interesting to test if increases in axonal calcium with normal ATP 
levels can also cause spontaneous degeneration in a Sarm-dependent manner. 
This dual-activation model with both CaMKK2 and AMPK predicts that there 
are two essential “injury signals:” high calcium levels and a depletion of cellular energy 
levels. This model therefore suggests an additional function for how Wlds protects 
severed axons: Wlds keeps cellular energy levels high, preventing AMPK (and then 
Sarm) activation. However, because Wlds blocks auto-activated dSarmΔARM, Wlds 
must be functioning in a capacity beyond inhibiting AMPK activity, as the above model 
puts AMPK upstream of Sarm activation. Alternatively, AMPK could potentially bind 
another domain in Sarm, and Wlds would protect by preventing AMPK activation. 
However, this model would suggest that expression of dSarmΔARM could somehow 
lower ATP to a level that would activate AMPK signaling, and then this activated 
AMPK signaling is required to further activate Sarm to induce Wallerian-like 
degeneration. However, there are no other predicted AMPK binding sites in Sarm 
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outside of the ARM domain (Xue et al., 2011); while this does not exclude this 
alternative model, it would predict a self-activation loop for Sarm. This alternative 
model suggests that the ARM domain is the “calcium sensitive” part of Sarm, while 
another domain is the “ATP-loss” sensitive section; this would predict that loss of the 
SAM or TIR domain might be able to functionally rescue loss-of-function mutants in the 
presence of an injury-induced calcium rise, which is not the case (Figure 4-2).  
Further studies should clarify the importance of AMPK and CaMKK2 in 
Wallerian degeneration. Biochemical studies on AMPK binding sites in Sarm are needed, 
as are subsequent mutagenesis of these sites and the effect on AMPK-Sarm binding. 
Work on dAMPK mutants and their effect on Wallerian degeneration will also help this 
mechanism; the model suggested here predicts that these mutants will block Wallerian 
degeneration, but not dSarmΔARM-induced degeneration. There are also a variety of 
biochemical and immunohistochemical tools available to test AMPK activation 
following axon injury. There is a Drosophila ortholog of CaMKK2, CG17698, however 
no mutants have been published. A targeted deletion may be a feasible method to 
produce a loss-of-function allele; alternatively, expression of transgenic constructs with 
mutated catalytic domains (based on the high degree of homology between mammalian 
and Drosophila CaMKK2) may alter the normal function of CaMKK2 in Wallerian 
degeneration. Together, these experiments may help decode the role of AMPK and 
CaMKK2 activity upstream of Sarm. In addition, there are a multitude of other predicted 
kinase binding sites in Sarm, and it remains important to discover which of these sites 
are actually responsible for producing a biologically relevant interaction in the context of 
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axon degeneration. The important kinase binding sites may actually reside outside of 
the ARM domain. Currently, we have no data to indicate what importance, if any, these 
predicted sites have in mediating Wallerian degeneration. 
Calcium influx and Sarm 
There are many morphological and molecular changes downstream of Sarm 
during Wallerian degeneration, and it remains unknown what processes Sarm directly 
initiates. However, an important step in axon degeneration appears to be the influx of 
calcium through L-type calcium channels in the severed axon, as pharmalogical 
blockade of these channels potently blocks Wallerian degeneration (Deckwerth and 
Johnson, 1994). One of the ways in which Sarm activity promotes Wallerian 
degeneration may involve these voltage-gated channels. Effector kinase activity 
downstream of Sarm may open these channels; alternatively, Sarm may bind L-type 
calcium channels directly through its SAM domain. However, direct opening of these 
channels would likely result in a rapid increase in intra-axonal calcium, similar to what 
is observed during an action potential, which is not seen after axotomy (Avery et al., 
2012; Adalbert et al., 2012). It is more likely therefore that the depletion of energy levels 
after injury prevents the maintenance of the membrane potential in the injured axon, and 
these intra-axonal energetic changes cause ion leaking through the L-type calcium 
channels. Why this ionic leak occurs specifically through L-type channels is unknown, 
but it is well established that this channel type specifically is at fault (George et al., 
1994). Alternatively, Sarm activity may directly contribute to this leaking by binding the 
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channels directly. In support of this, data from C. elegans suggests that TIR-1 
directly binds the L-type calcium channel UNC-2 (see below) (Chang et al., 2011).  
Experiments with L-type calcium channel agonists and antagonists in both wild 
type and Sarm KO neurons should illuminate the relationship between channel opening 
and Sarm activity, as well as electrophysiological recordings and calcium imaging from 
Sarm KO severed axons. If Sarm is acting upstream of channel opening, then channel 
agonists should induce spontaneous degeneration in wild type and Sarm KO axons; 
however, if Sarm is downstream of L-type calcium channels, then Sarm KO axons 
would be protected from agonist-induced degeneration. Alternatively, agonist could be 
added to severed Sarm KO axons, and if Sarm is upstream of calcium channels then the 
agonist should restore Wallerian degeneration to severed Sarm KO axons. In addition, if 
Sarm acts upstream of L-type calcium channels, then channel antagonists should block 
dSarmΔARM-induced degeneration; however, if antagonists have no effect on this 
construct, then Sarm likely acts downstream of channel opening. Measuring calcium 
levels in severed Sarm KO axons is also needed; if slow leakage through these channels 
is required for full Sarm activation (i.e., via CaMKK2-AMPK), then the normal calcium 
rise after injury should still occur in Sarm KO axons; alternatively, if Sarm activity is 
required for the calcium rise, then it should not occur in Sarm KO axons. 
 Based on the interaction in C. elegans, I predict that AMPK partially activates 
Sarm, which dissociates it from microtubules (destabilizing them, see above) and re-
distributes Sarm to L-type calcium channels. Following redistribution, CaMKK2 (having 
been activated by the calcium spike during AAD) binds to and activates Sarm. This 
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interaction, potentially in conjunction with changes in axonal metabolism, causes L-
type calcium channels to slowly leak calcium into the severed axon. Over time, this raise 
in intra-axonal calcium reaches a threshold level at which calpains become activated and 
mitochondrial swell and rupture. This model suggests that it is the calcium influx that 
causes cytoskeletal disintegration and mitochondrial bursting, instead of Sarm acting on 
a signal cascade that would activate these two events separately; however, we currently 
have little data to distinguish these two possibilities. Sarm may also regulate 
neurofilament or microtubule degradation; in vitro biochemical assays are needed to 
determine if a direct interaction between Sarm and cytoskeleton elements exists, as 
neurofilaments behave differently in the presence of Wlds in vitro (Bernier et al., 1999). 
This degradation however may be a result of the increases in calcium levels, not by 
direct association with Sarm. 
The above model predicts that Sarm is required upstream of L-type channels. 
While Sarm-null axons will undergo normal AAD, the slow intra-axonal calcium rise 
will not occur during the latency period because Sarm is required for L-type channels to 
leak after injury (Figure 5-1).  If this is true, then a biochemical interaction between 
Sarm and a subunit of L-type calcium channels should be detectable. TIR-1 has been 
shown to interact genetically and biochemically with the L-type channel UNC-2 (Chang 
et al., 2011); unfortunately, loss-of-function clones in ORNs of the unc-2 ortholog 
cacophony appear to degenerate spontaneously, and thus far we have not been able to 
test its role in Wallerian degeneration (work not presented here). It remains to be tested 
if cacophony mutant neurons undergo Wallerian-like degeneration (i.e., degeneration 
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can be blocked by expression of Wlds), or if they are developmentally highly 
irregular. I would predict that Sarm co-localizes with cacophony after injury, but not 
before, and this interaction is necessary for the calcium-dependent processes of 
Wallerian degeneration, although this remains to be tested. I would also predict that a 
calcium ionophore would restore Wallerian degeneration to cut Sarm KO axons and that 
chelating calcium from wild type axons during the late stages of the latency period 
would block degeneration. It is possible however that calcium influx occurs before Sarm 
activation after injury; if this is the case, then an interaction with a calcium channel such 
as Cacophony may or may not be required before injury to promote Sarm-dependent 
signaling. Again, more genetic and biochemical experiments are needed to test the link, 
if it does exist, between Sarm and L-type calcium channels directly. 
Molecules downstream of Sarm activation 
 Following increases in intra-axonal calcium in a severed axon, a variety of 
calcium-dependent processes occur: microtubules and neurofilaments are degraded by 
activated calpains; mitochondria swell and rupture; and the membrane eventually beads 
and fragments (Wang and Barres, 2012). While all of these processes are blocked in 
severed Sarm KO axons, it is unknown which of these processes (possibly all) are due to 
direct interactions with Sarm or if they are a byproduct of Sarm-dependent processes. 
For example, effector kinase signaling downstream of Sarm may be responsible for 
many aspects of Wallerian degeneration. It is unknown what effector kinase acts 
downstream of Sarm; an obvious candidate, based on C. elegans data, is dAsk1 (Chuang 
and Bargmann, 2005; Chang et al., 2011; Hayakawa et al., 2011); however, the only 
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available tool in Drosophila, a dominant negative transgene, has no impact on 
Wallerian degeneration (Table 2-1), and attempts at generating a mutant through 
imprecise excision of an existing Minos element and FLP-mediated recombination 
between FRT-bearing transposon insertions flanking dASK1 have not been fruitful (N. 
Fox, personal communication). Thus, we cannot rule out the involvement of this 
molecule in Wallerian degeneration, especially because ASK1 has a well-established 
role in mediating a variety of cellular stress responses, including calcium influx and 
oxidative stress (Hattori et al., 2009; Shiizaki et al., 2013). 
 If not ASK1, then what other molecules are downstream of Sarm? Based on 
Sarm’s structure, it is predicted that the TIR domain plays an important role in signal 
transduction. There are a variety of predicted kinase binding sites in the TIR domain, 
and it remains to be seen if these potential sites are biologically relevant in terms of 
Wallerian degeneration. TIR domains are traditionally found in TLRs and their 
downstream adaptors and are responsible for innate immune signaling (O’Neil et al., 
2006). However, we have found no evidence for Toll-signaling in Wallerian 
degeneration, as loss of function mutants in Tolls 6-9 do not impact Wallerian 
degeneration in Drosophila (Table 2-1; work not presented here) nor do TLR3 or 
UNC93B mutants in mice (T. Rooney, personal communication). TIR domains tend to 
be “sticky” biochemically, so pull-downs with this domain are likely to produce large 
sets of potential interacting proteins, which may or may not be relevant for Wallerian 
degeneration. This interaction may also be dependent on “activation” of Sarm, and at the 
moment this is not possible in vitro; furthermore, dSarm::GFP, when expressed in 
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sensory neurons, does not localize to axons (Figure 4-3), so there is no way to injure 
these neurons and then pull down dSarm::GFP from the injured axons. A more targeted 
approach would be to screen for suppressors of dSarmΔARM-induced degeneration; 
mutants in downstream pathways should block or delay this cell death.  
 Five candidate binding partners can be found from a yeast two-hydrid screen 
with horseshoe crab Sarm: Hax-1, SUMO-1, proteasome subunit alpha, Hsp40, and 
CaMKI (Belinda et al., 2008). Interestingly, CaMKI is predicted to interact with the TIR 
domain, while the other is predicted to bind the SAM domain. Unfortunately, CaMKI is 
on the forth chromosome, next to CaMKII, in Drosophila, making it difficult to test and 
no reagents are available currently. However, this possible interaction is worth studying 
in vitro in mammals. In work not presented here, I cloned Drosophila hax-1 into a UAS-
vector, as it is predicted to be anti-apoptotic (Simmen, 2011). Unfortunately, 
overexpression of Hax-1 had no affect on Wallerian degeneration and loss-of-function 
mutants are not available. The other molecules have not been tested to date but remain 
candidates in Wallerian degeneration. 
 It remains possible that the main function of Sarm is to activate the intra-axonal 
calcium influx, and it is this influx of calcium that directly causes the morphological 
changes associated with Wallerian degeneration. For example, high levels of axonal 
calcium during excitotoxicity in the retina can lead to degeneration that looks very 
similar to Wallerian degeneration (Saggu et al., 2010) and is blocked by expression of 
Wlds (Bull et al., 2012). This would predict that the intra-axonal calcium rise after 
axotomy does not happen in Sarm KO axons, but addition of a calcium ionophore (or a 
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L-type channel agonist) to these severed axons would restore degeneration to Sarm 
KO axons. Thus, L-type calcium channels could be the only molecule to act directly 
downstream of Sarm. Channel mutants that block an interaction with Sarm, but not 
normal channel function, should block Wallerian degeneration. If this is true, and the 
earlier model is correct, then CaMKK2 becomes activated during AAD, not the latent 
phase, to promote Sarm activity.  
 Despite the predicted connection between Sarm activity and calcium, it is 
unknown if calcium-dependent processes during Wallerian degeneration are changed in 
severed Sarm KO axons. Ultrastructural analysis by electron microscopy of severed wild 
type axons treated with EGTA showed intact neurofilament, but not microtubule, fibers 
(Park et al., 2013). Interestingly, microtubule “clumps” were still detected with 
immunohistochemistry, suggesting that calcium is required for neurofilament breakdown 
and microtubule degradation, but not for microtubule strand disruption. It remains to be 
seen if microtubules depolymerize in severed Sarm1 KO axons, as this process appears 
to be calcium independent (Park et al., 2013). However, thus far Sarm1 KO axons have 
pheno-copied both Wlds-expressing and EGTA-treated severed axons, suggesting that 
Sarm regulates the calcium-dependent changes that occur during Wallerian degeneration, 
but this remains to be tested. 
 Calcium influx during Wallerian degeneration may activate catastrophic changes 
in mitochondria. After injury, mitochondria in wild type severed axon eventually 
undergo mitochondrial permeability transition pore (MPTP) opening, causing them to 
swell and burst (Barrientos et al., 2011). Sarm1 KO mitochondria do not swell after 
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injury (Chapter 2), although it is unclear if this is due a fundamental change in the 
MPTP in Sarm KO neurons or due to the loss of an upstream activator of pore opening. 
High calcium levels are known to cause pore opening (Ikegami and Koike, 2003), so it 
will be interesting to see if mitochondria swell and rupture in Sarm KO axons after 
addition of a calcium ionophore. I would predict this to be the case, as Sarm in this 
model is upstream of an intra-axonal calcium rise that would cause MPTP opening. It 
will also be interesting to see if loss of Sarm changes mitochondrial responses to other 
stressors, such as uncouplers and electron transport change complex inhibitors; the 
model here predicts that loss of Sarm would have no affect on these toxins, but further 
work on the molecular differences in Sarm KO mitochondria compared to wild type and 
Wlds mitochondria is needed.  
It is also possible that the calcium leak through L-type channels occurs 
independently of Sarm activity, but high intra-axonal calcium levels “fully” activate 
Sarm through CaMKK2 to promote Wallerian degeneration. What this active form of 
Sarm interacts with is unknown, but this highlights the importance of screening for 
suppressors of dSarmΔARM-induced spontaneous degeneration. If Sarm acts only on L-
type channels, then L-type channel antagonists should block dSarmΔARM-induced 
degeneration. However, a suppressor screen may identify a variety of cellular targets, 
such as factors regulating cytoskeletal degradation and mitochondrial homeostasis, that 
would argue for a wide-spread role for Sarm in promoting Wallerian degeneration 
beyond increasing intra-axonal calcium. 
 
138 
Wlds and Sarm 
 Where does Wlds fit in with Sarm and Wallerian degeneration? In our initial 
observations on the robust protection from Wallerian degeneration in Sarm KO axons, 
we were unable to distinguish any differences between Sarm KO and Wlds-expressing 
axons (Chapter 2). If Sarm1 KO axons are phenol-copying Wlds-expressing axons, then 
Wlds may act by directly offsetting normal Sarm function. Recent evidence suggests that 
Wlds may be acting by increasing mitochondrial buffering capacity (Avery et al., 2012). 
Calcium dynamics have not been tested in Sarm-null axons, but initial experiments show 
that Sarm1 KO mitochondria have normal levels of calcium buffering (P. Sullivan, 
personal communication). This suggests that Sarm1 KO axons are not identical to Wlds-
expressing axons, and implies that the slow intra-axonal calcium rise during the latency 
period, which does not occur in Wlds-expressing axons (Adalbert et al., 2012; Avery et 
al., 2012), may occur in Sarm-null axons. If true, this would suggest that Sarm-null 
axons can survive even with persistently high calcium levels. However, calcium-imaging 
studies have not been done on Sarm KO axons, and work presented in Chapter 4 using 
the dSarmΔARM construct argues that Wlds acts downstream of this construct of to 
block axon degeneration. 
I propose that Wlds can prevent Sarm-mediated axon destruction in multiple 
ways (Figure 5-2). First, Wlds could act upstream of Sarm by buffering calcium rises 
during AAD, which would prevent CaMKK2 activity. Without an activated calcium-
dependent kinase, Sarm remains in its auto-inhibited state and thus cannot promote 
Wallerian degeneration. In support of this, it has been shown previously that Wlds-
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expressing axons also do not undergo AAD (Kerschensteiner et al., 2005) and Wlds-
expressing mitochondria can buffer more calcium than their wild type counterparts 
(Avery et al., 2009); however these studies need to be repeated in Sarm KO neurons and 
mitochondria.  
An alternative way by which Wlds can protect severed axons from Sarm-
mediated Wallerian degeneration may be through the enzymatic function of Wlds. Wlds 
contains an active Nmnat1 that is required for protection (Avery et al., 2009; Conforti et 
al., 2009), which may help stabilize axonal energetics after injury. This activity may 
prevent AMPK activation, which would prevent Sarm activation independent of calcium 
levels. Both of these explanations are feasible, and immunohistochemical studies on 
severed Wlds and wild type axons may show differences in CaMKK2 and AMPK 
activation or phosphorylation levels.  
In wild type severed axons, the above model predicts that Wlds acts upstream of 
Sarm and prevents its activation by buffering calcium and maintaining ATP levels, and I 
predict that this same activity can also work downstream of Sarm to block Wallerian 
degeneration. Based on data presented in Chapter 3, the spontaneous degeneration that 
occurs in uninjured neurons expressing the dSarmΔARM construct may be due to the 
activation of L-type calcium channels by “auto-activated” Sarm. Wlds-expressing 
mitochondria can buffer these increases in intra-axonal calcium due to L-type calcium 
channel activation. Without increases in intra-axonal calcium, mitochondria stay healthy 
and calpains are not activated, resulting in maintenance of neuronal integrity. However, 
calcium-imaging studies need to be done on dSarmΔARM-expressing neurons. This 
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model would predict that dSarmΔARM expression causes increases in neuronal 
calcium levels, and these increases should be blocked by co-expression of Wlds. 
Expression of a calcium-chelating agent with the ability to prevent axonal calcium rises 
should also mimic Wlds. This explanation also supports a model in which Sarm acts only 
upstream of L-type calcium channels; furthermore, treatment of dSarmΔARM-
expressing axons with a L-type calcium channel antagonist should prevent spontaneous 
degeneration.  
Notably, no one has published experiments regarding calcium-ionophore induced 
spontaneous axon degeneration in Wlds axons, and it would be interesting to determine if 
Sarm-null axons do not spontaneously degenerate due to this ionophore, even in the 
presence of very high calcium levels. Furthermore, work on wild type axons has shown 
that L-type calcium channels are required for severed axons to undergo Wallerian 
degeneration, and it remains to be seen if treatment with a L-type calcium agonist, such 
as FPL-64176 (Liu et al., 2003) can activate Wallerian-like degeneration in wild type or 
Sarm1 KO axons. If Sarm is downstream of this calcium signal, than Sarm1 KO axons 
should be resistant to this agonist-induced axon degeneration. It would also be 
interesting to look at cytoskeletal changes in wild type axons with agonist treatment in 
order to better understand the role of calcium in cytoskeletal changes during axon 
degeneration. 
Molecular Injury Signal(s) 
 The above model predicts that decreases in ATP levels after injury and a calcium 
spike during AAD are the two molecular injury signals that are required for Wallerian 
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degeneration. However, it is unknown if these (or other) intrinsic injury signal(s) 
persist after injury; they could be a momentary “SOS” to the axon that is lost over time. 
This suggests that Sarm could be re-introduced to a severed Sarm KO axon but may not 
be able to restore Wallerian degeneration unless the calcium-sensitive signal (i.e., 
CaMKK2) is still active. No reports have been published to date regarding the effect of a 
second lesion within a previously severed axon. For example, if functional Sarm protein 
were supplied to severed Sarm-null axon, would the additional Sarm initiate 
degeneration? Or, would a second lesion be needed to supply the activating injury 
signal? It has been shown previously through virally-delivered particles that cytosolic 
Nmnat can protect axons when delivered to the severed axon after injury (Sasaki and 
Milbrandt, 2010). Resupplying Sarm1 to severed Sarm1-KO axons may induce 
degeneration, suggesting that the injury signal persists even after the severed axon has 
resealed. However, if resupplied Sarm1 does not rescue the blockade of axon 
degeneration, then a second lesion may be needed to activate Sarm1. If this is the case, 
then blocking the initial signal alone may be enough to prevent axon degeneration. If not, 
then the “SOS” signal, indicating that the axon has been severed, likely persists 
throughout the rest of the latency period. 
AAD and regeneration without Sarm 
AAD is believed to be an important first step in activating axon regeneration in 
the proximal injured axon (Kerschensteiner et al., 2005; Knoferle et al., 2010).  It 
remains to be tested if regeneration is indeed inhibited in transected Sarm1 KO axons; 
however, if Sarm1 KO axons behave similar to Wlds axons (Kerschensteiner et al., 2005), 
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AAD will be severely inhibited and regeneration will be stalled. Live-imaging of 
severed Sarm1 KO axons will help to address this question, as will looking at long-term 
in vivo regeneration. However, the model presented here predicts that AAD will occur 
normally, so regeneration initiation should not be hindered. However, the regenerating 
axon is likely to run into a large roadblock (i.e., the remaining severed axon stump). 
Could a regenerating axon fuse with an intact severed axon? This is found in C. elegans 
(Neumann et al., 2011), where severed axons do not undergo Wallerian degeneration. 
This would be an exciting possibility for treatment of nerve injuries, particularly if a 
method for allowing CNS regeneration were established. A regenerating axon could 
theoretically rejoin the old axon and restore function through the original connections 
without having to completely rewire the circuit, which can take years in the human PNS 
and does not occur in the CNS. Together, these techniques are exciting possibilities for 
treating a variety of traumatic neuronal injuries, including spinal cord damage. 
Sarm and Calpains 
 Calpains and calcium are the driving force behind AAD, and the impact of loss 
of Sarm on calpain activation remains to be seen. Addition of calcium to nerve extracts 
will induce neurofilament degeneration in a dose-dependent manner by calpain 
activation; this occurs in Wlds extracts but requires a higher calcium concentration 
(Glass et al., 1994). Interestingly, Wlds nerve extracts were resistant to degradation in 
vitro by added activated calpains (Bernier et al., 1999), suggesting that there is (1) an 
intrinsic, calcium-activated process that makes neurofilaments succeptable to 
degeneration or (2) axons possess a protective mechanism that normally inhibits 
143 
neurofilaments breakdown. It will be interesting to test Sarm1 KO axon extracts to 
see if there is a difference in calpain activity and activation, as it remains possible that 
Sarm’s normal function is to aide in activation of calpains or to make cytoskeletal 
proteins such as neurofilaments more succeptable to calpain-mediated proteolysis. This 
would imply that Sarm functions beyond opening L-type calcium channels and plays a 
more direct role in axonal destruction and degradation. It would be interesting to add 
recombinant Sarm to neurofilaments or microtubules, followed by activated calpains, to 
determine if Sarm can mediate calpain cleavage of the cytoskeleton directly. This more 
direct role may instead be executed by downstream effector kinases that interact with the 
TIR domain of activated Sarm. 
Microtubules and Sarm 
Recent results have suggested that calcium is required for neurofilament 
breakdown but not microtubule disruption (Park et al., 2013), suggesting that two 
parallel pathways exist in severed axons to execute GCD. There is evidence that calpains 
are responsible for neurofilament degeneration during GCD (Ma et al., 2013), but less is 
known about microtubule disruption. Wlds and Nmnat2 overexpression block 
microtubule fragmentation (Feng et al., 2010) but fibrous integrity has not been assayed. 
Unlike in wild type nerves, microtubules do not fragment in cut Sarm1 KO axons 
(Figure 2-11); however, microtubule integrity at the ultrastructural level was not assayed. 
This fiberous integrity is crucial for axon health, as addition of microtubule-destabilizing 
agents such as vinblastine induce spontaneous Wallerian-like degeneration (Ikegami and 
Koike, 2003). Interestingly, while mitochondrial failure and ATP loss are consequences 
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of vinblastine-induced degeneration, treatment with a mitochondrial uncoupler, 
which recapitulates the same effects without disrupting microtubules, induced 
degeneration in both wild type and Wlds axons (Ikegami and Koike, 2003), suggesting 
that microtubule integrity specifically is a key component of Wlds protection. In vitro 
Sarm1 appears to co-localize with microtubules (Kim et al., 2007) and promotes 
stabilizing tubulin acetylation when overexpressed in neurons (Chen et al., 2011), 
supporting the idea that Sarm1 is interacting with, and possibly stabilizing, microtubule 
fibers. If this interaction is calcium dependent or changes with calcium fluctuation 
remains to be tested.  
Sarm1’s role in neuronal development and polarity (Chen et al., 2011) further 
supports this idea, and biochemical interactions with tubulin may classify Sarm as a 
microtubule-associated protein (MAP). Studying the effect of microtubule disrupting 
drugs on Sarm1 KO axons may provide further insights into this interaction. This is 
particularly intriguing because dysfunction of another MAP, Tau, has been implicated in 
neurodegenerative disease, and stabilization of microtubules can offset disease 
progression (Zhang et al., 2012). While microtubule inhibitors can prevent axon 
degeneration after stretch injury (Tang-Schomer et al., 2012), long-term treatment with 
microtubule stabilizers, such as during chemotherapy, induce peripheral neuropathies 
(Lee and Swain, 2006). Thus, even though microtubule-disrupting drugs induce 
Wallerian-like degeneration, microtubule stability is not the only factor contributing to 
axon degeneration after injury. However, microtubule destabilizing agents may provide 
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a potential means by which we can “cut” axons without physically lesioning them 
and help to decipher different components of Wallerian degeneration. 
It is also unclear if microtubule binding is essential for Sarm function; the fact 
that the dSarmΔSAM construct is unable to rescue loss-of-function mutants suggests this, 
but specific point mutants that block microtubule association directly without grossly 
altering protein folding should clarify this. It would also be interesting to see if knock-in 
of a mutant with microtubule localization disruption renders a loss-of-function 
phenotype. It may alter developmental functions of Sarm potentially without blocking 
Wallerian degeneration; according to the model presented here, disrupting the 
microtubule binding itself should not alter the AMPK or CaMKK2 binding (and 
activating) sites. This localization however may be important for interactions with 
downstream signaling molecules. 
MAPK activity and Wallerian degeneration 
MAPKs are known to regulate some components of TIR-1 signaling (Chuang 
and Bargmann, 2005; Chang et al., 2011) and their inhibition can slightly delay but not 
completely inhibit axon degeneration (MacInnis and Campenot, 2005; Miller et al., 
2009; Gerdts et al., 2011). Interestingly, the protective effect of proteasome inhibitors 
has been suggested to be the result of increased levels of MAPKs in severed axons 
(MacInnis and Campenot, 2005).  In support of this, loss-of-function JNK mutant 
neurons exhibit spontaneous Wallerian-like degeneration that is blocked with Wlds 
expression (Rallis et al., 2013) but not p35 expression (J. Osterloh and M. Freeman, 
unpublished observation), suggesting that in this case loss of JNK does not simply 
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induce caspase-dependent cell death. It is unknown what during injury activates 
these stress-induced pro-survival kinases, and because chemical inhibition only delays 
degeneration, MAPK activation may be a result of, but not a causative agent in, 
Wallerian degeneration. As with all kinase cascades, there is likely context-dependent 
fine-tuning; further assaying activation and interactions after injury may illuminate 
potential roles for these molecules during axon degeneration. Nevertheless, calcium is a 
known activator of some kinase signaling pathways (Hattori et al., 2009; Song, 2013), 
and it remains possible that calcium activates a MAPK pathway through Sarm in a 
manner or combination that has not previously been tested.  
The potential involvement of CaMKK2 in Wallerian degeneration could link 
Sarm with previous in vitro results in which knock down of some MAPKs delay 
Wallerian degeneration. The MAPK GSK3 can phosphorylate CaMKK2, and this 
phosphorylation is a crucial factor in regulating CaMKK2 protein stability and 
protecting it from degeneration. Thus, knockdown of GSK3 would decrease levels of 
CaMKK2, which could delay Sarm activation; this would explain why knockdown of 
GSK3 delays, but does not block, Wallerian degeneration (Gerdts et al., 2011). Further 
proteomic studies are needed to determine the relationships between molecules like 
GSK3 and the stability of potential Sarm-interacting proteins, such as AMPK and 
CaMKK2. There are likely other proteins that regulate stability of Sarm and its upstream 
partners, and this stability may explain why UPS inhibitors delay but not block 
Wallerian degeneration: proteins that normally negatively regulate Sarm (or upstream 
147 
molecules like AMPK and CaMKK2) activity or levels are more abundant with UPS 
inhibition, which slows Sarm activation and delays Wallerian degeneration. 
Mechanism of Sarm regulation  
UPS regulation (see above) likely plays an important role in regulation of Sarm 
levels and activation, as UPS inhibition strongly delays Wallerian degeneration (Zhai et 
al., 2003). Intriguingly, loss-of-function mutants in the E3 ubiquitin ligase highwire 
(hiw) have recently been found to potently block injury induced Wallerian degeneration 
(Xiong et al., 2012). highwire acts by directing protein targets for ubiquitination, 
suggesting that there is a specific protein(s) that either (1) block Wallerian degeneration 
themselves, and loss of hiw increases these to a threshold that blocks axon destruction or 
(2) promote Wallerian degeneration, and these are regulated by proteins that are 
regulated by hiw. The model presented here would suggest that hiw acts by regulating 
proteins that control Sarm, CaMKK2, and/or AMPK levels; loss of hiw increases the 
levels of proteins that ultimately result in Sarm suppression. CaMKK2 and AMPK 
activity in hiw mutants should be tested, and I would predict that protein levels of these 
kinases would be lower or their activity would be severely inhibited. If the model 
presented here is correct, then overexpression of Sarm, CaMKK2, and/or AMPK 
together or alone may be able to restore Wallerian degeneration in hiw mutants. 
The regulation of Sarm by UPS degradation remains unknown, but there is 
evidence for Sarm regulation by another method: RNA interference. Human cDNA 
studies have detected the presence of an endogenous microRNA targeted to Sarm1 
(Mink et al., 2001), as well as one in worms (Hsieh et al., 2012) although no such 
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microRNA has been reported in mice or Drosophila. Because endogenous 
expression of dSarm and Sarm1 are very low (Kim et al., 2007; Osterloh et al., 2012), it 
is possible that an endogenous RNA mechanism exists to control and limit Sarm levels. 
It would be interesting to determine if loss of interfering RNA machinery induces 
spontaneous Wallerian-like degeneration. 
It is also possible that Sarm protein is expressed at minimal levels before injury, 
and injury induces local axonal translation of Sarm protein. This is option is not likely 
however, as addition of ribosomal inhibitors just before injury do not block Wallerian 
degeneration (Gilley and Coleman, 2010). It is possible, however, that these inhibitors 
are not complete, and some small amount of Sarm is still translated. mRNA levels in the 
axon before and after injury should be assayed to address this. 
When and where is Sarm required to promote axon death? 
Is Sarm required before, after, or during injury to signal for axon degeneration? 
While the simplest explanation is that injury induces some sort of cascade through Sarm, 
it remains unknown if Sarm-null neurons are fundamentally changed before injury in 
such a manner that would prevent degeneration. Sarm could be acting by altering 
transcription or translation in a way that primes axons for death after injury. Proteomic 
or transcriptome profiling would address this question: are there any differences pre-
injury, other than a loss of Sarm, in Sarm1 KO verses wild type neurons? Could Sarm be 
involved in pro-Wallerian degeneration gene regulation? If so, are these changes 
relevant to axon degeneration, or are they related to the potential developmental function 
of Sarm? 
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 Another possibility is that Sarm is required after injury. To test this, one 
could resupply Sarm into Sarm1 KO axons through a viral vector, similar to the Nmnat 
transduction experiments (Sasaki and Milbrandt, 2010). If this alone is enough to 
activate Wallerian degeneration, then Sarm is required after injury. Sarm could also be 
required during the injury event itself; if this is the case, then the Sarm1 KO axon, after 
being re-supplied with Sarm1, would have to be cut a second time to activate Sarm-
induced Wallerian degeneration. These experiments would also shed light on the 
persistence of the injury signal (see above). While we favor the hypothesis that 
resupplying Sarm1 to a severed Sarm1 KO axon will activate Wallerian degeneration for 
the sake of simplicity, there is no evidence to date that suggests one possibility is more 
likely over the others. 
 Is Sarm required in the axon to promote Wallerian degeneration? This question is 
to be approached with caution, as much time was spent on understanding the 
predominantly nuclear localization of Wlds (Coleman, 2005) even though we know now 
that small amounts of Wlds act in the axon to prevent Wallerian degeneration (Coleman 
and Freeman, 2010). One approach to this question would be to resupply Sarm1 to uncut 
Sarm1 KO axons in the presence of an axon transport inhibitor, similar to the Nmnat2 
expression study (Gilley and Coleman, 2010). If Sarm1 was re-expressed but excluded 
from the axon, and then did not promote axon degeneration after lesion, Sarm is likely 
(1) required in the axon to promote degeneration and (2) not acting outside the axon (i.e., 
in the soma) to “prime” axons for degeneration. 
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 Work presented here unfortunately does not clarify the localization of Sarm. 
While it localizes to mitochondria in kidney cell lines in vitro, Sarm does not localize to 
mitochondria in neurons and instead appears in a punctate pattern (Figure 2-14). 
Expression of a dSarm::GFP construct varies slightly in vivo in different neuron sub-
types, and no clear sub-cellular localization pattern has emerged. What could account for 
the differences in dSarm localization? This may be indicative of the variety of other 
functions of dSarm beyond controlling Wallerian degeneration. It could also be due to a 
variety of levels of regulatory factors or binding partners in these difference neurons. At 
this time, it is unknown if varying localization of Sarm confers different sensitivities or 
timing to Wallerian degeneration. In sensory neurons, dSarm::GFP is excluded from the 
axon, so we are unfortunately unable to assay localization changes after injury. Live 
imaging studies in Drosophila larvae of dSarm::GFP does not appear to be moving 
throughout the axon (T. Rooney, personal communication), and instead appears to be 
localized primarily around the cell body and main neurite branches. However, these 
experiments were done with an overexpression system and may not represent 
endogenous localization. Studies of endogenous localization with a recombineered GFP-
tag (not presented here) may shed some light on any injury-induced changes. Sarm 
expression may be upregulated after injury; if this is the case, then more GFP+ signal 
should be detected with this tool. The GFP-tagged BAC may also help determine Sarm 
expression regulators. Treatment with a UPS inhibitor may increase Sarm-GFP levels, 
and this may be a device with which to screen for Sarm managers.  
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The dSarmΔARM construct also allows us to investigate the necessity of 
subcellular localization and dSarm activity. While the SAM domain does direct 
localization, it remains unclear if this is important for function. By targeting 
dSarmΔARM to a variety of areas, such as the mitochondria matrix, the nucleus, or the 
cell membrane, we can determine if a discrete location is necessary for dSarmΔARM-
induced death. In addition, we may be able to restore function (i.e., the ability to rescue a 
loss-of-function mutant) to the dSarmΔSAM construct by targeting this mislocalized 
molecule to a specific subcellular localization. 
Studying dSarm activation in cell culture 
Further work with the dSarmΔARM construct in vitro may elucidate a method by 
which to study axon degeneration in cell culture. A current limitation of using cell 
culture to study Sarm and Wallerian degeneration is that there is no way to “injure” and 
subsequently look at Sarm activation in an S2 cell, and overexpression of dSarm does 
not induce cell death. Thus, expression in S2 cells may provide us with downstream 
markers of dSarm activation that could be used as an in vitro cell culture read out for 
Wallerian degeneration, even though these cells have no axons. Possible targets include 
phosphorylation or ubiquitination changes in these cells, as well as microtubule stability.. 
Sarm beyond Wallerian degeneration 
 The above models only address the role of Sarm in promoting Wallerian 
degeneration. Sarm likely has other functions in cells, possibly as a negative regulator of 
innate immunity and a microtubule stabilizer. Sarm overexpression in hippocampal 
cultures increases stabilizing tubulin acetylation (Chen et al., 2011). However, if Sarm is 
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involved in microtubule stability, this function may also be important during 
Wallerian degeneration. Activation of Sarm, possibly by AMPK during local decreases 
in ATP, may remove Sarm-microtubule interactions, thereby destabilizing microtubules 
independent of the proposed kinase scaffolding function of Sarm. This is consistent with 
the observation that microtubule depolymerization occurs very early in Wallerian 
degeneration. Interestingly, AMPK is not required for cortical development, but 
activation does inhibit axonal outgrowth and polarization (Williams et al., 2011). AMPK 
does have many targets in different contexts, and it remains unclear if AMPK interacts 
with Sarm under any condition. 
 Is Sarm required in non-neuronal tissues? dSarm loss-of-function mutants are 
lethal at L1 larval stages; surprisingly, dSarm expression only in neurons is not enough 
to rescue lethality, indicating that dSarm plays essential functions in another, non-
neuronal tissue. However, broad misexpression with an abundant driver, such as tubulin-
Gal4, ubiquitin-Gal4, or actin-Gal4, also does not rescue lethality. Together, this 
suggests that dSarm is normally required in low levels in small set of non-neuronal cells. 
Interestingly, too much dSarm is likely toxic, and we have not identified a specific 
subset of cells (neuronal or otherwise) that require Sarm function for animal viability. 
dSarm loss-of-function mutants show reduced numbers of clones in ORNs with 
MARCM, indicating that dSarm may play an unknown function in neuronal 
development or maintenance. Clonal induction numbers seem too decline with age, 
suggesting an important role for dSarm in neuronal, or at least axonal, maintenance. It is 
unknown if this sensitivity is restricted to ORNs however, as similar observations have 
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not been seen in wing sensory neurons (L. Neukomm, personal communication). 
There is a recent report of dSarm being involved in tollo/toll-8 –dependent innate 
immunity in the Drosophila gut; however, the mutants tested were not loss-of-function 
but instead weak hypomorphs (Akhouayri et al., 2011), so it is difficult to interpret the 
role of dSarm in the Drosophila gut and immune system. Whatever this function of 
dSarm may be, it is either not required in mammals, or other gene(s) have assumed this 
role(s), as Sarm loss-of-function mice are viable and seemingly normal. 
How do severed axons survive without somal support? 
The protection of axons by loss of Sarm (and by expression of Wlds) is 
remarkable for many reasons, and raises an important question about basic axonal 
biology: how can axons survive without trophic support from the soma for weeks? There 
are many examples in invertebrates where severed axons survive and potentially 
function for extended periods of time (months after lesion) (Parnas et al., 1991; Stengl, 
1995). There are also examples in invertebrates where neuronal nuclei lyse during the 
final stages of development, leaving behind functional, anucleated neurons (Polilov, 
2012). This suggests that axons are not dependent on soma-derived nutrient support, and 
instead may function metabolically independently of other cellular processes. 
At first it may seem advantageous for cells to forgo their cell bodies once post-
mitotically differentiated with all connections formed; this could prevent tumors and 
other detrimental consequences of unregulated mitosis. However, cell body-derived 
growths or regeneration would also be prevented. This would substantially limit an 
organism’s ability to recover from a neuronal injury, assuming of course that an axon 
154 
would be unable to induce regeneration from itself without somal support. It is 
unknown at this time if severing a Sarm KO axon would destroy the ability for the 
severed axon or the synapse to remodel; while it may be assumed that somal support is 
required for synaptic plasticity, there have not been genetic tools to test this until now. If 
axons can indeed grow without a soma, then this would highlight the importance of 
axonal biology while diminishing the role of the nucleus and soma in the function of 
adult neurons. 
 There is evidence of protein transfer from surrounding glia (Lasek et al., 1977; 
Sheller et al., 1995; Fruhbeis et al., 2012), even to cut axons (Court et al., 2008), 
suggesting that glia may be able to adopt the traditional roles of the soma for the axon. 
While it is likely that glial support is necessary for long-term survival of severed axons, 
the mechanisms of this trophic support remain unknown. Glia are known to be involved 
in phagocytosis of axonal debris (MacDonald et al., 2006; Doherty et al., 2009; 
Ziegenfuss et al., 2012), but this process is not believed to be an initiating factor in axon 
degeneration. However, a lack of glial support can negatively affect axons (Yamanaka et 
al., 2008; Ilieva et al., 2009). Further studies are needed to understand the molecular 
mechanisms regarding glial support of severed axons. It is likely that many nutrient 
transporters are needed to pass metabolites from glia to neurons, but the nature of this 
transfer, if it does indeed occur, remains a mystery. This relationship may explain why 
cut axons undergo Wallerian degeneration so much more quickly in vitro versus in vivo 
after axotomy (approximately 6-8 hours compared to 24-28 hours). Glia may also 
contribute to the functional preservation of severed Sarm and Wlds axons by providing 
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factors that assist in maintaining the resting membrane potential despite the lack of 
input signals after injury. 
Functional preservation of severed axons 
 A major area of interest surrounding protected severed axons is their preservation 
of functionality: could they fire an action potential if stimulated, even though there are 
no longer any “fire” signals from the rest of the neuron? Wlds motor neurons show some 
conservation of axonal function after injury, as their synapses are able to contract 
connecting muscle even a week after axotomy, albeit at a greatly diminished force 
compared to uncut nerves (Moldovan et al., 2009). Severed Wlds axons even maintain 
bidirectional axon transport at speeds similar to uncut axons at least 8 days after lesion 
(Smith and Bisby, 1993). While we have not assayed organelle transport in severed Sarm 
KO axons, they do exhibit similar declines in CMAP levels after injury as Wlds mice 
(work not presented here). Together, this suggests that either (1) synapses need somal-
derived support factors for maintenance, so axotomy removes the source of trophic 
support causing synaptic degeneration; (2) regular firing of action potentials are required 
for maintenance of synaptic architecture; or (3) synapses possess their own self-
destruction program that is independent of Sarm or Wlds. In support of the later model, 
preliminary experiments with double Bax KO-Sarm1 KO mice, which are deficient in 
axon death and most cell death mechanisms, show substantial increases in CMAP 
protection: 40-80% of uninjured CMAP levels remain 6 days after injury, compared with 
5% in Sarm1 KO alone or Wlds mice. This suggests that synapses, like axons, have their 
own self-destruct program that may be triggered by similar initiating events. More work 
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is needed on synapse preservation in the absence of axon degeneration to understand 
this phenomenon further. 
Why undergo Wallerian degeneration? 
 The relationship been axons and surrounding glia may hint at the importance of 
Wallerian degeneration in biology: the injured limb needs to be able to recover as much 
as functionally possible. Wallerian degeneration allows for a sick nerve to be removed 
while activating the surrounding tissue to do so. This allows for theoretically unhindered 
regrowth of a new axon from the soma in the PNS. There have been many reported cases 
where presence of the severed axon obstructs axonal regrowth. While the initiation of 
axon sprouting is unhindered in Wlds nerves (Lunn et al., 1989), axon regeneration is 
functionally highly impaired (Brown et al., 1992; Martin et al., 2010), as it appears the 
fragments act as a physical blockade to the regenerating axon. Similarly during 
development, new axon growth is not impeded by a severed axon; however, the new 
axon recognizes the severed axon as a “sibling” outgrowth and overlaps (Wang and 
Macagno, 1998), which potentially alters functionality of that neuron. Thus, it appears 
that severed axons fragment to allow a passageway for the regenerating axon to 
reinnervate the same targets. However, some studies have found that regenerating axons 
can actually fuse with the severed axon, resulting in a functional re-connection in the 
leech (Deriemer et al., 1983), Aplysia californica (Bedi and Glanzman, 2001), and C. 
elegans (Ghosh-Roy and Chisholm, 2010; Neumann et al., 2011). Unfortunately, this 
capability may not be conserved in vertebrates: Wlds mice show minimal functional 
fusions in motor neurons, and a highly reduced number in sensory neurons (Brown et al., 
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1992). However, with a better understanding of cellular regeneration mechanisms 
and developmental tiling, it may be possible to block Sarm (and axon degeneration) after 
injury, followed by regeneration induction and fusion of the new axon to the old. This 
would greatly speed up functional recovery after PNS injuries and may even be a way to 
recover from CNS insults, such as strokes and traumatic brain injuries. Sarm seems 
poised as a key initial player in uncovering this area of therapeutic importance. 
 The biological importance of Wallerian degeneration may also be embodied 
within this first key gene: a supposed “innate immunity” molecule is required for axons 
to degeneration after physical lesion. It is possible that Wallerian degeneration exists to 
aid in the removal of cellular debris, as this could potentially become a target of 
autoimmune activity. Or, perhaps mammalian nerves have evolved to degenerate to 
remove any sort of “corrupt” or toxic component, and the neuron would rather start over 
than try to repair. 
 This self-destruction process may have initially evolved for more chronic insults, 
as axons self-destruct in order to conserve resources for the animal (Raff et al., 2002) 
while preventing any sort of pathogenic spread.  The broad range of animal 
neurodegeneration models that are delayed by Wlds expression supports this hypothesis 
(Coleman, 2011), as do recent studies on Sarm’s role in immunology. Sarm1 KO mice 
show increases in viral load and mortality after WNV infection (Szretter et al., 2009), 
suggesting that axons may initiate their own self-destruction to prevent further viral 
spreading. Perhaps this mechanism of auto-activation during infection will shed light on 
how Sarm is activated after physical lesion, as they might overlap significantly. It 
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appears that axons either (1) have a common self-destruct pathway that is activated 
by multiple stress signaling pathways, including lesion, or (2) a common overreaching 
“axon-health” signal that can be diminished by multiple insults. Further work on Sarm-
null animals and suppression of axon degeneration via multiple mechanisms, including 
injury, neurodegenerative disease models, and infection, is needed to elucidate this 
further. 
Axon death in disease 
Work presented here (Chapter 4) suggests that Sarm-regulated axon death 
pathways are activated during neuronal death in a mouse model of ALS. While blocking 
axon death does not substantially prolong lifespan (Figure 4-2), Sarm1 presents itself as 
a candidate therapeutic to potentially delay symptoms in this disease. Cell body 
protection is likely also required to attenuate motor neuron loss in this disease, so a 
combinatorial approach of blocking axon death by inhibiting Sarm while also blocking 
cell body death (potentially with Bax or Bak inhibitors) may synergistically improve 
neuronal function and survival. Further studies on other neurodegenerative disease 
models in the Sarm-null background are needed to determine if axon death pathways are 
activated in other diseases. 
It is also unknown if Sarm-dependent axon death is activated by the same 
mechanisms that promote somal death, or if axon death is at the beginning of a whole 
cell destruction cascade. Is there a universal “stress signal” or response within a neuron 
that activates multiple death programs, or is there an overall threshold that sums various 
types of cellular stress that eventually signals death programs once a threshold is 
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reached? The model presented here suggests that low cellular energy levels coupled 
with influxes in calcium may contribute to disease progression. Detailed bioenergetics 
and calcium level studies have not been done in ALS mice, although they present 
challenges experimentally for studying such transient changes over the long course of 
disease progression. It remains possible that cellular stresses related to the diseased state 
triggers energetic fluxes that in conjunction with an inability to maintain proper 
membrane potential can slowly activate Sarm and other destructive mechanisms. More 
work is needed on pre-disease states in mutant neurons to determine what axonal 
changes could potentially trigger Sarm-mediated destruction. It is unknown if a few 
“regulatory” triggers, such as energy or calcium levels, control degeneration directly, or 
instead are part of many factors that contribute to an overall cellular stress state. 
Despite the wealth of research being done on neurodegenerative disease, it is still 
unknown what ultimately fates certain adult neuron populations to die during these 
diseases. While the ultimate result (i.e., cell death) is the same, the commonality among 
disease pathways remains unclear, as many animal models of multiple diseases show 
similar intracellular irregularities and disruptions (Gilley et al., 2011). For example, ALS 
models have increases in oxidative stress, ER stress, and mitochondrial disruption 
(Rothstein, 2009), but it is unclear if any of these catalyze cell death or are merely the 
result of a sick motor neuron trying to stay alive under the dire circumstances at hand. 
Regardless, the ability to genetically “save” a part of a neuron from death and 
destruction is exciting and may be the tipping point for discovering ways to save a sick 
neuron from dying. 
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 Sarm modification presents a potential therapeutic target for diseases of axon 
loss, particularly CIPNs (Lee and Swain, 2006). Assaying conditional loss of Sarm in 
adult neurons is an important next step, as it is important to determine if loss of Sarm1 
specifically in adult neurons will fundamentally change them, either morphologically or 
electrophysiologically. However, Sarm1 KO mice are viable, and there are no known 
behavioral defects in these animals, making Sarm inhibition an even more promising 
target. In addition, blocking Sarm function in adult hood would eliminate any potential 
developmental issues, as suggested by the in vitro hippocampal work (Chen et al., 2011). 
Axon death components may be important for plasticity, or even the brain’s response to 
infection so care must be used. This potential conflict highlights the importance of 
ultimately uncovering more elements that initiate cellular destruction.   
 Because loss of Sarm potently protects axons from Wallerian degeneration, it 
would be interesting to look at Sarm mutations in human genomic studies to determine if 
mutations altering Sarm function can decrease susceptibility for or the severity of 
neurological diseases. For example, there is a well-studied ALS-linked SOD mutation, 
D90A, which causes a slowly progressing form of ALS and is recessive in Scandinavian 
populations; however, this same mutation is dominant and causes classical ALS 
pathogenesis is non-Scandinavians (Pasinelli and Brown, 2006). It is possible that a 
resistant population may have mutations in Sarm that hinder its function; or, groups that 
are more susceptible to degeneration may have defects in Sarm regulation that produces 
higher levels of Sarm expression. Further bioinformatics studies are needed to determine 
what link, if any, exists between Sarm mutations and disease susceptibility.  
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It is unlikely that a single mutation will greatly increase susceptibility to a 
disease; it is more likely that Sarm will be one of many genes that together either 
weaken a neuron or strengthen its cellular defenses against the onslaught of aging. It 
remains important therefore to assemble large amounts of genetic data, including 
epigenetic regulators, on a diverse group of both healthy and diseased populations. As 
with work on regenerative and axon-death therapies, Sarm’s importance may ultimately 
be its position as the initial gene to catalyze discovery of many factors that function in 
balancing axonal health with death. 
Conclusions 
Work presented here provides the first direct evidence that a conserved axon 
death program exists and is activated in some forms of neurodegenerative disease. We 
have shown strong evidence that Wallerian degeneration is indeed a unique genetically 
encoded destructive program, joining developmental pruning and apoptosis as ways in 
which neurons can execute the demise of their processes.  Sarm provides an exciting 
target for not only understanding axon death under a variety of circumstances, but also 
for potentially treating neuropathies. While many questions regarding axon death and 
Sarm function remain unanswered, it is clear that axons have a unique biology separate 
from the neuron as a whole, and this unique biology has a large importance in the 
understanding and treatment of neurological disease. 
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Figure 5-1. Proposed mechanism of Sarm-mediated Wallerian degeneration 
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Figure 5-1. Proposed mechanism of Sarm-mediated Wallerian degeneration 
Calcium enters the severed axon during AAD and activates a calcium-sensitive kinase, 
represented here as CaMK. CaMK binds to the auto-inhibitory ARM domain, induces a 
conformation change within the SAM domain that releases Sarm from microtubules. 
This release de-stabilizes microtubules. ATP levels in the severed axon fall, which 
activates AMPK to bind to the ARM domain. This dual-activation induces activated 
Sarm to either directly associate with L-type calcium channels or signals through the 
TIR domain to induce kinase activity; the result of either of these steps is that L-type 
calcium channels gradually open to increase axonal levels of calcium. Once a threshold 
is reached, high intra-axonal calcium induces a variety of changes associated with 
Wallerian degeneration: calpain activation; cytoskeletal breakdown; mitochondrial 
swelling and rupture and eventual membrane fragmentation. 
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Figure 5-2. Revised mechanism for Wlds-mediated protection  
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Figure 5-2. Revised mechanism for Wlds-mediated protection  
A. Calcium enters the severed axon during AAD; instead of activating a calcium-
dependent kinase (CaMK), the calcium is taken up by the mitochondira 
containing Wlds. This prevents CaMK from binding the ARM domain of Sarm. 
Wlds also prevents AMPK activation by keeping axonal ATP levels high through 
the enzymatic activity of Nmnat. Without this dual-activating signaling complex, 
Sarm remains bound to microtubules and is unable to associate with L-type 
calcium channels. This prevents the slow intra-axonal calcium rise. 
B. dSarmΔARM-induces degeneration independent of upstream calcium and energy 
homeostasis sensors. This molecule, either directly of through association with 
downstream kinases, opens L-type calcium channels and causes rises in calcium 
levels through the entire neuron. This increase would normally cause 
mitochondrial rupture and calpain activation; however, Wlds-expressing 
mitochondria buffer any rises in calcium, which prevents mitochondrial rupture 
and calpain activation. 
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